Welcome to Arctom, sign up to enjoy up to 20% OFF

Search in Small Molecules Search in Biologics

Structure Search

Cart - 0 item(s)
$0.00

Your shopping cart is empty!

Chemistry
Bioactive Molecules
Natural Products
ADCs
Antibodies
- Primary Antibodies
- Secondary Antibodies
Multiplex IHC
Material Science
Others

[CAS NO. 174722-31-7] Rituximab (anti-CD20)

Ships within

Stock

Price

Qty

Total

COA

Please click "REQUEST A QUOTE" button if there is no stock, or you need other sizes or custom synthesis.

Catalog:	HY-P9913A
Brand:	MCE
CAS:	174722-31-7

Overview

MDL	-
Molecular Weight	144544.44
Molecular Formula	Unspecified
SMILES	[Rituximab (anti-CD20)]

For research use only. We do not sell to patients.

4 Publications Citing Use of MCE

[1]Signal Transduct Target Ther. 2020 Sep 14;5(1):200.
[2]Anal Chim Acta. 2021, 338306.
[3]Cancer Biol Med. 2020 Nov 15;17(4):1026-1038.
[4]Research Square Preprint. 2022 Mar.

Summary

Rituximab (anti-CD20) is an anti-CD20 chimeric monoclonal antibody used to treat certain autoimmune diseases and types of cancer ^[1] .

In Vitro

Rituximab (anti-CD20) inhibits the proliferation of stimulated human B cells, which is associated with a relative increase of B cells with an activated naive phenotype. Aside from this population shift, there are no major changes in phenotype or cytokine profile of the various B-cell subsets. B cells stimulated in the presence of rituximab induces stronger T-cell proliferation, compared to B cells stimulated in the absence of rituximab ^[1] . All lymphoma cells tested are equally sensitive to antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-mediated phagocytosis of tumor cells, and rituximab-induced apoptosis. Rituximab (anti-CD20) induces high CDC killing of follicular lymphoma cells ^[2] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

A single injection of rituximab or the murine anti-CD20 Ab 1F5, given i.p. 1 day after the tumor, cures 100% of the animals. Depletion of either NK cells or neutrophils or both in tumor-injected animals does not affect the therapeutic activity of the drug. Similarly, rituximab is able to eradicate tumor cells in athymic nude mice, suggesting that its activity is T cell independent ^[3] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT04978584	M.D. Anderson Cancer Center	Diffuse Large B-Cell Lymphoma	March 3, 2022	Phase 2
NCT03834688	PrECOG, LLC.\|Genentech, Inc.	Mantle Cell Lymphoma	January 13, 2020	Phase 2
NCT03332888	Instituto de Cardiología y Medicina Vascular Hospital Zambrano-Hellion Tec Salud	Heart Failure With Reduced Ejection Fraction	January 1, 2021	Phase 2
NCT00280878	Bayside Health	Non-Hodgkin´s Lymphoma (CD20&addition;)	January 2006	Phase 2
NCT00258336	Favrille\|National Cancer Institute (NCI)	Lymphoma	August 2004	Phase 2
NCT02187861	Hoffmann-La Roche\|AbbVie	Follicular Lymphoma	December 1, 2014	Phase 2
NCT00960713	University Hospital, Toulouse	Pemphigus\|Auto-immune Thrombocytopenic Purpura\|Hemolytic Auto-immune Anaemia\|Cold Agglutinin Disease\|Cryoglobulinemia	June 2009
NCT03704714	Northwestern University\|Bristol-Myers Squibb\|National Cancer Institute (NCI)	Aggressive Non-Hodgkin Lymphoma\|B-Cell Non-Hodgkin Lymphoma\|CD20 Positive\|Diffuse Large B-Cell Lymphoma Unclassifiable\|Intravascular Large B-Cell Lymphoma\|Primary Mediastinal (Thymic) Large B-Cell Lymphoma\|T-Cell+Histiocyte-Rich Large B-Cell Lymphoma\|Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma	November 20, 2018	Phase 1\|Phase 2
NCT02128061	The Lymphoma Academic Research Organisation\|Centre Henri Becquerel	Diffuse Large B Cell Lymphoma	August 2014	Phase 3
NCT00517699	Hoffmann-La Roche	Lymphoma	September 2007	Phase 2
NCT00567229	Memorial Sloan Kettering Cancer Center\|National Cancer Institute (NCI)	Multiple Myeloma and Plasma Cell Neoplasm	November 2007	Phase 2
NCT05073250	Chinese PLA General Hospital	Inert Non Hodgkin´s Lymphoma	December 31, 2021	Phase 2
NCT02378298	Göteborg University\|Sahlgrenska University Hospital, Sweden	Ophthalmopathy, Thyroid-Associated	December 2011	Phase 4
NCT00899431	M.D. Anderson Cancer Center\|Celgene Corporation	Chronic Lymphocytic Leukemia	May 6, 2009	Phase 2
NCT00070018	Southwest Oncology Group\|National Cancer Institute (NCI)	Lymphoma	February 2004	Phase 2
NCT01719692	Institute of Hematology & Blood Diseases Hospital\|National Natural Science Foundation of China	Immune Thrombocytopenic Purpura	August 2012	Not Applicable
NCT00908986	Northwell Health	Lupus Nephritis	December 2008	Not Applicable
NCT00274924	Eastern Cooperative Oncology Group\|National Cancer Institute (NCI)	Lymphoma	April 2006	Phase 2
NCT02260804	Celltrion	Follicular Lymphoma	November 9, 2015	Phase 3
NCT00364819	University of California, Davis\|Genentech, Inc.	Primary Biliary Cirrhosis	January 2007	Phase 1\|Phase 2
NCT00087009	Memorial Sloan Kettering Cancer Center\|National Cancer Institute (NCI)	Leukemia\|Lymphoma\|Lymphoproliferative Disorder	May 2004	Phase 1
NCT00258206	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins\|National Cancer Institute (NCI)	Multiple Myeloma and Plasma Cell Neoplasm	December 2004	Phase 2
NCT03804359	Centre Hospitalier Universitaire de Nice	Idiopathic Membranous Nephropathy	January 14, 2020	Phase 2
NCT01973062	Case Comprehensive Cancer Center	Primary Central Nervous System Non-Hodgkin Lymphoma	March 2014	Phase 2
NCT02433522	Assistance Publique - Hôpitaux de Paris\|Roche Pharma AG	ANCA-associated Vasculitides	March 31, 2015	Phase 3
NCT02752815	Ruijin Hospital	Diffuse Large B-cell Lymphoma	April 2016	Phase 4
NCT00100737	Chiron Corporation	Non-Hodgkin Lymphoma		Phase 2
NCT05457556	Children´s Oncology Group	Acute Lymphoblastic Leukemia\|Acute Myeloid Leukemia\|Myelodysplastic Syndrome	November 23, 2022	Phase 3
NCT00282347	Genentech, Inc.	Lupus Nephritis	January 2006	Phase 3
NCT04626791	Academic and Community Cancer Research United\|National Cancer Institute (NCI)	Mantle Cell Lymphoma	August 3, 2021	Phase 2
NCT01476787	Celgene\|The Lymphoma Academic Research Organisation	Follicular Lymphoma	December 29, 2011	Phase 3
NCT01470456	Sanofi	Diffuse Large B-Cell Lymphoma	November 2011	Phase 2
NCT00070083	British Columbia Cancer Agency\|National Cancer Institute (NCI)	Lymphoma	July 2003	Phase 1
NCT02966717	Zhujiang Hospital	Renal Insufficiency, Chronic\|Nephrotic Syndrome	August 2016	Phase 2
NCT00381004	M.D. Anderson Cancer Center\|Bayer	Chronic Lymphocytic Leukemia	September 2006	Phase 2
NCT00092222	National Cancer Institute (NCI)\|National Institutes of Health Clinical Center (CC)	Lymphoproliferative Disorder\|HHV-8\|Malignancy\|HIV	October 28, 2004	Phase 2
NCT02304354	University Hospital, Tours	Rheumatoid Arthritis	March 9, 2015	Phase 3
NCT00058422	Memorial Sloan Kettering Cancer Center\|National Cancer Institute (NCI)	Lymphoma	February 10, 2003	Phase 2
NCT04659044	Academic and Community Cancer Research United\|National Cancer Institute (NCI)	Recurrent B-Cell Non-Hodgkin Lymphoma\|Recurrent Grade 1 Follicular Lymphoma\|Recurrent Grade 2 Follicular Lymphoma\|Recurrent Grade 3a Follicular Lymphoma\|Recurrent Mantle Cell Lymphoma\|Recurrent Marginal Zone Lymphoma\|Recurrent Small Lymphocytic Lymphoma\|Refractory B-Cell Non-Hodgkin Lymphoma\|Refractory Grade 1 Follicular Lymphoma\|Refractory Grade 2 Follicular Lymphoma\|Refractory Grade 3a Follicular Lymphoma\|Refractory Mantle Cell Lymphoma\|Refractory Marginal Zone Lymphoma\|Refractory Small Lymphocytic Lymphoma	April 1, 2021	Phase 2
NCT00086944	National Cancer Institute (NCI)	Recurrent Adult Diffuse Large Cell Lymphoma\|Recurrent Grade 3 Follicular Lymphoma\|Recurrent Mantle Cell Lymphoma	May 2004	Phase 1\|Phase 2
NCT00147121	Haruhiko Fukuda\|Ministry of Health, Labour and Welfare, Japan\|Japan Clinical Oncology Group	Lymphoma, B-Cell	September 2002	Phase 2\|Phase 3
NCT00078949	NCIC Clinical Trials Group\|Canadian Cancer Trials Group	Lymphoma	August 7, 2003	Phase 3
NCT00905034	M.D. Anderson Cancer Center\|Leadiant Biosciences, Inc.	Leukemia, Lymphocytic, Acute	March 2009	Phase 2
NCT01021735	University of Glasgow\|Arthritis Research UK\|NHS Lothian\|NHS Grampian\|NHS Tayside\|NHS Borders\|NHS Fife	Rheumatoid Arthritis	April 2010	Phase 4
NCT02219737	National Cancer Institute (NCI)	CD20 Positive\|Recurrent Diffuse Large B-Cell Lymphoma\|Refractory Diffuse Large B-Cell Lymphoma	September 12, 2014	Phase 1
NCT04840602	National Cancer Institute (NCI)	Lymphoplasmacytic Lymphoma\|Waldenstrom Macroglobulinemia	June 24, 2021	Phase 2
NCT01490723	M.D. Anderson Cancer Center\|Spectrum Pharmaceuticals, Inc	Leukemia\|Lymphoma	January 2013	Phase 2
NCT00290667	German High-Grade Non-Hodgkin´s Lymphoma Study Group\|Universität des Saarlandes	Lymphoma	February 2004	Phase 2
NCT05100862	BeiGene	Relapsed+Refractory Follicular Lymphoma\|Marginal Zone Lymphoma	March 10, 2022	Phase 3
NCT00934648	Hoffmann-La Roche	Rheumatoid Arthritis	October 2007	Phase 4
NCT00238238	Alliance for Clinical Trials in Oncology\|National Cancer Institute (NCI)	Lymphoma	March 2006	Phase 2
NCT00057447	InterMune	Non-Hodgkin´s Lymphoma	March 2003	Phase 1\|Phase 2
NCT02339922	University of Washington\|Millennium Pharmaceuticals, Inc.	Chronic Lymphocytic Leukemia\|Follicular Lymphoma\|Lymphoplasmacytic Lymphoma\|Mantle Cell Lymphoma\|Marginal Zone Lymphoma\|Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue\|Refractory Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue\|Small Lymphocytic Lymphoma\|Waldenstrom Macroglobulinemia	May 19, 2016	Phase 2
NCT01744626	Celgene Corporation	Leukemia Lymphocytic Chronic B-Cell	December 2012	Phase 1
NCT00299494	Pfizer\|UCB Pharma	B-Cell Lymphoma	May 4, 2006	Phase 1\|Phase 2
NCT03467373	Hoffmann-La Roche	B-Cell Lymphoma\|Non-Hodgkin Lymphoma	March 13, 2018	Phase 1
NCT00869999	Massachusetts General Hospital\|Beth Israel Deaconess Medical Center\|Dana-Farber Cancer Institute\|Novartis	Diffuse Large B-cell Lymphoma	May 2009	Phase 2
NCT00050245	National Institute of Neurological Disorders and Stroke (NINDS)\|National Institutes of Health Clinical Center (CC)	Polyneuropathies	November 27, 2002	Phase 2
NCT00140595	Lymphoma Study Association\|Amgen	Diffuse Large-Cell Lymphoma	December 2003	Phase 3
NCT00167791	University of Wisconsin, Madison\|Genentech, Inc.	End Stage Renal Disease	July 2005	Not Applicable
NCT00486421	Mayo Clinic\|National Cancer Institute (NCI)	Nonneoplastic Condition	January 2007	Early Phase 1
NCT02367196	Celgene	Hematologic Neoplasms	March 12, 2015	Phase 1
NCT00088530	CTI BioPharma	Lymphoma, Non-Hodgkin	July 2004	Phase 3
NCT04375228	Columbia University\|Genentech, Inc.	Immune-related Adverse Events\|Advanced Solid Tumor	September 25, 2020	Phase 2
NCT01446133	M.D. Anderson Cancer Center\|Celgene Corporation	Leukemia\|Lymphoma	December 12, 2011	Phase 2
NCT00923013	National Cancer Institute (NCI)\|National Institutes of Health Clinical Center (CC)	Hairy Cell Leukemia	October 20, 2008	Phase 2
NCT03919175	Massachusetts General Hospital\|TG Therapeutics	Lymphoma\|Follicular Lymphoma\|Follicular Lymphoma, Grade 1\|Follicular Lymphoma Grade 2\|Follicular Lymphoma Grade IIIa\|Marginal Zone Lymphoma\|Marginal Zone B Cell Lymphoma	September 1, 2019	Phase 2
NCT00110149	Beth Israel Deaconess Medical Center	Lymphoma	May 2004	Phase 2
NCT00740415	French Innovative Leukemia Organisation\|Janssen, LP\|Mundipharma Pte Ltd.	Lymphoma	June 2007	Phase 2
NCT01718691	SymBio Pharmaceuticals	Low-grade B Cell Non-Hodgkin´s Lymphoma\|Mantle Cell Lymphoma Where Hematopoietic Stem Cell Transplantation is Not Indicated	November 2011	Phase 2
NCT02767674	The First Affiliated Hospital with Nanjing Medical University	Diffuse Large B Cell Lymphoma	May 2016	Phase 3
NCT04319601	Zhejiang Cancer Hospital	Angioimmunoblastic T-cell Lymphoma\|Chemotherapy Effect\|Chemotherapeutic Toxicity	March 13, 2020	Not Applicable
NCT02947347	Pharmacyclics LLC.	Follicular Lymphoma	January 2017	Phase 3
NCT02753062	Asan Medical Center\|Cheolwon Suh	Diffuse Large B Cell Lymphoma	August 2015	Phase 2
NCT02727803	M.D. Anderson Cancer Center\|National Cancer Institute (NCI)	Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive\|Acute Biphenotypic Leukemia\|Acute Lymphoblastic Leukemia\|Acute Lymphoblastic Leukemia in Remission\|Acute Myeloid Leukemia With Myelodysplasia-Related Changes\|Acute Myeloid Leukemia With Variant MLL Translocations\|B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1\|Chemotherapy-Related Leukemia\|Chronic Myelomonocytic Leukemia\|Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive\|High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements\|ISS Stage II Plasma Cell Myeloma\|ISS Stage III Plasma Cell Myeloma\|Myelodysplastic Syndrome\|Myelodysplastic Syndrome With Excess Blasts\|Myelodysplastic Syndrome With Gene Mutation\|Myelodysplastic+Myeloproliferative Neoplasm\|Previously Treated Myelodysplastic Syndrome\|Recurrent Acute Myeloid Leukemia\|Recurrent Adult Acute Myeloid Leukemia\|Recurrent Hodgkin Lymphoma\|Recurrent Non-Hodgkin Lymphoma\|Refractory Acute Lymphoblastic Leukemia\|Refractory Adult Acute Lymphoblastic Leukemia\|Secondary Acute Myeloid Leukemia\|Therapy-Related Myelodysplastic Syndrome	May 19, 2016	Phase 2
NCT01181154	Assistance Publique - Hôpitaux de Paris\|Hoffmann-La Roche	Warm Autoimmune Hemolytic Anemia	March 3, 2011	Phase 3
NCT03763643	University of Minnesota\|United States Department of Defense	Focal Segmental Glomerulosclerosis	July 1, 2019	Early Phase 1
NCT00980304	Shanghai Jiao Tong University School of Medicine	Lymphomas		Phase 2
NCT00242996	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins\|National Cancer Institute (NCI)	Lymphoma	March 2004	Phase 2
NCT00280241	University of Pittsburgh\|Genentech, Inc.\|Biogen	Chronic Lymphocytic Leukemia	June 2004	Phase 2
NCT01754870	University of Wisconsin, Madison\|Celgene Corporation\|Genentech, Inc.	Chronic Lymphocytic Leukemia (CLL)\|Small Lymphocytic Lymphoma (SLL)	November 2013	Phase 2
NCT00372905	Northwestern University\|Robert H. Lurie Cancer Center	Lymphoma	July 24, 2007	Phase 1\|Phase 2
NCT01701232	Biocad	Follicular Non-Hodgkin´s Lymphoma\|Nodal Marginal Zone Lymphoma\|Splenic Marginal Zone Lymphoma	September 2011	Phase 3
NCT01619761	M.D. Anderson Cancer Center\|National Cancer Institute (NCI)	Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive\|Acute Biphenotypic Leukemia\|Acute Lymphoblastic Leukemia in Remission\|Acute Myeloid Leukemia in Remission\|Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive\|DS Stage II Plasma Cell Myeloma\|DS Stage III Plasma Cell Myeloma\|High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements\|ISS Stage II Plasma Cell Myeloma\|ISS Stage III Plasma Cell Myeloma\|Myelodysplastic Syndrome\|Recurrent Acute Lymphoblastic Leukemia\|Recurrent Acute Myeloid Leukemia\|Recurrent Chronic Lymphocytic Leukemia\|Recurrent Hodgkin Lymphoma\|Recurrent Non-Hodgkin Lymphoma\|Recurrent Small Lymphocytic Lymphoma\|Refractory Acute Lymphoblastic Leukemia\|Refractory Chronic Lymphocytic Leukemia\|Refractory Hodgkin Lymphoma\|Refractory Non-Hodgkin Lymphoma\|Refractory Small Lymphocytic Lymphoma\|Secondary Acute Myeloid Leukemia\|Therapy-Related Acute Myeloid Leukemia\|Therapy-Related Myelodysplastic Syndrome	May 3, 2013	Phase 1
NCT00001563	National Cancer Institute (NCI)\|National Institutes of Health Clinical Center (CC)	AIDS Related Lymphoma\|AIDS-Associated Lymphoma	January 8, 1997	Phase 2
NCT00290511	M.D. Anderson Cancer Center\|Genentech, Inc.\|Biogen	Lymphoma	June 29, 2004	Phase 2
NCT00335140	Eastern Cooperative Oncology Group	Lymphoma	December 2006	Phase 2
NCT00119730	Dana-Farber Cancer Institute\|Massachusetts General Hospital\|Biogen	Mantle Cell Lymphoma	February 2005	Phase 2
NCT01412879	Southwest Oncology Group\|National Cancer Institute (NCI)	Lymphoma	November 2011	Phase 2
NCT05600660	Second Affiliated Hospital, School of Medicine, Zhejiang University	Primary Central Nervous System Lymphoma	August 1, 2022	Phase 2
NCT02168907	Wake Forest University Health Sciences\|National Cancer Institute (NCI)	B-cell Adult Acute Lymphoblastic Leukemia\|B-cell Chronic Lymphocytic Leukemia\|Cutaneous B-cell Non-Hodgkin Lymphoma\|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue\|Intraocular Lymphoma\|Nodal Marginal Zone B-cell Lymphoma\|Recurrent Adult Acute Lymphoblastic Leukemia\|Recurrent Adult Burkitt Lymphoma\|Recurrent Adult Diffuse Large Cell Lymphoma\|Recurrent Adult Diffuse Mixed Cell Lymphoma\|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma\|Recurrent Adult Grade III Lymphomatoid Granulomatosis\|Recurrent Adult Immunoblastic Large Cell Lymphoma\|Recurrent Adult Lymphoblastic Lymphoma\|Recurrent Grade 1 Follicular Lymphoma\|Recurrent Grade 2 Follicular Lymphoma\|Recurrent Grade 3 Follicular Lymphoma\|Recurrent Mantle Cell Lymphoma\|Recurrent Marginal Zone Lymphoma\|Recurrent Mycosis Fungoides+Sezary Syndrome\|Recurrent Small Lymphocytic Lymphoma\|Refractory Chronic Lymphocytic Leukemia\|Refractory Hairy Cell Leukemia\|Small Intestine Lymphoma\|Splenic Marginal Zone Lymphoma\|Testicular Lymphoma\|Waldenström Macroglobulinemia	December 2014	Phase 1
NCT01421173	M.D. Anderson Cancer Center	Lymphoma	August 2011	Phase 1
NCT04849715	Incyte Corporation	Mantle Cell Lymphoma	March 11, 2022	Phase 3
NCT01998893	Hoffmann-La Roche	Non-Hodgkin´s Lymphoma	January 1997	Phase 2
NCT00115700	Trans Tasman Radiation Oncology Group\|Australasian Leukaemia and Lymphoma Group	Follicular Lymphoma	February 2000	Phase 3
NCT03096782	M.D. Anderson Cancer Center\|National Cancer Institute (NCI)	Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive\|Acute Biphenotypic Leukemia\|Acute Leukemia\|Acute Lymphoblastic Leukemia\|Acute Lymphoblastic Leukemia in Remission\|Acute Myeloid Leukemia\|Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome\|Chemotherapy-Related Leukemia\|Chronic Lymphocytic Leukemia\|Chronic Myelogenous Leukemia, BCR-ABL1 Positive\|Chronic Myelomonocytic Leukemia\|Hodgkin Lymphoma\|Langerhans Cell Histiocytosis\|Minimal Residual Disease\|Myelodysplastic Syndrome\|Myelodysplastic Syndrome With Excess Blasts\|Non-Hodgkin Lymphoma\|Recurrent Hodgkin Lymphoma\|Refractory Acute Lymphoblastic Leukemia\|Refractory Myelodysplastic Syndrome\|Small Lymphocytic Lymphoma\|Therapy-Related Myelodysplastic Syndrome	October 13, 2017	Phase 2
NCT00265928	University of Virginia\|National Cancer Institute (NCI)	Lymphoma		Phase 2
NCT00143871	University of Michigan Rogel Cancer Center	Lymphoma, Non-Hodgkin´s	April 2001	Phase 2
NCT01650727	Merck Sharp & Dohme LLC	Chronic Lymphocytic Leukemia\|Small Lymphocytic Lymphoma	October 2012	Phase 1
NCT00981838	Mario Negri Institute for Pharmacological Research\|Agenzia Italiana del Farmaco	Nephrotic Syndrome	April 2009	Phase 3
NCT00501748	University of California, San Francisco\|Genentech, Inc.	Neuromyelitis Optica	January 2004	Phase 1
NCT02525172	National Taiwan University Hospital	Pompe Disease	August 2015	Phase 4
NCT02961816	M.D. Anderson Cancer Center	Lymphoma	June 2017	Phase 2
NCT04442022	Karyopharm Therapeutics Inc	Relapsed+Refractory Diffuse Large B-cell Lymphoma	September 3, 2020	Phase 2\|Phase 3
NCT04743739	Peking Union Medical College Hospital\|Beijing Tongren Hospital\|Chinese Academy of Medical Sciences, Fuwai Hospital\|The Luhe Teaching Hospital of the Capital Medical University\|The Seventh Affiliated Hospital of Sun Yat-sen University\|First Affiliated Hospital of Xinjiang Medical University\|Nanyang Nanshi Hospital of Henan University\|Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.	Idiopathic Membranous Nephropathy	April 14, 2021	Phase 3
NCT00771875	University of Cincinnati	Graft Rejection	September 2008	Phase 2
NCT02043587	University of California, San Diego\|Leadiant Biosciences, Inc.	Acute Lymphocytic Leukemia\|Adult Lymphoblastic Lymphoma	January 2014	Phase 2
NCT01205737	Teva Branded Pharmaceutical Products R&D, Inc.	DLBCL	September 2010	Phase 1
NCT00455897	Massachusetts General Hospital\|Beth Israel Deaconess Medical Center\|Brigham and Women´s Hospital\|Dana-Farber Cancer Institute\|Bayer	Lymphoma, Non-Hodgkin\|Lymphoma, B-Cell\|Lymphoma, Diffuse	December 2006	Phase 2
NCT01593332	Mashhad University of Medical Sciences\|Roche Pharma AG	DMARD Resistant Rheumatoid Arthritis	July 2010	Phase 4
NCT03623373	Washington University School of Medicine\|Acerta Pharma BV	Mantle Cell Lymphoma	November 29, 2018	Phase 2
NCT00003849	Alliance for Clinical Trials in Oncology\|National Cancer Institute (NCI)	Lymphoma	July 1999	Phase 2
NCT04989621	Sun Yat-sen University	Follicular Lymphoma\|Relapsed and Refractory Follicular Lymphoma	August 1, 2021	Phase 2
NCT00764517	OHSU Knight Cancer Institute\|National Cancer Institute (NCI)	Recurrent B-Cell Non-Hodgkin Lymphoma\|Recurrent Chronic Lymphocytic Leukemia\|Recurrent Indolent Adult Non-Hodgkin Lymphoma\|Refractory B-Cell Non-Hodgkin Lymphoma	August 2008	Phase 2
NCT01135641	Nantes University Hospital	Graft Versus Host Disease	June 2010	Phase 2
NCT00058292	Northwestern University\|National Cancer Institute (NCI)	Lymphoma	April 2000	Phase 1
NCT00208975	Emory University\|Bayer	Lymphoma	July 2002	Phase 2
NCT00005609	Eastern Cooperative Oncology Group\|National Cancer Institute (NCI)	Lymphoma	April 2000	Phase 2
NCT02747043	Amgen	Lymphoma, Non-Hodgkin	May 25, 2016	Phase 3
NCT00577278	City of Hope Medical Center\|National Cancer Institute (NCI)	Graft Versus Host Disease\|Leukemia\|Lymphoma	October 3, 2007	Phase 2
NCT00797810	University of Bologna	Acute Lymphoblastic Leukemia\|Non-Hodgkin´s Lymphoma	December 2006	Phase 4
NCT04899453	Peking Union Medical College Hospital	Primary Vitreoretinal Lymphoma	August 1, 2020	Phase 2
NCT03492125	MingSight Pharmaceuticals, Inc	Chronic Lymphocytic Leukemia\|Small Lymphocytic Lymphoma\|Aggressive Lymphoma	May 25, 2018	Phase 1\|Phase 2
NCT02282514	Northwestern University	Stiff-Person Syndrome	October 2014	Phase 1\|Phase 2
NCT05384743	Beijing Friendship Hospital	Secondary Hemophagocytic Lymphohistiocytosis\|Chronic Active Epstein-Barr Virus Infection	February 1, 2022	Phase 3
NCT05171647	Hoffmann-La Roche	Non-Hodgkin Lymphoma	April 25, 2022	Phase 3
NCT01232556	Pfizer\|UCB Pharma	Lymphoma, Non-Hodgkin	April 4, 2011	Phase 3
NCT00858117	Northwestern University\|Bayer	Leukemia	September 26, 2005	Phase 2
NCT01998880	Hoffmann-La Roche\|German CLL Study Group\|Genentech, Inc.	Lymphocytic Leukemia, Chronic	December 22, 2009	Phase 3
NCT00017381	National Cancer Institute (NCI)	Contiguous Stage II Adult Diffuse Large Cell Lymphoma\|Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma\|Contiguous Stage II Grade 1 Follicular Lymphoma\|Contiguous Stage II Grade 2 Follicular Lymphoma\|Contiguous Stage II Grade 3 Follicular Lymphoma\|Contiguous Stage II Mantle Cell Lymphoma\|Contiguous Stage II Marginal Zone Lymphoma\|Contiguous Stage II Small Lymphocytic Lymphoma\|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue\|Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma\|Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma\|Noncontiguous Stage II Grade 1 Follicular Lymphoma\|Noncontiguous Stage II Grade 2 Follicular Lymphoma\|Noncontiguous Stage II Grade 3 Follicular Lymphoma\|Noncontiguous Stage II Mantle Cell Lymphoma\|Noncontiguous Stage II Marginal Zone Lymphoma\|Noncontiguous Stage II Small Lymphocytic Lymphoma\|Recurrent Adult Diffuse Large Cell Lymphoma\|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma\|Recurrent Grade 1 Follicular Lymphoma\|Recurrent Grade 2 Follicular Lymphoma\|Recurrent Grade 3 Follicular Lymphoma\|Recurrent Mantle Cell Lymphoma\|Recurrent Marginal Zone Lymphoma\|Recurrent Small Lymphocytic Lymphoma\|Stage I Adult Diffuse Large Cell Lymphoma\|Stage I Adult Diffuse Small Cleaved Cell Lymphoma\|Stage I Grade 1 Follicular Lymphoma\|Stage I Grade 2 Follicular Lymphoma\|Stage I Grade 3 Follicular Lymphoma\|Stage I Mantle Cell Lymphoma\|Stage I Marginal Zone Lymphoma\|Stage I Small Lymphocytic Lymphoma\|Stage III Adult Diffuse Large Cell Lymphoma\|Stage III Adult Diffuse Small Cleaved Cell Lymphoma\|Stage III Grade 1 Follicular Lymphoma\|Stage III Grade 2 Follicular Lymphoma\|Stage III Grade 3 Follicular Lymphoma\|Stage III Mantle Cell Lymphoma\|Stage III Marginal Zone Lymphoma\|Stage III Small Lymphocytic Lymphoma\|Stage IV Adult Diffuse Large Cell Lymphoma\|Stage IV Adult Diffuse Small Cleaved Cell Lymphoma\|Stage IV Grade 1 Follicular Lymphoma\|Stage IV Grade 2 Follicular Lymphoma\|Stage IV Grade 3 Follicular Lymphoma\|Stage IV Mantle Cell Lymphoma\|Stage IV Marginal Zone Lymphoma\|Stage IV Small Lymphocytic Lymphoma\|Waldenström Macroglobulinemia	April 2001	Early Phase 1
NCT01200589	Novartis Pharmaceuticals\|GlaxoSmithKline\|Novartis	Non-Hodgkin´s Lymphoma	October 11, 2010	Phase 3
NCT04965493	Loxo Oncology, Inc.\|Eli Lilly and Company	Chronic Lymphocytic Leukemia\|Small Lymphocytic Lymphoma	September 20, 2021	Phase 3
NCT00120198	Geriatric Oncology Consortium\|Tibotec Pharmaceutical Limited	Non-Hodgkin´s Lymphoma	March 2005	Phase 2
NCT03636503	Dana-Farber Cancer Institute\|Pfizer	Follicular Lymphoma	October 30, 2018	Phase 1
NCT01181258	Masonic Cancer Center, University of Minnesota	Non-Hodgkin Lymphoma\|Chronic Lymphocytic Leukemia	August 2010	Phase 2
NCT02018861	Incyte Corporation	B-Cell Malignancies	September 22, 2016	Phase 1\|Phase 2
NCT00444912	Genzyme, a Sanofi Company\|Sanofi	Non-Hodgkin Lymphoma\|Hodgkin Disease	February 2006	Phase 2
NCT01406782	Eastern Cooperative Oncology Group\|National Cancer Institute (NCI)	Lymphoma	December 13, 2011
NCT00129090	German High-Grade Non-Hodgkin´s Lymphoma Study Group\|Deutsche Krebshilfe e.V., Bonn (Germany)	Non-Hodgkin´s Lymphoma (NHL)	March 2003	Phase 3
NCT05392257	Qingdao Central Hospital	Overall Survival	May 1, 2022	Phase 2
NCT00748644	Assistance Publique - Hôpitaux de Paris	Wegener Granulomatosis\|Microscopic Polyangiitis	October 2008	Phase 3
NCT00908583	University of Cincinnati\|Millennium Pharmaceuticals, Inc.	HLA Sensitization	May 2009	Phase 4
NCT00475423	Hoffmann-La Roche	Idiopathic Thrombocytopenic Purpura	May 2007	Phase 2
NCT05023980	Loxo Oncology, Inc.\|Eli Lilly and Company	Chronic Lymphocytic Leukemia\|Small Lymphocytic Lymphoma	September 23, 2021	Phase 3
NCT03920722	Assistance Publique - Hôpitaux de Paris\|French Vasculitis Study Group	Microscopic Polyangiitis (MPA)	October 24, 2020	Phase 3
NCT03598725	Beijing Children´s Hospital	Hemophilia A With Inhibitor	January 1, 2016	Phase 4
NCT02594384	AI Therapeutics, Inc.	Lymphoma, Non-Hodgkin; Leukemia, Chronic Lymphocytic	October 2015	Phase 1
NCT00412594	M.D. Anderson Cancer Center\|National Cancer Institute (NCI)	Hairy Cell Leukemia\|Recurrent Hairy Cell Leukemia	June 10, 2004	Phase 2
NCT00891839	Cephalon\|Teva Branded Pharmaceutical Products R&D, Inc.	Mantle Cell Lymphoma	June 2009	Phase 2
NCT01456351	University of Giessen	Non-Hodgkin´s Lymphoma\|Mantle Cell Lymphoma	September 2003	Phase 3
NCT04660799	Hoffmann-La Roche	Lymphoma, Large B-Cell, Diffuse	February 24, 2021	Phase 2
NCT04425824	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	Diffuse Large B-cell Lymphoma\|Rituximab\|Toripalimab	June 15, 2020	Phase 2
NCT00067002	M.D. Anderson Cancer Center\|National Cancer Institute (NCI)\|Cellgenix	Leukemia, Lymphocytic, Acute\|Leukemia, Myelocytic, Acute\|Leukemia, Myeloid, Chronic\|Lymphoma, Non-Hodgkin	April 2003	Phase 2
NCT02950051	German CLL Study Group\|Janssen-Cilag Ltd.\|Hoffmann-La Roche\|AbbVie\|Stichting Hemato-Oncologie voor Volwassenen Nederland\|Nordic CLL Study Group (NCLLSG)\|Swiss Group for Clinical Cancer Research\|Cancer Trials Ireland\|Israeli CLL Study Group	Chronic Lymphocytic Leukemia	December 13, 2016	Phase 3
NCT00070447	National Cancer Institute (NCI)	Lymphoma	November 2003	Phase 2
NCT00715208	Millennium Pharmaceuticals, Inc.	Relapsed Follicular Lymphoma	September 2008	Phase 2
NCT02536664	Hoffmann-La Roche	Follicular Lymphoma	September 2009
NCT04765111	M.D. Anderson Cancer Center	Mantle Cell Lymphoma	June 30, 2021	Phase 2
NCT00601718	University of Washington\|National Cancer Institute (NCI)	Adult Nasal Type Extranodal NK+T-cell Lymphoma\|Anaplastic Large Cell Lymphoma\|Angioimmunoblastic T-cell Lymphoma\|Contiguous Stage II Mantle Cell Lymphoma\|Cutaneous B-cell Non-Hodgkin Lymphoma\|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue\|Nodal Marginal Zone B-cell Lymphoma\|Noncontiguous Stage II Mantle Cell Lymphoma\|Recurrent Adult Burkitt Lymphoma\|Recurrent Adult Diffuse Large Cell Lymphoma\|Recurrent Adult Diffuse Mixed Cell Lymphoma\|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma\|Recurrent Adult Grade III Lymphomatoid Granulomatosis\|Recurrent Adult Hodgkin Lymphoma\|Recurrent Adult Immunoblastic Large Cell Lymphoma\|Recurrent Adult Lymphoblastic Lymphoma\|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma\|Recurrent Grade 1 Follicular Lymphoma\|Recurrent Grade 2 Follicular Lymphoma\|Recurrent Grade 3 Follicular Lymphoma\|Recurrent Mantle Cell Lymphoma\|Recurrent Marginal Zone Lymphoma\|Recurrent Mycosis Fungoides+Sezary Syndrome\|Recurrent Small Lymphocytic Lymphoma\|Splenic Marginal Zone Lymphoma\|Stage I Cutaneous T-cell Non-Hodgkin Lymphoma\|Stage I Mantle Cell Lymphoma\|Stage I Mycosis Fungoides+Sezary Syndrome\|Stage II Cutaneous T-cell Non-Hodgkin Lymphoma\|Stage II Mycosis Fungoides+Sezary Syndrome\|Stage III Cutaneous T-cell Non-Hodgkin Lymphoma\|Stage III Mantle Cell Lymphoma\|Stage III Mycosis Fungoides+Sezary Syndrome\|Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma\|Stage IV Mantle Cell Lymphoma\|Stage IV Mycosis Fungoides+Sezary Syndrome\|Waldenström Macroglobulinemia	December 2007	Phase 1\|Phase 2
NCT00169468	Lymphoma Study Association\|Association pour le Développement de la Recherche Clinique et Informatique en Onco-Hématologie	B Cell Lymphoma	January 2005	Phase 2
NCT00476229	M.D. Anderson Cancer Center\|Genzyme, a Sanofi Company	Lymphoma\|Leukemia	June 2006	Not Applicable
NCT00398372	Stanford University\|Amgen\|National Institutes of Health (NIH)	Lymphoma, Non-Hodgkin\|Lymphomas: Non-Hodgkin\|Lymphomas: Non-Hodgkin Cutaneous Lymphoma\|Lymphomas: Non-Hodgkin Diffuse Large B-Cell\|Lymphomas: Non-Hodgkin Follicular + Indolent B-Cell\|Lymphomas: Non-Hodgkin Mantle Cell\|Lymphomas: Non-Hodgkin Marginal Zone\|Lymphomas: Non-Hodgkin Peripheral T-Cell\|Lymphomas: Non-Hodgkin Waldenstr Macroglobulinemia	November 2000	Not Applicable
NCT02732236	Dong-A University Hospital	Lymphoma, B-Cell, Marginal Zone	March 2013
NCT03684980	Memorial Sloan Kettering Cancer Center\|University of Alabama at Birmingham	Central Nervous System Lymphoma	November 14, 2018	Early Phase 1
NCT04762160	Epizyme, Inc.\|Swedish Cancer Institute	Follicular Lymphoma	February 3, 2021	Phase 2
NCT00450801	University of Miami	Lymphoma	April 2004	Phase 2
NCT00568815	Fudan University	Lymphoma	April 2007	Phase 2
NCT00831597	Pharmatech\|Cephalon	Diffuse Large B-Cell Lymphoma	November 2008	Phase 2
NCT00251394	Dana-Farber Cancer Institute\|Dynavax Technologies Corporation\|James P. Wilmot Cancer Center\|University of Rochester\|Brigham and Women´s Hospital\|Massachusetts General Hospital	Non-Hodgkin´s Lymphoma	July 2004	Phase 2
NCT00785330	Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH\|University Hospital Goettingen\|German High-Grade Non-Hodgkin´s Lymphoma Study Group	Non-Hodgkin´s Lymphoma	April 2004	Phase 2
NCT03740529	Loxo Oncology, Inc.\|Eli Lilly and Company	Chronic Lymphocytic Leukemia\|Waldenstrom Macroglobulinemia\|Mantle Cell Lymphoma\|Marginal Zone Lymphoma\|B-cell Lymphoma\|Small Lymphocytic Lymphoma	November 16, 2018	Phase 1\|Phase 2
NCT04507477	University Health Network, Toronto	Epstein-Barr Virus Infections\|Post-transplant Lymphoproliferative Disorder	July 7, 2020	Phase 1\|Phase 2
NCT03151044	FENG Ji-feng\|Chinese Anti-Cancer Association\|Jiangsu Cancer Institute & Hospital	Diffuse Large B-cell Lymphoma	July 2016	Phase 3
NCT03013218	ALX Oncology Inc.	Metastatic Cancer\|Solid Tumor\|Advanced Cancer\|NonHodgkin Lymphoma	February 3, 2017	Phase 1
NCT01830478	Gruppo Italiano Studio Linfomi	Indolent Non Hodgkin Lymphoma	April 2009	Phase 2
NCT02779283	OHSU Knight Cancer Institute\|National Cancer Institute (NCI)	Acute Lymphoblastic Leukemia\|Acute Myeloid Leukemia	January 13, 2016	Phase 1
NCT00565331	Radboud University Medical Center\|Hoffmann-La Roche\|Astellas Pharma GmbH	Kidney Transplantation	December 2007	Phase 2\|Phase 3
NCT01054781	Samsung Medical Center	Diffuse Large B-cell Lymphoma (DLBCL)	January 2009	Phase 2
NCT02073097	Case Comprehensive Cancer Center	Contiguous Stage II Adult Diffuse Large Cell Lymphoma\|Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma\|Stage I Adult Diffuse Large Cell Lymphoma\|Stage III Adult Diffuse Large Cell Lymphoma\|Stage IV Adult Diffuse Large Cell Lymphoma	January 28, 2015	Phase 1\|Phase 2
NCT00369707	Northwestern University\|Robert H. Lurie Cancer Center	Non-Hodgkin´s Lymphoma	August 9, 2006	Phase 2
NCT00901927	M.D. Anderson Cancer Center\|Cephalon	Follicular Lymphoma	May 2009	Phase 2
NCT00036491	National Institute of Allergy and Infectious Diseases (NIAID)\|Autoimmunity Centers of Excellence	Lupus Erythematosus, Systemic	January 2001	Phase 1\|Phase 2
NCT00005959	Amgen\|National Cancer Institute (NCI)	Lymphoma	December 1999	Phase 2
NCT00104299	National Institute of Allergy and Infectious Diseases (NIAID)\|Immune Tolerance Network (ITN)\|Genentech, Inc.	Vasculitis\|Wegener´s Granulomatosis\|Microscopic Polyangiitis	January 2005	Phase 2\|Phase 3
NCT02110394	Astellas Pharma Europe B.V.\|Astellas Pharma Inc	Chronic Lymphocytic Leukemia	June 2012
NCT00443651	Genentech, Inc.\|Biogen	Rheumatoid Arthritis	January 2007	Phase 3
NCT00001586	National Cancer Institute (NCI)\|National Institutes of Health Clinical Center (CC)	Chronic Lymphocytic Leukemia	September 1997	Phase 2
NCT00921414	French Innovative Leukemia Organisation\|Lymphoma Study Association	Mantle Cell Lymphoma	September 2008	Phase 3
NCT03808610	M.D. Anderson Cancer Center\|National Cancer Institute (NCI)	Recurrent B Acute Lymphoblastic Leukemia\|Recurrent T Acute Lymphoblastic Leukemia\|Refractory B Acute Lymphoblastic Leukemia\|Refractory T Acute Lymphoblastic Leukemia	April 3, 2019	Phase 1\|Phase 2
NCT00413959	Oncology Specialists, S.C.\|Millennium Pharmaceuticals, Inc.	Lymphoma, Non-Hodgkin\|Lymphoma, B-Cell	August 2006	Phase 2
NCT01117662	Hannover Medical School\|German Federal Ministry of Education and Research	Acute Rejection	May 2012	Phase 3
NCT01478542	Universität des Saarlandes\|German High-Grade Non-Hodgkin´s Lymphoma Study Group\|Spectrum Pharmaceuticals, Inc	CD20&addition; Aggressive B-Cell Lymphoma	November 2011	Phase 3
NCT00117156	Dana-Farber Cancer Institute\|Beth Israel Deaconess Medical Center\|Massachusetts General Hospital\|University of Rochester\|Genentech, Inc.\|Biogen	Lymphoma, Non-Hodgkin\|MALT Lymphoma	December 2003	Phase 2
NCT00003659	Memorial Sloan Kettering Cancer Center\|National Cancer Institute (NCI)	Leukemia	September 1998	Phase 2
NCT00427791	M.D. Anderson Cancer Center	Leukemia	July 2005	Phase 2
NCT05179733	Ruijin Hospital\|Wuhan Union Hospital, China\|Ningbo No. 1 Hospital\|National Naval Medical Center\|Shanghai Fengxian District Central Hospital\|YANCHENG NO.1 PEOPLE´S HOSPITAL\|The First Affiliated Hospital of Nanchang University\|Affiliated Hospital of Nantong University\|Wuxi Branch of Ruijin Hospital\|Sir Run Run Shaw Hospital\|Northern Jiangsu Province People´s Hospital\|The First People´s Hospital of Changde City\|The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School\|Changzhou No.2 People´s Hospital\|The Affiliated Hospital of Xuzhou Medical University\|Huai´an First People´s Hospital\|Taizhou Hospital\|The First people´s Hospital of Kunshan\|First Affiliated Hospital of Fujian Medical University\|Huadong Hospital\|Henan Provincial People´s Hospital\|First Hospital of China Medical University	Diffuse Large B-Cell Lymphoma	March 2, 2022	Phase 3
NCT00114738	National Cancer Institute (NCI)\|National Institutes of Health Clinical Center (CC)	Lymphoma, Mantle Cell\|Mantle Cell Lymphoma	June 15, 2005	Phase 2
NCT04220008	M.D. Anderson Cancer Center\|National Cancer Institute (NCI)	Recurrent Aggressive Non-Hodgkin Lymphoma\|Recurrent B-Cell Non-Hodgkin Lymphoma\|Recurrent Burkitt Lymphoma\|Recurrent Diffuse Large B-Cell Lymphoma\|Recurrent High Grade B-Cell Lymphoma\|Recurrent T-Cell Non-Hodgkin Lymphoma\|Recurrent Transformed B-Cell Non-Hodgkin Lymphoma	June 1, 2023	Phase 2
NCT01679119	University College, London\|Pfizer\|Cancer Research UK	Diffuse Large B Cell Lymphoma	October 2013	Phase 2
NCT03161054	Fondazione Italiana Linfomi ONLUS	Aggressive Non-Hodgkin Lymphoma	September 12, 2017	Phase 2
NCT02491398	Gruppo Italiano Malattie EMatologiche dell´Adulto	Chronic Lymphocytic Leukemia	February 2016
NCT00591630	M.D. Anderson Cancer Center	Diffuse Large Cell Lymphoma\|Lymphoma	November 14, 2007	Phase 2
NCT05018520	Ruijin Hospital	Diffuse Large B Cell Lymphoma	September 17, 2021	Phase 3
NCT03274492	Hoffmann-La Roche	Diffuse Large B-Cell Lymphoma	November 16, 2017	Phase 3
NCT04668365	Henan Cancer Hospital	Diffuse Large B Cell Lymphoma\|CD79A Gene Mutation\|CD79B Gene Mutation	December 25, 2020	Phase 2
NCT00001805	National Cancer Institute (NCI)\|National Institutes of Health Clinical Center (CC)	Breast Neoplasms\|Colonic Neoplasms\|Lung Neoplasms\|Pancreatic Neoplasms\|Stomach Neoplasms	March 1999	Phase 2
NCT00193466	SCRI Development Innovations, LLC\|Bayer	Non-Hodgkins Lymphoma	January 2002	Phase 2
NCT01810926	Franco Locatelli\|University of Milano Bicocca\|medac GmbH\|Fresenius AG\|Bambino Gesù Hospital and Research Institute	Graft Versus Host Disease	September 2011	Phase 2
NCT02632396	Emory University\|Millennium Pharmaceuticals, Inc.	Mantle Cell Lymphoma	March 1, 2016	Phase 1\|Phase 2
NCT02594163	Seagen Inc.	Diffuse Large B-cell Lymphoma Refractory\|Follicular B-cell Non-Hodgkin´s Lymphoma	October 2015	Phase 2
NCT04279938	Royal Marsden NHS Foundation Trust\|Merck Sharp & Dohme LLC\|Mundipharma-EDO GmbH	Relapsed or Refractory Diffuse Large B-cell Lymphoma	September 2018	Phase 1
NCT02419469	M.D. Anderson Cancer Center\|Jazz Pharmaceuticals	Leukemia\|Precursor-B Acute Lymphoblastic Leukemia\|Lymphoblastic Lymphoma\|Lymphoma	November 13, 2015	Phase 2
NCT03697512	International Extranodal Lymphoma Study Group (IELSG)	Marginal Zone Lymphoma\|Nodal Marginal Zone Lymphoma\|Splenic Marginal Zone Lymphoma	September 27, 2019	Phase 2
NCT01316523	University of California, Davis\|Celgene	Non Hodgkin´s Lymphoma	December 2010	Phase 2
NCT02757196	Peking University People´s Hospital\|Beijing Hospital	Immune Thrombocytopenia	May 2016	Phase 2
NCT00641095	University College, London\|Cancer Research UK	Lymphoma	December 7, 2006	Phase 2\|Phase 3
NCT03064867	Molly Gallogly\|Case Comprehensive Cancer Center	Diffuse Large B-cell-lymphoma	June 26, 2017	Phase 1\|Phase 2
NCT00556192	Chinese University of Hong Kong	Systemic Lupus Erythematosus	June 2006	Phase 2
NCT01493479	The Christie NHS Foundation Trust\|Bayer	Follicular Lymphoma	June 6, 2007	Phase 2
NCT04688151	National Health Research Institutes, Taiwan\|National Taiwan University Hospital\|National Cheng-Kung University Hospital\|China Medical University Hospital\|Chang Gung Memorial Hospital	Primary Central Nervous System Lymphoma (PCNSL)	February 1, 2021	Phase 1
NCT00363636	Biogen	Lymphoma, Non-Hodgkin´s	September 2006	Phase 3
NCT00055640	Case Comprehensive Cancer Center\|National Cancer Institute (NCI)	Lymphoma	October 2002	Phase 2
NCT03069703	Assistance Publique - Hôpitaux de Paris\|EUCLID Clinical Trial Platform\|Recherche Clinique Paris Descartes Necker Cochin Sainte Anne\|CIC 1417 Cochin-Pasteur\|Groupe Français d´Etude des Vascularites (GFEV)	Invasive Pneumococcal Infection	February 5, 2018	Phase 2
NCT03507348	University Hospital, Grenoble	End-stage Renal Disease\|Kidney Transplantation\|Hla-incompatible Kidney Transplant Candidates	July 1, 2018	Not Applicable
NCT03164473	Assistance Publique - Hôpitaux de Paris\|French Vasculitis Study Group	Eosinophilic Granulomatosis With Polyangiitis	March 7, 2018	Phase 4
NCT00425802	Memorial Sloan Kettering Cancer Center\|National Cancer Institute (NCI)	Leukemia\|Lymphoma	November 28, 2006	Phase 2
NCT00537290	Hospital for Special Surgery, New York\|Genentech, Inc.	Antiphospholipid Syndrome	September 2007	Phase 2
NCT04023071	Fate Therapeutics	Acute Myelogenous Leukemia\|B-cell Lymphoma	October 4, 2019	Phase 1
NCT05615974	LaNova Medicines Limited	Malignant Tumors	January 2023	Phase 1\|Phase 2
NCT00127569	French National Agency for Research on AIDS and Viral Hepatitis\|Hoffmann-La Roche	HIV Infections\|Giant Lymph Node Hyperplasia	May 2003	Phase 2
NCT01419665	Sandoz\|Novartis Pharmaceuticals	Follicular Lymphoma	December 1, 2011	Phase 3
NCT04004819	First Affiliated Hospital of Fujian Medical University	HTLV-1-associated Myelopathy	August 15, 2019	Phase 2
NCT00003595	National Cancer Institute (NCI)	Lymphoma	January 1999	Phase 3
NCT02229942	Haukeland University Hospital\|The Research Council of Norway\|Norwegian Department of Health and Social Affairs\|The Kavli Foundation\|Oslo University Hospital\|Trondheim University Hospital\|University Hospital of North Norway\|Sykehuset Telemark\|MEandYou Foundation\|The Norwegian ME association	Chronic Fatigue Syndrome+ Myalgic Encephalitis (CFS+ME)	September 2014	Phase 3
NCT02427620	M.D. Anderson Cancer Center\|National Cancer Institute (NCI)	Blastoid Variant Mantle Cell Lymphoma\|Mantle Cell Lymphoma\|Pleomorphic Variant Mantle Cell Lymphoma	June 3, 2015	Phase 2
NCT00651755	M.D. Anderson Cancer Center\|Merck Sharp & Dohme LLC	Lymphoma	March 2008	Not Applicable
NCT00269113	Hoffmann-La Roche	Non-Hodgkin´s Lymphoma	September 1998	Phase 3
NCT03304288	Peking University People´s Hospital\|Beijing Hospital\|Navy General Hospital, Beijing\|Beijing Tongren Hospital	Immune Thrombocytopenia	October 11, 2017	Phase 2
NCT00476164	King´s College London\|Medical Research Council\|Roche Pharma AG	Kidney Transplantation\|Graft Rejection\|Immunosuppression	January 2007	Phase 4
NCT02232386	Gruppo Italiano Malattie EMatologiche dell´Adulto	Chronic Lymphocyte Leukemia\|Adult Patients	February 2015	Phase 2
NCT00628238	Chronic Lymphocytic Leukemia Research Consortium\|Celgene Corporation	Chronic Lymphocytic Leukemia\|CLL\|Untreated\|Front-line\|First-Line\|Initial Therapy	February 2008	Phase 2
NCT03749018	David Bond, MD\|Bristol-Myers Squibb\|Ohio State University Comprehensive Cancer Center	Aggressive Non-Hodgkin Lymphoma\|Ann Arbor Stage I Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma\|Ann Arbor Stage II B-Cell Non-Hodgkin Lymphoma\|Ann Arbor Stage II Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma\|Ann Arbor Stage III B-Cell Non-Hodgkin Lymphoma\|Ann Arbor Stage III Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma\|Ann Arbor Stage IV B-Cell Non-Hodgkin Lymphoma\|Ann Arbor Stage IV Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma\|Diffuse Large B-Cell Lymphoma\|High Grade B-Cell Lymphoma With MYC and BCL2 and+or BCL6 Rearrangements\|High Grade B-Cell Lymphoma, Not Otherwise Specified\|Indolent Non-Hodgkin Lymphoma\|Mediastinal B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma\|Transformed Non-Hodgkin Lymphoma	January 2, 2019	Phase 2
NCT03321643	National Cancer Institute (NCI)	Recurrent Diffuse Large B-Cell Lymphoma\|Recurrent Transformed Non-Hodgkin Lymphoma\|Refractory Diffuse Large B-Cell Lymphoma\|Refractory Transformed Non-Hodgkin Lymphoma\|Richter Syndrome\|Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma	March 7, 2018	Phase 1
NCT04609046	National Cancer Institute (NCI)	Central Nervous System Lymphoma\|Diffuse Large B-Cell Lymphoma	January 15, 2021	Phase 1
NCT03788291	University of Rochester	Chronic Lymphocytic Leukemia (CLL)\|Small Lymphocytic Lymphoma (SLL)	March 25, 2019	Phase 2
NCT02877303	M.D. Anderson Cancer Center\|National Cancer Institute (NCI)	B Acute Lymphoblastic Leukemia\|B Lymphoblastic Lymphoma	November 1, 2016	Phase 2
NCT02436707	Canadian Cancer Trials Group\|Janssen, LP\|Roche Pharma AG\|Karyopharm Therapeutics Inc	Lymphoma	May 5, 2015	Phase 2
NCT03983018	Region Örebro County\|Örebro University, Sweden	Schizophrenia Spectrum and Other Psychotic Disorders\|Treatment-resistant Schizophrenia	August 7, 2019	Phase 1
NCT04531865	Children´s Hospital of Fudan University\|Xinhua Hospital, Shanghai Jiao Tong University School of Medicine\|Shanghai Children´s Medical Center\|Shanghai Children´s Hospital	Frequently Relapsing Nephrotic Syndrome\|Steroid-Dependent Nephrotic Syndrome	January 1, 2021	Phase 3
NCT05498259	The First Affiliated Hospital of Soochow University	Diffuse Large B-Cell Lymphoma	July 27, 2022	Phase 2
NCT00669877	M.D. Anderson Cancer Center	Burkitt´s Lymphoma\|Burkitt´S-like Lymphoma	August 2002	Phase 2
NCT00074438	Genentech, Inc.\|Roche Pharma AG	Rheumatoid Arthritis	June 2003	Phase 2
NCT02649504	Weill Medical College of Cornell University	Immune Thrombocytopenia	December 1, 2016	Phase 3
NCT00770562	Hoffmann-La Roche	Idiopathic Thrombocytopenic Purpura	July 2005	Phase 3
NCT03432741	Mayo Clinic\|National Cancer Institute (NCI)	Breast Adenocarcinoma\|Metastatic Breast Carcinoma\|Recurrent Breast Carcinoma\|Recurrent Hodgkin Lymphoma\|Recurrent Mycosis Fungoides\|Recurrent Non-Hodgkin Lymphoma\|Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma\|Refractory Breast Carcinoma\|Refractory Hodgkin Lymphoma\|Refractory Mycosis Fungoides\|Refractory Nodal Marginal Zone Lymphoma\|Refractory Non-Hodgkin Lymphoma\|Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma\|Stage IV Breast Cancer AJCC v6 and v7	March 27, 2018	Phase 1
NCT00543114	Dana-Farber Cancer Institute\|Brigham and Women´s Hospital\|Massachusetts General Hospital\|Beth Israel Deaconess Medical Center\|Celgene Corporation	Chronic Lymphocytic Leukemia\|Small Lymphocytic Leukemia	October 2007	Phase 1
NCT00588822	Mayo Clinic\|Genentech, Inc.\|Biogen\|National Center for Research Resources (NCRR)	Precancerous Condition	January 2005	Phase 2
NCT02772822	Sinocelltech Ltd.	Diffuse Large B Cell Lymphoma	June 2016	Phase 3
NCT01472562	Weill Medical College of Cornell University\|Celgene	Mantle Cell Lymphoma	July 29, 2011	Phase 2
NCT00142155	Dana-Farber Cancer Institute	Waldenstrom´s Macroglobulinemia	January 2002	Not Applicable
NCT00689169	Lymphoma Study Association\|Bayer	Lymphoma, Large Cell, Diffuse	August 2007	Phase 2
NCT00161564	Weill Medical College of Cornell University\|Genentech, Inc.	Idiopathic Thrombocytopenic Purpura (ITP)	February 2004	Phase 2
NCT01959698	Roswell Park Cancer Institute\|National Cancer Institute (NCI)\|Amgen	CD20 Positive\|Recurrent Diffuse Large B-Cell Lymphoma\|Refractory Diffuse Large B-Cell Lymphoma\|Stage I Diffuse Large B-Cell Lymphoma\|Stage II Diffuse Large B-Cell Lymphoma\|Stage III Diffuse Large B-Cell Lymphoma\|Stage IV Diffuse Large B-Cell Lymphoma	April 17, 2014	Phase 1
NCT00732498	University of Arizona\|National Cancer Institute (NCI)	Lymphoma	May 15, 2006	Phase 2
NCT00250718	New Mexico Cancer Care Alliance	Non-Hodgkin´s Lymphoma\|Cancer	October 2004	Phase 2
NCT01453205	MedImmune LLC	Diffuse Large B-Cell Lymphoma	February 27, 2012	Phase 2
NCT00907751	Assistance Publique - Hôpitaux de Paris	Thrombotic Thrombocytopenic Purpura	May 2010	Phase 2
NCT04529772	Acerta Pharma BV\|AstraZeneca	Diffuse Large B-Cell Lymphoma	October 8, 2020	Phase 3
NCT05600686	Joseph Tuscano\|National Cancer Institute (NCI)\|ADC Therapeutics\|University of California, Davis	Double-Expressor Lymphoma\|High Grade B-Cell Lymphoma With MYC and BCL2 and+or BCL6 Rearrangements\|High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements\|High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements	December 1, 2022	Phase 2
NCT01855750	Janssen Research & Development, LLC\|Pharmacyclics LLC.	Lymphoma	September 3, 2013	Phase 3
NCT00818961	Northside Hospital, Inc.\|Blood and Marrow Transplant Group of Georgia	Leukemia\|Lymphoma\|Myelodysplastic Syndromes\|Myelodysplastic+Myeloproliferative Diseases	May 2005	Phase 2
NCT00637832	University of Southampton	Lymphoma	April 1, 2008	Phase 2
NCT00267865	National Cancer Institute (NCI)\|National Institutes of Health Clinical Center (CC)	AIDS-Related-Primary Central Nervous System Lymphoma	September 14, 2006	Phase 2
NCT05376319	Mayo Clinic	Granulomatosis With Polyangiitis\|Microscopic Polyangiitis\|ANCA Associated Vasculitis	November 2022	Phase 2
NCT03789240	National Cancer Institute (NCI)\|National Institutes of Health Clinical Center (CC)	Follicular Lymphoma\|Non-Hodgkin´s Lymphoma\|NHL	August 22, 2019	Phase 2
NCT00096044	Roswell Park Cancer Institute\|Celgene	Leukemia	March 2004	Phase 2
NCT02285062	Celgene	Lymphoma, Large B-Cell, Diffuse	January 21, 2015	Phase 3
NCT00671658	M.D. Anderson Cancer Center	Leukemia\|Acute Lymphoblastic Leukemia	November 2002	Phase 2
NCT01290549	Genentech, Inc.	Non-Hodgkins Lymphoma\|Chronic Lymphocytic Leukemia	March 22, 2011	Phase 1
NCT00416819	University of California, San Francisco\|National Cancer Institute (NCI)	Brain and Central Nervous System Tumors\|Lymphoma	September 2003	Not Applicable
NCT01088048	Gilead Sciences	Indolent Non-Hodgkin´s Lymphoma\|Chronic Lymphocytic Leukemia\|Mantle Cell Lymphoma	March 25, 2010	Phase 1
NCT00306670	Georgetown University\|Genentech, Inc.	Hemophilia A	April 2006	Phase 2\|Phase 3
NCT00076752	National Cancer Institute (NCI)\|National Institutes of Health Clinical Center (CC)	Lupus Erythematosus, Systemic	January 30, 2004	Phase 2
NCT00799773	HealthCore-NERI\|National Heart, Lung, and Blood Institute (NHLBI)\|Genentech, Inc.	Thrombotic Thrombocytopenic Purpura	April 2009	Phase 3
NCT00383994	M.D. Anderson Cancer Center\|Bayer Healthcare Pharmaceuticals, Inc.+Bayer Schering Pharma	Lymphoma\|Leukemia\|Transplantation, Stem Cell\|Lymphoid Malignancies\|Disorder Related to Transplantation	September 2006	Phase 1
NCT04128176	University of California, Davis	Bullous Pemphigoid	May 25, 2023	Phase 3
NCT02871869	Xinjiang Medical University	Diffuse, Large B-Cell, Lymphoma	September 2016	Phase 2\|Phase 3
NCT00472056	M.D. Anderson Cancer Center	Lymphoma	March 2005	Phase 2
NCT03458260	The Lymphoma Academic Research Organisation	Aggressive Non-Hodgkin Lymphoma	March 26, 2018	Phase 2
NCT02545959	Centre Hospitalier de PAU\|University Hospital, Bordeaux	Multiple Sclerosis, Chronic Progressive\|Nervous System Diseases	November 30, 2015	Phase 2
NCT01044745	University of Nebraska\|National Cancer Institute (NCI)	Accelerated Phase Chronic Myelogenous Leukemia\|Adult Acute Lymphoblastic Leukemia in Remission\|Adult Acute Myeloid Leukemia in Remission\|Adult Nasal Type Extranodal NK+T-cell Lymphoma\|Blastic Phase Chronic Myelogenous Leukemia\|Contiguous Stage II Adult Burkitt Lymphoma\|Contiguous Stage II Adult Diffuse Large Cell Lymphoma\|Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma\|Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma\|Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma\|Contiguous Stage II Adult Lymphoblastic Lymphoma\|Contiguous Stage II Grade 1 Follicular Lymphoma\|Contiguous Stage II Grade 2 Follicular Lymphoma\|Contiguous Stage II Grade 3 Follicular Lymphoma\|Contiguous Stage II Mantle Cell Lymphoma\|Contiguous Stage II Marginal Zone Lymphoma\|Contiguous Stage II Small Lymphocytic Lymphoma\|de Novo Myelodysplastic Syndromes\|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue\|Graft Versus Host Disease\|Nodal Marginal Zone B-cell Lymphoma\|Noncontiguous Stage II Adult Burkitt Lymphoma\|Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma\|Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma\|Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma\|Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma\|Noncontiguous Stage II Adult Lymphoblastic Lymphoma\|Noncontiguous Stage II Grade 1 Follicular Lymphoma\|Noncontiguous Stage II Grade 2 Follicular Lymphoma\|Noncontiguous Stage II Grade 3 Follicular Lymphoma\|Noncontiguous Stage II Mantle Cell Lymphoma\|Noncontiguous Stage II Marginal Zone Lymphoma\|Noncontiguous Stage II Small Lymphocytic Lymphoma\|Previously Treated Myelodysplastic Syndromes\|Recurrent Adult Acute Lymphoblastic Leukemia\|Recurrent Adult Acute Myeloid Leukemia\|Recurrent Adult Burkitt Lymphoma\|Recurrent Adult Diffuse Large Cell Lymphoma\|Recurrent Adult Diffuse Mixed Cell Lymphoma\|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma\|Recurrent Adult Grade III Lymphomatoid Granulomatosis\|Recurrent Adult Immunoblastic Large Cell Lymphoma\|Recurrent Adult Lymphoblastic Lymphoma\|Recurrent Adult T-cell Leukemia+Lymphoma\|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma\|Recurrent Grade 1 Follicular Lymphoma\|Recurrent Grade 2 Follicular Lymphoma\|Recurrent Grade 3 Follicular Lymphoma\|Recurrent Mantle Cell Lymphoma\|Recurrent Marginal Zone Lymphoma\|Recurrent Mycosis Fungoides+Sezary Syndrome\|Recurrent Small Lymphocytic Lymphoma\|Refractory Chronic Lymphocytic Leukemia\|Relapsing Chronic Myelogenous Leukemia\|Secondary Myelodysplastic Syndromes\|Splenic Marginal Zone Lymphoma\|Stage I Adult Burkitt Lymphoma\|Stage I Adult Diffuse Large Cell Lymphoma\|Stage I Adult Diffuse Mixed Cell Lymphoma\|Stage I Adult Diffuse Small Cleaved Cell Lymphoma\|Stage I Adult Immunoblastic Large Cell Lymphoma\|Stage I Adult Lymphoblastic Lymphoma\|Stage I Adult T-cell Leukemia+Lymphoma\|Stage I Chronic Lymphocytic Leukemia\|Stage I Cutaneous T-cell Non-Hodgkin Lymphoma\|Stage I Grade 1 Follicular Lymphoma\|Stage I Grade 2 Follicular Lymphoma\|Stage I Grade 3 Follicular Lymphoma\|Stage I Mantle Cell Lymphoma\|Stage I Marginal Zone Lymphoma\|Stage I Mycosis Fungoides+Sezary Syndrome\|Stage I Small Lymphocytic Lymphoma\|Stage II Adult T-cell Leukemia+Lymphoma\|Stage II Chronic Lymphocytic Leukemia\|Stage II Cutaneous T-cell Non-Hodgkin Lymphoma\|Stage II Mycosis Fungoides+Sezary Syndrome\|Stage III Adult Burkitt Lymphoma\|Stage III Adult Diffuse Large Cell Lymphoma\|Stage III Adult Diffuse Mixed Cell Lymphoma\|Stage III Adult Diffuse Small Cleaved Cell Lymphoma\|Stage III Adult Immunoblastic Large Cell Lymphoma\|Stage III Adult Lymphoblastic Lymphoma\|Stage III Adult T-cell Leukemia+Lymphoma\|Stage III Chronic Lymphocytic Leukemia\|Stage III Cutaneous T-cell Non-Hodgkin Lymphoma\|Stage III Grade 1 Follicular Lymphoma\|Stage III Grade 2 Follicular Lymphoma\|Stage III Grade 3 Follicular Lymphoma\|Stage III Mantle Cell Lymphoma\|Stage III Marginal Zone Lymphoma\|Stage III Mycosis Fungoides+Sezary Syndrome\|Stage III Small Lymphocytic Lymphoma\|Stage IV Adult Burkitt Lymphoma\|Stage IV Adult Diffuse Large Cell Lymphoma\|Stage IV Adult Diffuse Mixed Cell Lymphoma\|Stage IV Adult Diffuse Small Cleaved Cell Lymphoma\|Stage IV Adult Immunoblastic Large Cell Lymphoma\|Stage IV Adult Lymphoblastic Lymphoma\|Stage IV Adult T-cell Leukemia+Lymphoma\|Stage IV Chronic Lymphocytic Leukemia\|Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma\|Stage IV Grade 1 Follicular Lymphoma\|Stage IV Grade 2 Follicular Lymphoma\|Stage IV Grade 3 Follicular Lymphoma\|Stage IV Mantle Cell Lymphoma\|Stage IV Marginal Zone Lymphoma\|Stage IV Mycosis Fungoides+Sezary Syndrome\|Stage IV Small Lymphocytic Lymphoma\|Untreated Adult Acute Lymphoblastic Leukemia\|Untreated Adult Acute Myeloid Leukemia\|Waldenström Macroglobulinemia	December 2009	Phase 2
NCT03002038	Isfahan University of Medical Sciences	Neuromyelitis Optica Spectrum Disorder	September 2015	Phase 2\|Phase 3
NCT00151281	Weill Medical College of Cornell University	Non-Hodgkin´s Lymphoma	November 2004	Phase 2
NCT01185262	MD Anderson International Spain SA\|Celgene Corporation	Chronic Lymphocytic Leukemia	April 2009	Phase 1
NCT02406092	Hoffmann-La Roche	Non-Hodgkin Lymphoma	October 13, 2015	Phase 3
NCT00690560	Centre Antoine Lacassagne	Lymphoma	May 2007	Phase 2
NCT00720135	City of Hope Medical Center\|National Cancer Institute (NCI)	Anaplastic Large Cell Lymphoma\|Cutaneous B-cell Non-Hodgkin Lymphoma\|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue\|Intraocular Lymphoma\|Nodal Marginal Zone B-cell Lymphoma\|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma\|Recurrent Adult Grade III Lymphomatoid Granulomatosis\|Recurrent Grade 1 Follicular Lymphoma\|Recurrent Grade 2 Follicular Lymphoma\|Recurrent Marginal Zone Lymphoma\|Small Intestine Lymphoma\|Splenic Marginal Zone Lymphoma\|Testicular Lymphoma\|Waldenstrom Macroglobulinemia	January 2008	Phase 1
NCT00801281	Polish Lymphoma Research Group	Follicular Lymphoma\|Marginal Zone Lymphoma\|Small Lymphocytic Lymphoma\|Lymphoplasmacytic Lymphoma	February 2007	Phase 3
NCT00392834	AIDS Malignancy Consortium\|National Cancer Institute (NCI)\|The Emmes Company, LLC	Lymphoma	September 2006	Phase 2
NCT01423539	Genentech, Inc.\|AbbVie (prior sponsor, Abbott)	Diffuse Large B-Cell Lymphoma	October 2011	Phase 2
NCT01742988	Curis, Inc.\|The Leukemia and Lymphoma Society	Lymphoma\|Relapsed Lymphoma\|Refractory Lymphoma\|Relapsed and+or Refractory Lymphoma\|Relapsed Ddiffuse Large B-Cell Lymphoma (DLBCL)\|Refractory Diffuse Large B-Cell Lymphoma (DLBCL)\|Relapsed and+or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)\|Double-hit Lymphoma (DHL)\|Triple-hit Lymphoma (THL)\|Double-expressor Lymphoma (DEL)\|High-grade B-cell Lymphoma (HGBL)	December 2012	Phase 1
NCT00689845	University Hospital Southampton NHS Foundation Trust\|National Cancer Institute (NCI)	Lymphoma	June 2007	Not Applicable
NCT04688788	Rigshospitalet, Denmark\|Odense University Hospital\|Aarhus University Hospital\|Aalborg University Hospital\|Herlev Hospital\|Hillerod Hospital, Denmark\|Zealand University Hospital\|Kolding Sygehus\|Regional Hospital Holstebro\|Hvidovre University Hospital\|Hospital of South West Jutland, Esbjerg, Denmark\|GCP unit, Copenhagen University Hospital\|GCP-unit at Aarhus University Hospital, Aarhus, Denmark\|Hospital of Southern Jutland, Sønderborg, Denmark\|Hospital of Central Denmark Region, Viborg, Denmark\|Danske Regioner	Relapsing Remitting Multiple Sclerosis\|Secondary Progressive Multiple Sclerosis\|Primary Progressive Multiple Sclerosis	April 28, 2021	Phase 3
NCT00290407	University of Louisville\|James Graham Brown Cancer Center	Leukemia, Lymphocytic, Chronic\|Lymphoma, Small Lymphocytic	March 2006	Phase 2
NCT03003520	Celgene	Lymphoma, Large B-Cell, Diffuse	February 28, 2017	Phase 2
NCT02472756	Hoffmann-La Roche	Lymphoma, Follicular	September 19, 2008
NCT00071396	M.D. Anderson Cancer Center\|Bayer	Chronic Lymphocytic Leukemia	October 2002	Phase 2
NCT01161628	Northside Hospital, Inc.\|Blood and Marrow Transplant Group of Georgia	Chronic Graft-versus-host Disease	April 2011	Phase 2
NCT02048813	National Cancer Institute (NCI)	Anemia\|Chronic Lymphocytic Leukemia\|Small Lymphocytic Lymphoma	February 20, 2014	Phase 3
NCT02042391	Diako Ev. Diakonie-Krankenhaus gemeinnützige GmbH	Posttransplant Lymphoproliferative Disorder	February 3, 2015	Phase 2
NCT00029107	National Institute of Allergy and Infectious Diseases (NIAID)\|National Institutes of Health Clinical Center (CC)	Hepatitis C\|Vasculitis	December 2001	Phase 2
NCT00031902	Lymphoma Trials Office\|National Cancer Institute (NCI)	Lymphoma	October 2001	Phase 1
NCT05040906	Shandong New Time Pharmaceutical Co., LTD	Recruiting	October 13, 2020	Phase 3
NCT00425932	Gaylis, Norman B., M.D.\|Oklahoma Medical Research Foundation\|Genentech, Inc.	Rheumatoid Arthritis	February 2007	Phase 2
NCT01359592	Southwest Oncology Group\|National Cancer Institute (NCI)	Lymphoma	September 2011	Phase 2
NCT03440567	City of Hope Medical Center\|National Cancer Institute (NCI)	Recurrent Diffuse Large B-Cell Lymphoma\|Recurrent Mantle Cell Lymphoma\|Refractory Diffuse Large B-Cell Lymphoma\|Refractory Mantle Cell Lymphoma\|Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma	April 2, 2018	Phase 1
NCT03892421	La Raza Medical Center	Relapsed Non Hodgkin Lymphoma\|Refractory Non-Hodgkin Lymphoma	April 5, 2018	Phase 1\|Phase 2
NCT00079443	National Cancer Institute (NCI)	Recurrent Grade 1 Follicular Lymphoma\|Recurrent Grade 2 Follicular Lymphoma\|Recurrent Small Lymphocytic Lymphoma	January 2004	Phase 2
NCT01644253	Aptevo Therapeutics	Chronic Lymphocytic Leukemia\|Peripheral T-cell Lymphoma	September 2012	Phase 1
NCT00307125	National Institute of Allergy and Infectious Diseases (NIAID)\|Clinical Trials in Organ Transplantation\|Cooperative Clinical Trials in Pediatric Transplantation (CCTPT)	Kidney Transplant\|Kidney Transplant Recipient\|Graft Function+Survival\|de Novo HLA Antibodies Development	March 2006	Phase 2
NCT00482053	Stanford University	Lymphoma, B-cell\|Lymphoma, Non-Hodgkin\|Diffuse Large B-cell Lymphoma (DLBCL)\|Malignant Lymphoma, Non-Hodgkin	October 2006	Phase 2
NCT00003248	Alliance for Clinical Trials in Oncology\|National Cancer Institute (NCI)	Leukemia	March 1998	Phase 2
NCT00022971	National Cancer Institute (NCI)\|National Institutes of Health Clinical Center (CC)	Diffuse Large B-Cell Lymphoma\|Follicular Lymphoma\|Chronic Lymphocytic Leukemia\|Mantle Cell Lymphoma\|Small Lymphocytic Lymphoma	August 15, 2001	Phase 1
NCT01334502	Alliance for Clinical Trials in Oncology\|National Cancer Institute (NCI)	Lymphoma	March 2012	Phase 1
NCT00531089	Hamilton Health Sciences Corporation\|Canadian Apheresis Group\|Hoffmann-La Roche\|McMaster University	Thrombotic Thrombocytopenic Purpura\|Hemolytic Uremic Syndrome	December 2007	Phase 2
NCT01345708	Fondazione IRCCS Ca´ Granda, Ospedale Maggiore Policlinico\|University Hospital, Udine, Italy	Autoimmune Hemolytic Disease (Cold Type) (Warm Type)	January 2009	Phase 2
NCT02391545	SecuraBio	CD20&addition; Follicular Lymphoma	December 2014	Phase 1\|Phase 2
NCT02622503	Hoffmann-La Roche	Rheumatoid Arthritis	April 2008
NCT01087151	Genentech, Inc.\|AbbVie (prior sponsor, Abbott)	Chronic Lymphocytic Leukemia	August 2010	Phase 2
NCT01178086	Hoffmann-La Roche	Lymphocytic Leukemia, Chronic	February 22, 2010
NCT01611090	Janssen Research & Development, LLC\|Pharmacyclics LLC.	Chronic Lymphocytic Leukemia\|Small Lymphocytic Lymphoma	September 19, 2012	Phase 3
NCT01186458	Hoosier Cancer Research Network\|Genentech, Inc.\|Millennium Pharmaceuticals, Inc.	Lymphoma, Non-Hodgkin	October 2010	Phase 2
NCT04033276	Seoul National University Hospital\|Severance Hospital\|GC Biopharma Corp	Renal Transplant	January 8, 2019	Phase 4
NCT01292603	Hoffmann-La Roche	Lymphocytic Leukemia, Chronic	April 18, 2011	Phase 1
NCT00081861	M.D. Anderson Cancer Center\|Genentech, Inc.	Lymphoma	March 2004	Phase 2
NCT00036855	National Cancer Institute (NCI)	AIDS-related Peripheral+Systemic Lymphoma\|AIDS-related Primary CNS Lymphoma\|Post-transplant Lymphoproliferative Disorder\|Recurrent Childhood Large Cell Lymphoma\|Recurrent Childhood Lymphoblastic Lymphoma\|Recurrent Childhood Small Noncleaved Cell Lymphoma\|Recurrent+Refractory Childhood Hodgkin Lymphoma	June 2002	Phase 1
NCT01078974	Steven P. Treon, MD, PhD\|Celgene Corporation\|Dana-Farber Cancer Institute	Waldenstrom´s Macroglobulinemia	May 2010	Phase 1
NCT02584920	Shanghai Henlius Biotech	B-cell Non Hodgkin´s Lymphoma	October 2014	Phase 1\|Phase 2
NCT00845832	Hoffmann-La Roche	Rheumatoid Arthritis	March 2009	Phase 2
NCT02251548	Dana-Farber Cancer Institute\|Pharmacyclics LLC.\|The Leukemia and Lymphoma Society\|Blood Cancer Research Partnership	Chronic Lymphocytic Leukemia\|Leukemia	October 2014	Phase 2
NCT01193842	National Cancer Institute (NCI)	AIDS-Related Plasmablastic Lymphoma\|AIDS-Related Primary Effusion Lymphoma\|Ann Arbor Stage I Diffuse Large B-Cell Lymphoma\|Ann Arbor Stage I Grade 3 Follicular Lymphoma\|Ann Arbor Stage II Diffuse Large B-Cell Lymphoma\|Ann Arbor Stage II Grade 3 Contiguous Follicular Lymphoma\|Ann Arbor Stage II Grade 3 Non-Contiguous Follicular Lymphoma\|Ann Arbor Stage III Diffuse Large B-Cell Lymphoma\|Ann Arbor Stage III Grade 3 Follicular Lymphoma\|Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma\|Ann Arbor Stage IV Grade 3 Follicular Lymphoma\|HIV Infection\|Plasmablastic Lymphoma\|Primary Effusion Lymphoma\|Recurrent Diffuse Large B-Cell Lymphoma\|Recurrent Grade 3 Follicular Lymphoma	October 6, 2010	Phase 1\|Phase 2
NCT00312845	Millennium Pharmaceuticals, Inc.\|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	Non-Hodgkin´s Lymphoma	March 2006	Phase 3
NCT00422942	Hoffmann-La Roche	Rheumatoid Arthritis	January 2006	Phase 2
NCT01987505	Hoffmann-La Roche	Lymphoma, Non Hodgkin	November 11, 2013	Phase 3
NCT04480450	University of Kansas Medical Center	Chronic Inflammatory Demyelinating Polyneuropathy	July 2023	Phase 2
NCT05533775	Hoffmann-La Roche	Mature B-Cell Non-Hodgkin Lymphoma	November 30, 2022	Phase 1\|Phase 2
NCT02446457	M.D. Anderson Cancer Center\|National Cancer Institute (NCI)	Recurrent Diffuse Large B-Cell Lymphoma\|Recurrent Grade 1 Follicular Lymphoma\|Recurrent Grade 2 Follicular Lymphoma\|Recurrent Grade 3a Follicular Lymphoma	July 31, 2015	Phase 2
NCT00719472	Genentech, Inc.	Non-Hodgkin´s Lymphoma	July 2008	Phase 3
NCT02734771	Patrick Reagan\|Seagen Inc.\|University of Rochester	Diffuse Large B-Cell Lymphoma	June 2016	Phase 2
NCT05545384	Assistance Publique - Hôpitaux de Paris\|Institut National de la Santé Et de la Recherche Médicale, France	Acute Demyelinating Syndrome	November 2022	Phase 2\|Phase 3
NCT01148446	Fondazione Italiana Linfomi ONLUS	Elderly Patients (>65 Years)\|Diffuse Large B Cell Lymphoma (DLBCL)	January 2003	Phase 3
NCT01868269	Institut Curie	Opsoclonus Myoclonus Syndrome\|Neuroblastoma	April 18, 2013	Phase 3
NCT00440388	Ascenta Therapeutics	Follicular Lymphoma	October 2006	Phase 2
NCT01269385	Mayo Clinic\|National Cancer Institute (NCI)	B-cell Chronic Lymphocytic Leukemia\|Refractory Chronic Lymphocytic Leukemia\|Stage 0 Chronic Lymphocytic Leukemia\|Stage I Chronic Lymphocytic Leukemia\|Stage II Chronic Lymphocytic Leukemia	January 2011	Phase 1\|Phase 2
NCT02741388	The Lymphoma Academic Research Organisation\|Karyopharm Therapeutics Inc	B-cell Lymphoma	October 2016	Phase 1
NCT01216683	ECOG-ACRIN Cancer Research Group\|National Cancer Institute (NCI)\|Eastern Cooperative Oncology Group	Lymphoma	December 13, 2010	Phase 2
NCT01682044	Roswell Park Cancer Institute\|National Cancer Institute (NCI)	Contiguous Stage II Grade 1 Follicular Lymphoma\|Contiguous Stage II Grade 2 Follicular Lymphoma\|Contiguous Stage II Grade 3 Follicular Lymphoma\|Contiguous Stage II Marginal Zone Lymphoma\|Contiguous Stage II Small Lymphocytic Lymphoma\|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue\|Nodal Marginal Zone B-cell Lymphoma\|Noncontiguous Stage II Grade 1 Follicular Lymphoma\|Noncontiguous Stage II Grade 2 Follicular Lymphoma\|Noncontiguous Stage II Grade 3 Follicular Lymphoma\|Noncontiguous Stage II Marginal Zone Lymphoma\|Noncontiguous Stage II Small Lymphocytic Lymphoma\|Recurrent Grade 1 Follicular Lymphoma\|Recurrent Grade 2 Follicular Lymphoma\|Recurrent Grade 3 Follicular Lymphoma\|Recurrent Marginal Zone Lymphoma\|Recurrent Small Lymphocytic Lymphoma\|Splenic Marginal Zone Lymphoma\|Stage I Grade 1 Follicular Lymphoma\|Stage I Grade 2 Follicular Lymphoma\|Stage I Grade 3 Follicular Lymphoma\|Stage I Marginal Zone Lymphoma\|Stage I Small Lymphocytic Lymphoma\|Stage III Grade 1 Follicular Lymphoma\|Stage III Grade 2 Follicular Lymphoma\|Stage III Grade 3 Follicular Lymphoma\|Stage III Marginal Zone Lymphoma\|Stage III Small Lymphocytic Lymphoma\|Stage IV Grade 1 Follicular Lymphoma\|Stage IV Grade 2 Follicular Lymphoma\|Stage IV Grade 3 Follicular Lymphoma\|Stage IV Marginal Zone Lymphoma\|Stage IV Small Lymphocytic Lymphoma	April 17, 2007	Phase 2
NCT05293509	M.D. Anderson Cancer Center	Stem Cell Transplantation	September 30, 2022	Phase 2
NCT00472420	Hoffmann-La Roche	Mantle Cell Lymphoma	June 27, 2007	Phase 2
NCT04318678	St. Jude Children´s Research Hospital	AML\|B-ALL\|T-ALL\|BPDCN\|MDS	May 27, 2020	Phase 1
NCT00769522	German CLL Study Group\|Roche Pharma AG\|Mundipharma Pte Ltd.	Chronic Lymphocytic Leukemia	October 2, 2008	Phase 3
NCT00576433	Hoffmann-La Roche	Rheumatoid Arthritis	December 2007	Phase 4
NCT00433537	National Cancer Institute (NCI)	Contiguous Stage II Mantle Cell Lymphoma\|Noncontiguous Stage II Mantle Cell Lymphoma\|Stage I Mantle Cell Lymphoma\|Stage III Mantle Cell Lymphoma\|Stage IV Mantle Cell Lymphoma	May 2007	Phase 2
NCT05032183	M.D. Anderson Cancer Center	Recurrent Adult Lymphoblastic Lymphoma\|Recurrent B Acute Lymphoblastic Leukemia\|Recurrent T Acute Lymphoblastic Leukemia\|Refractory B Acute Lymphoblastic Leukemia\|Refractory Lymphoblastic Lymphoma\|Refractory T Acute Lymphoblastic Leukemia	February 17, 2022	Phase 1\|Phase 2
NCT03952637	National Human Genome Research Institute (NHGRI)\|Sio Gene Therapies\|National Institutes of Health Clinical Center (CC)	Lysosomal Diseases\|Gangliosidosis\|GM1	August 19, 2019	Phase 1\|Phase 2
NCT00578591	Baylor College of Medicine	Graft vs Host Disease\|Alogenic Hematopoietic Transplant	June 2007	Phase 2
NCT00088881	National Cancer Institute (NCI)	Contiguous Stage II Adult Diffuse Large Cell Lymphoma\|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue\|Nodal Marginal Zone B-cell Lymphoma\|Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma\|Splenic Marginal Zone Lymphoma\|Stage I Adult Diffuse Large Cell Lymphoma\|Testicular Lymphoma\|Waldenström Macroglobulinemia	December 2004	Phase 2
NCT01862926	Royal Brompton & Harefield NHS Foundation Trust\|Imperial College London\|University of East Anglia\|University College London Hospitals	Interstitial Lung Disease\|Scleroderma\|Idiopathic Inflammatory Myositis\|Mixed Connective Tissue Disease	November 2014	Phase 2\|Phase 3
NCT01889797	PrECOG, LLC.\|Genentech, Inc.	Indolent Non-Hodgkin´s Lymphoma	December 2013	Phase 2
NCT00005652	University of Alabama at Birmingham\|Office of Rare Diseases (ORD)	Purpura, Thrombocytopenic, Idiopathic	December 2000	Phase 2
NCT04872790	OHSU Knight Cancer Institute\|AbbVie\|Oregon Health and Science University	B Acute Lymphoblastic Leukemia\|B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1\|Recurrent B Acute Lymphoblastic Leukemia	October 2, 2022	Phase 1
NCT05605899	Kite, A Gilead Company\|Gilead Sciences	High-risk Large B-cell Lymphoma (LBCL)	November 2022	Phase 3
NCT04156828	University of Washington\|Bayer	Grade 3b Follicular Lymphoma\|Recurrent Diffuse Large B-Cell Lymphoma\|Recurrent Follicular Lymphoma\|Refractory Diffuse Large B-Cell Lymphoma\|Non-Hodgkin´s Lymphoma	March 31, 2020	Phase 1
NCT02654379	Hoffmann-La Roche	Off-Label Use	December 18, 2015
NCT00427856	Gemin X\|Teva Branded Pharmaceutical Products R&D, Inc.	Lymphoma, Follicular	March 2007	Phase 2
NCT04212013	Memorial Sloan Kettering Cancer Center\|Pharmacyclics LLC.	Marginal Zone Lymphoma	December 23, 2019	Phase 3
NCT00193492	SCRI Development Innovations, LLC\|Genentech, Inc.	Lymphoma, Follicular	September 2005	Phase 2
NCT01295151	Julia Brown\|University of Leeds	Rheumatoid Arthritis	August 2011	Phase 4
NCT00143065	Ohio State University Comprehensive Cancer Center	Lymphoma, Small Lymphocytic\|Lymphocytic Leukemia, Chronic	August 2005	Phase 2
NCT04120350	Peking Union Medical College Hospital\|Beijing Tiantan Hospital\|Xuanwu Hospital, Beijing\|Peking University Third Hospital\|Beijing Hospital\|Peking University First Hospital\|Chinese PLA General Hospital	Primary Central Nervous System Lymphoma	August 16, 2019	Phase 1\|Phase 2
NCT00267826	University of Bern\|Hoffmann-La Roche\|Swiss National Science Foundation	Dermatitis, Atopic	December 2005	Not Applicable
NCT01992653	Genentech, Inc.	Lymphoma, Non Hodgkin	November 29, 2013	Phase 1\|Phase 2
NCT00850499	Millennium Pharmaceuticals, Inc.\|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	Follicular Lymphoma	September 2009	Phase 2
NCT02596971	Hoffmann-La Roche	Diffuse Large B-Cell Lymphoma, Lymphoma Follicular	December 22, 2015	Phase 1\|Phase 2
NCT01701986	M.D. Anderson Cancer Center\|National Cancer Institute (NCI)	Hematopoietic Cell Transplantation Recipient\|Refractory B-Cell Non-Hodgkin Lymphoma\|Refractory Hodgkin Lymphoma\|Refractory T-Cell Non-Hodgkin Lymphoma	October 25, 2012	Phase 1\|Phase 2
NCT00422383	Hoffmann-La Roche	Rheumatoid Arthritis	February 2006	Phase 3
NCT00500058	GlaxoSmithKline	Lymphoma, Non-Hodgkin	July 31, 2007	Phase 1
NCT00004179	European Organisation for Research and Treatment of Cancer - EORTC\|Lymphoma Trials Office\|Stichting Hemato-Oncologie voor Volwassenen Nederland\|Australasian Leukaemia and Lymphoma Group\|NCIC Clinical Trials Group\|Nordic Lymphoma Group	Lymphoma	May 1999	Phase 3
NCT00430352	Hoffmann-La Roche	Non-Hodgkin´s Lymphoma	September 4, 2006	Phase 4
NCT00946023	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	Lymphoma\|B-cell Lymphoma\|Non Hodgkin Lymphoma\|Chronic Lymphocytic Leukemia	July 2009	Phase 2
NCT00448019	M.D. Anderson Cancer Center\|Genentech, Inc.	Chronic Lymphocytic Leukemia	February 2007	Phase 2
NCT05398224	Peking University	Secondary Central Nervous System Lymphoma	February 26, 2021	Phase 2
NCT00547534	University of Rochester\|Millennium Pharmaceuticals, Inc.\|Cephalon	Non-Hodgkin´s Lymphoma	October 2007	Phase 2
NCT00379431	University Hospital, Ghent	Early and Severe Systemic Sclerosis	November 2006	Phase 2
NCT00544219	Swiss Group for Clinical Cancer Research	Lymphoma	September 2007	Not Applicable
NCT04323956	Mayo Clinic\|National Cancer Institute (NCI)	Ann Arbor Stage II Diffuse Large B-Cell Lymphoma\|Ann Arbor Stage II Follicular Lymphoma\|Ann Arbor Stage II Marginal Zone Lymphoma\|Ann Arbor Stage III Diffuse Large B-Cell Lymphoma\|Ann Arbor Stage III Follicular Lymphoma\|Ann Arbor Stage III Marginal Zone Lymphoma\|Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma\|Ann Arbor Stage IV Follicular Lymphoma\|Ann Arbor Stage IV Marginal Zone Lymphoma\|Diffuse Large B-Cell Lymphoma\|High Grade B-Cell Lymphoma With MYC and BCL2 and+or BCL6 Rearrangements\|High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements\|High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements\|Indolent Non-Hodgkin Lymphoma	June 15, 2020	Phase 1
NCT00346684	University of Cologne	Lymphocyte Predominant Hodgkin´s Lymphoma (LPHD)	July 2006	Phase 2
NCT01382940	Hoffmann-La Roche	Rheumatoid Arthritis	July 26, 2011	Phase 4
NCT02200848	Georgetown University\|National Cancer Institute (NCI)	Chronic Lymphocytic Leukemia\|Small Lymphocytic Lymphoma	April 2014	Phase 1
NCT04994626	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	DLBCL\|MYD88 Gene Mutation\|CD79A Gene Mutation\|CD79B Gene Mutation\|Relapse\|Refractory Lymphoma	October 1, 2021	Phase 2
NCT00562328	Mayo Clinic\|National Cancer Institute (NCI)	Leukemia	January 2008	Phase 2
NCT00361621	Dana-Farber Cancer Institute\|Brigham and Women´s Hospital\|Millennium Pharmaceuticals, Inc.	Non-Hodgkin´s Lymphoma	July 2006	Phase 2
NCT05049473	PETHEMA Foundation\|Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea	Mature B-Cell Leukemia Burkitt Type\|Burkitt Lymphoma (BL)\|Unclassifiable Lymphoma Between DCBL and BL	January 2014	Phase 2
NCT01731561	Assistance Publique - Hôpitaux de Paris	Granulomatosis With Polyangiitis\|Microscopic Polyangiitis\|Renal Limited Forms	November 16, 2012	Phase 3
NCT02787239	Shanghai Henlius Biotech	B-cell Non Hodgkin´s Lymphoma	October 2015	Phase 3
NCT03630211	Paul Szabolcs\|University of Pittsburgh	Systemic Sclerosis\|Diffuse Sclerosis Systemic\|Interstitial Lung Disease\|Pulmonary Hypertension	July 31, 2018	Phase 2
NCT01145495	National Cancer Institute (NCI)	Ann Arbor Stage II Grade 1 Contiguous Follicular Lymphoma\|Ann Arbor Stage II Grade 1 Non-Contiguous Follicular Lymphoma\|Ann Arbor Stage II Grade 2 Contiguous Follicular Lymphoma\|Ann Arbor Stage II Grade 2 Non-Contiguous Follicular Lymphoma\|Ann Arbor Stage II Grade 3 Contiguous Follicular Lymphoma\|Ann Arbor Stage II Grade 3 Non-Contiguous Follicular Lymphoma\|Ann Arbor Stage III Grade 1 Follicular Lymphoma\|Ann Arbor Stage III Grade 2 Follicular Lymphoma\|Ann Arbor Stage III Grade 3 Follicular Lymphoma\|Ann Arbor Stage IV Grade 1 Follicular Lymphoma\|Ann Arbor Stage IV Grade 2 Follicular Lymphoma\|Ann Arbor Stage IV Grade 3 Follicular Lymphoma	June 15, 2010	Phase 2
NCT01446900	European Institute of Oncology	Chronic Lymphocytic Leukaemia\|Small Lymphocytic Lymphoma	January 2011	Phase 2
NCT00669318	Mayo Clinic\|National Cancer Institute (NCI)	Leukemia\|Lymphoma	July 2008	Phase 2
NCT04479267	Barbara Ann Karmanos Cancer Institute\|National Cancer Institute (NCI)	Diffuse Large B-Cell Lymphoma\|High Grade B-Cell Lymphoma w+MYC & BCL2 or BCL6 Rearrangements\|High Grade B-Cell Lymphoma w+MYC, BCL2 & BCL6 Rearrangements	August 21, 2020	Phase 2
NCT01408342	Hospital Universitario Dr. Jose E. Gonzalez	Aplastic Anemia	July 2011	Not Applicable
NCT05156710	Sanofi	Transplant Rejection	June 9, 2022	Phase 2
NCT01596127	M.D. Anderson Cancer Center	Leukemia\|Lymphoid Malignancies\|Metastatic Malignant Neoplasm to the Leptomeninges	January 24, 2013	Phase 1\|Phase 2
NCT01312064	National Taiwan University Hospital	Renal Insufficiency	April 2011	Phase 4
NCT00451178	Eli Lilly and Company	Lymphoma	May 2007	Phase 2
NCT01040871	Millennium Pharmaceuticals, Inc.\|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	Diffuse Large B-Cell Lymphoma	January 2010	Phase 2
NCT00404157	Genentech, Inc.	Lupus Nephritis		Phase 3
NCT02315326	Memorial Sloan Kettering Cancer Center\|Pharmacyclics LLC.\|Janssen Biotech, Inc.	Adult Patients With Newly Diagnosed or Relapsed or Refractory Primary Central Nervous System Lymphoma (PCNSL)\|Or Relapsed or Refractory Secondary Central Nervous System Lymphoma (SCNSL)	December 2014	Phase 1\|Phase 2
NCT01173679	Massachusetts General Hospital\|Dana-Farber Cancer Institute\|Beth Israel Deaconess Medical Center\|Bristol-Myers Squibb	Chronic Lymphocytic Leukemia\|Small Lymphocytic Lymphoma	July 2010	Phase 2
NCT04588194	David Gomez Almaguer\|Hospital Universitario Dr. Jose E. Gonzalez	Immune Thrombocytopenia\|Thrombotic Thrombocytopenic Purpura	November 1, 2020	Phase 2
NCT02617485	Mabion SA	Diffuse Large B-Cell Lymphoma	December 2015	Phase 3
NCT04745832	MEI Pharma, Inc.\|Kyowa Kirin, Inc.	Follicular Lymphoma (FL)\|Non Hodgkin Lymphoma\|Marginal Zone Lymphoma	August 13, 2021	Phase 3
NCT02631538	GlaxoSmithKline	Sjogren´s Syndrome	February 17, 2016	Phase 2
NCT05057481	Assiut University	Autoimmune Hemolytic Anemia\|Systemic Lupus Erythematosus	September 15, 2021	Phase 3
NCT03531736	Memorial Sloan Kettering Cancer Center	Myeloid Diseases	May 9, 2018	Phase 1
NCT00877214	Jurgen Barth\|Sponsor GmbH\|University of Giessen	Follicular Lymphomas\|Immunocytomas\|Marginal Zone Lymphomas\|Mantle-Cell Lymphomas\|Lymphocytic Lymphoma\|Non-Hodgkin´s Lymphoma	April 1, 2009	Phase 3
NCT00131313	East Valley Hematology and Oncology Medical Group\|Mena, Raul, M.D.\|Pharmatech Oncology\|Astex Pharmaceuticals, Inc.	Chronic Lymphocytic Leukemia	January 2003	Phase 4
NCT00425217	Mayo Clinic\|Genentech, Inc.	Membranous Nephropathy	August 2004	Phase 2\|Phase 3
NCT01686165	University of Arizona\|National Cancer Institute (NCI)	Anaplastic Large Cell Lymphoma\|Recurrent Adult Diffuse Large Cell Lymphoma\|Recurrent Mantle Cell Lymphoma	August 31, 2012	Phase 2
NCT02169219	Massachusetts General Hospital\|Genentech, Inc.	Granulomatosis With Polyangiitis\|Microscopic Polyangiitis	June 2014	Phase 4
NCT00250861	US Oncology Research\|Chiron Corporation\|Fred Hutchinson Cancer Center	Non-Hodgkin´s Lymphoma	October 2005	Phase 2
NCT00829205	Cancer Research UK\|National Cancer Institute (NCI)	Lymphoma	January 2009	Phase 1\|Phase 2
NCT00426543	University of Copenhagen\|Rigshospitalet, Denmark	Primary Sjögren´s Syndrome\|Xerostomia\|Hyposalivation\|Keratoconjunctivitis Sicca\|Fatigue	January 2007	Phase 2
NCT04585893	UNC Lineberger Comprehensive Cancer Center\|Fogarty International Center of the National Institute of Health	Multicentric Castleman Disease	June 22, 2021	Phase 2
NCT02281279	Mayo Clinic\|National Cancer Institute (NCI)	B-cell Adult Acute Lymphoblastic Leukemia\|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue\|Intraocular Lymphoma\|Nodal Marginal Zone B-cell Lymphoma\|Recurrent Adult Acute Lymphoblastic Leukemia\|Recurrent Adult Burkitt Lymphoma\|Recurrent Adult Diffuse Large Cell Lymphoma\|Recurrent Adult Diffuse Mixed Cell Lymphoma\|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma\|Recurrent Adult Grade III Lymphomatoid Granulomatosis\|Recurrent Adult Immunoblastic Large Cell Lymphoma\|Recurrent Adult Lymphoblastic Lymphoma\|Recurrent Grade 1 Follicular Lymphoma\|Recurrent Grade 2 Follicular Lymphoma\|Recurrent Grade 3 Follicular Lymphoma\|Recurrent Mantle Cell Lymphoma\|Recurrent Marginal Zone Lymphoma\|Recurrent Small Lymphocytic Lymphoma\|Refractory Hairy Cell Leukemia\|Small Intestine Lymphoma\|Splenic Marginal Zone Lymphoma\|Testicular Lymphoma\|Waldenström Macroglobulinemia	October 2016	Phase 1\|Phase 2
NCT00429065	Instituto Nacional de Cancerologia de Mexico	Non-Hodgkin Lymphoma	January 2007
NCT01458548	Charite University, Berlin, Germany	Post-transplantation Lymphoproliferative Disorder	December 2002	Phase 2
NCT00759603	M.D. Anderson Cancer Center\|Celgene Corporation	Chronic Lymphocytic Leukemia\|Small Lymphocytic Lymphoma	September 2008	Phase 2
NCT00147953	University of Cologne	Non-Hodgkin´s Lymphoma	June 2004	Phase 2
NCT05371093	Kite, A Gilead Company\|Gilead Sciences	Relapsed+Refractory Follicular Lymphoma	September 12, 2022	Phase 3
NCT00049413	Hoag Memorial Hospital Presbyterian\|Cancer Biotherapy Research Group	Leukemia\|Lymphoma	June 2002	Phase 2
NCT00109967	National Cancer Institute (NCI)	Recurrent Mantle Cell Lymphoma	May 2005	Phase 2
NCT01358253	Ruijin Hospital	Acute Lymphoblastic Leukemia	December 2010	Phase 4
NCT05076097	Tianjin Medical University Cancer Institute and Hospital	Mantle Cell Lymphoma	September 30, 2021	Phase 2
NCT03081910	Baylor College of Medicine\|Center for Cell and Gene Therapy, Baylor College of Medicine\|The Methodist Hospital Research Institute	T-cell Acute Lymphoblastic Lymphoma\|T-non-Hodgkin Lymphoma\|T-cell Acute Lymphoblastic Leukemia	November 1, 2017	Phase 1
NCT03688451	Tahir Latif\|University of Cincinnati	Non Hodgkin Lymphoma	October 29, 2018	Phase 2
NCT05136976	Centre Hospitalier Universitaire de Saint Etienne\|Ministry of Health, France	Anti-MAG Neuropathy	June 2022	Phase 3
NCT04408625	Prevail Therapeutics\|Eli Lilly and Company	Frontotemporal Dementia	November 9, 2020	Phase 1\|Phase 2
NCT03863184	Weill Medical College of Cornell University\|AstraZeneca\|Celgene Corporation	Mantle Cell Lymphoma	October 11, 2019	Phase 2
NCT03778619	GC Cell Corporation	Relapsed Non Hodgkin Lymphoma\|Refractory Non-Hodgkin Lymphoma	November 28, 2018	Phase 1\|Phase 2
NCT01702038	National Institute of Allergy and Infectious Diseases (NIAID)	Lupus Erythematosus, Systemic	September 2009	Phase 2
NCT00667329	M.D. Anderson Cancer Center	Lymphoma	July 9, 1999	Phase 1
NCT05144009	ADC Therapeutics S.A.	Diffuse Large B-cell Lymphoma	June 21, 2022	Phase 2
NCT04884035	Celgene	Lymphoma, B-Cell	September 15, 2021	Phase 1
NCT03455517	Gruppo Italiano Malattie EMatologiche dell´Adulto	Chronic Myeloid Leukemia	October 31, 2018	Phase 2
NCT00940342	M.D. Anderson Cancer Center\|Bayer	Leukemia	October 12, 2004	Phase 2
NCT05390749	Peking Union Medical College Hospital\|Beijing Tiantan Hospital\|Sanbo Brain Hospital Capital Medical University	Primary Central Nervous System Lymphoma	April 11, 2022	Phase 2
NCT02079532	Hoffmann-La Roche	Rheumatoid Arthritis	November 2006	Phase 3
NCT00493454	M.D. Anderson Cancer Center\|Biogen	Lymphoma	April 2006	Phase 2
NCT00424502	Hoffmann-La Roche	Rheumatoid Arthritis	January 2007	Phase 4
NCT03361852	Dana-Farber Cancer Institute	Follicular Lymphoma	March 14, 2022	Phase 1
NCT02790515	St. Jude Children´s Research Hospital	Acute Lymphoblastic Leukemia (ALL)\|Acute Myeloid Leukemia (AML)\|Myeloid Sarcoma\|Chronic Myeloid Leukemia (CML)\|Juvenile Myelomonocytic Leukemia (JMML)\|Myelodysplastic Syndrome (MDS)\|Non-Hodgkin Lymphoma (NHL)	July 14, 2016	Phase 2
NCT04920968	Maria Sklodowska-Curie National Research Institute of Oncology\|KCRI	CD20-positive Acute Lymphoblastic Leukemia	June 30, 2021	Phase 2
NCT02605694	SecuraBio	Lymphoma	December 2015	Phase 2
NCT02405676	Children´s Cancer Group, China\|Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science & Technology, China\|Nanjing Children´s Hospital\|West China Second University Hospital\|Xiangya Hospital of Central South University\|Qilu Hospital of Shandong University\|Children´s Hospital Of Soochow University\|Tianjin Medical University Cancer Institute and Hospital	Mature B-cell Non-Hodgkin Lymphoma	January 2015	Phase 2\|Phase 3
NCT04572620	Federal Research Institute of Pediatric Hematology, Oncology and Immunology	Interstitial Lymphocytic Lung Disease	September 7, 2020
NCT00274794	The Cleveland Clinic\|National Cancer Institute (NCI)	Lymphoma	February 2000	Not Applicable
NCT00324779	University Hospital Erlangen\|National Cancer Institute (NCI)	Leukemia\|Lymphoma	March 2004	Phase 2
NCT02752204	University of Birmingham\|Bloodwise\|AstraZeneca\|Cancer Research UK	Diffuse Large B-Cell Lymphoma	October 2015	Phase 2
NCT01471067	M.D. Anderson Cancer Center\|American Stem Cell, Inc.\|National Cancer Institute (NCI)	Blood And Marrow Transplantation\|Leukemia\|Lymphoma\|Transplantation Infection\|Transplantation, Bone Marrow	July 13, 2012	Phase 1
NCT04361279	Shanghai Institute Of Biological Products	Diffuse Large B-Cell Lymphoma	July 25, 2019	Phase 3
NCT05065554	Jorge J. Castillo, MD\|AstraZeneca\|Dana-Farber Cancer Institute	IgM MGUS\|Waldenstrom Macroglobulinemia\|Neuropathy;Peripheral	November 16, 2021	Phase 2
NCT02954406	Millennium Pharmaceuticals, Inc.\|Takeda	Lymphoma, Non-Hodgkin	March 5, 2017	Phase 1
NCT00285389	French Innovative Leukemia Organisation\|Hoffmann-La Roche	Mantle Cell Lymphoma	February 2002	Phase 2
NCT00664599	Tehran University of Medical Sciences\|Hoffmann-La Roche	Behcet´s Syndrome	April 2006	Phase 2
NCT00848692	Haukeland University Hospital	Chronic Fatigue Syndrome	June 2008	Phase 2\|Phase 3
NCT01554514	Washington University School of Medicine\|National Heart, Lung, and Blood Institute (NHLBI)	Thrombotic Thrombocytopenic Purpura	August 2012	Phase 2
NCT03269552	University of Washington\|National Cancer Institute (NCI)	Marginal Zone Lymphoma\|Recurrent Marginal Zone Lymphoma\|Recurrent Waldenstrom Macroglobulinemia\|Refractory Marginal Zone Lymphoma\|Refractory Waldenstrom Macroglobulinemia\|Waldenstrom Macroglobulinemia	December 18, 2017	Phase 2
NCT04712097	Hoffmann-La Roche	Relapsed or Refractory Follicular Lymphoma	October 27, 2021	Phase 3
NCT00598169	AIDS Malignancy Consortium\|National Cancer Institute (NCI)\|The Emmes Company, LLC	Lymphoma	November 2007	Phase 1
NCT01830465	Gruppo Italiano Studio Linfomi	Non Hodgkin´s Follicular Lymphoma	August 2006	Phase 2
NCT05191225	Laida Cuevas Palomares\|Bioaraba Health Research Institute	Non-Hodgkin´s Lymphoma	September 28, 2021	Phase 4
NCT05303792	Alliance for Clinical Trials in Oncology\|National Cancer Institute (NCI)	B Acute Lymphoblastic Leukemia\|B Lymphoblastic Lymphoma	February 2023	Phase 2
NCT00052936	German High-Grade Non-Hodgkin´s Lymphoma Study Group\|Universität des Saarlandes	Lymphoma	January 2001	Phase 3
NCT03488225	M.D. Anderson Cancer Center\|National Cancer Institute (NCI)	Acute Lymphoblastic Leukemia in Remission\|B Acute Lymphoblastic Leukemia\|B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative	March 28, 2018	Phase 2
NCT00584935	University of Alabama at Birmingham\|Genentech, Inc.\|Biogen	Ocular Cicatricial Pemphigoid	January 2006	Phase 1\|Phase 2
NCT02110706	Yale University\|National Institute of Neurological Disorders and Stroke (NINDS)	Myasthenia Gravis	May 2014	Phase 2
NCT04517435	Deepa Jagadeesh\|Case Comprehensive Cancer Center	Diffuse Large B-Cell Lymphoma	April 28, 2021	Phase 1\|Phase 2
NCT00427557	M.D. Anderson Cancer Center	Multiple Myeloma\|Leukemia\|Lymphoma	October 2006	Phase 2
NCT00293072	Cambridge University Hospitals NHS Foundation Trust\|Roche Pharma AG	Systemic Lupus Erythematosus\|ANCA Associated Vasculitis	March 2002	Phase 2
NCT00387023	M.D. Anderson Cancer Center\|Biogen	Non-Hodgkin´s Lymphoma\|Lymphoma	February 2004	Not Applicable
NCT01759030	Biocad	Rheumatoid Arthritis	December 2012	Phase 3
NCT01165112	University of Washington\|National Cancer Institute (NCI)	Recurrent Adult Diffuse Large Cell Lymphoma\|Recurrent Adult Hodgkin Lymphoma	September 2010	Phase 1\|Phase 2
NCT00281918	Hoffmann-La Roche\|German CLL Study Group	Leukemia	July 2003	Phase 3
NCT00076349	Cephalon\|Teva Branded Pharmaceutical Products R&D, Inc.	Non-Hodgkin´s Lymphoma	April 2004	Phase 2
NCT02376335	Newcastle-upon-Tyne Hospitals NHS Trust\|National Institute for Health Research, United Kingdom\|Department of Health, United Kingdom\|Newcastle University	Fatigue\|Primary Biliary Cirrhosis	October 2012	Phase 2
NCT00376961	Southwest Oncology Group\|National Cancer Institute (NCI)	Lymphoma	August 2006	Phase 2
NCT00053027	Alliance for Clinical Trials in Oncology\|National Cancer Institute (NCI)	Lymphoma	February 2003	Phase 2
NCT00251277	Weill Medical College of Cornell University\|Genentech, Inc.	Thrombotic Thrombocytopenic Purpura	November 2005	Phase 1\|Phase 2
NCT03929601	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)\|National Institutes of Health (NIH)\|Juvenile Diabetes Research Foundation	Type 1 Diabetes Mellitus	February 17, 2020	Phase 2
NCT02807103	Assistance Publique - Hôpitaux de Paris\|French Vasculitis Study Group	Eosinophilic Granulomatosis With Polyangiitis (EGPA)	December 5, 2016	Phase 3
NCT01415765	National Cancer Institute (NCI)\|National Institutes of Health Clinical Center (CC)	Lymphoma, Diffuse Large-Cell B-cell\|Diffuse, Large B-cell Lymphoma\|Lymphoma, Diffuse Large-Cell\|Large-Cell Lymphoma, Diffuse	July 15, 2011	Phase 1\|Phase 2
NCT01045889	Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia	HIV-related Lymphoma\|HIV Infections	January 2007	Phase 2
NCT02531308	Rush University Medical Center	Diffuse Large B-Cell Lymphoma	July 2015	Phase 2
NCT03942887	Leiden University Medical Center	ANCA Associated Vasculitis	May 3, 2019	Phase 3
NCT00062114	Alliance for Clinical Trials in Oncology\|National Cancer Institute (NCI)	Lymphoma	April 2004	Phase 2
NCT01865110	The Lymphoma Academic Research Organisation	Mantle Cell Lymphoma	November 2013	Phase 3
NCT00183976	University of Southern California	Non-Hodgkin´s Lymphoma\|Burkitt Lymphoma\|Primary Effusion Lymphomas	April 2005	Phase 2
NCT04737889	Henan Cancer Hospital	Primary Central Nervous System Lymphoma	January 13, 2021	Phase 2
NCT02994927	ChemoCentryx	ANCA-Associated Vasculitis	March 15, 2017	Phase 3
NCT00986947	Johns Hopkins University	Kidney Failure	September 2009	Phase 2
NCT00169169	Lymphoma Study Association	CD20-Positive Large B-Cell Lymphoma	October 1999	Phase 3
NCT04432714	The First Affiliated Hospital with Nanjing Medical University	DLBCL\|Untreated\|MYC Gene Rearrangement	June 9, 2020	Phase 1\|Phase 2
NCT00609869	H. Lee Moffitt Cancer Center and Research Institute\|Celgene Corporation	Lymphocytic Leukemia\|Mantle Cell Lymphoma	October 2007	Phase 2
NCT01569451	University of Colorado, Denver\|Rocky Mountain MS Research Group, LLC	Multiple Sclerosis	February 2012	Phase 2
NCT05495464	M.D. Anderson Cancer Center\|Kite, A Gilead Company\|Acerta Pharma, LLC	Lymphoma\|Mantle Cell Lymphoma	November 18, 2022	Early Phase 1
NCT00787722	Northwestern University	Devic´s Disease	October 10, 2009	Phase 1\|Phase 2
NCT00774462	Assistance Publique - Hôpitaux de Paris\|Institut National de la Santé Et de la Recherche Médicale, France\|Roche Pharma AG	Myositis\|Myasthenia Gravis	January 2008	Phase 2
NCT01520519	M.D. Anderson Cancer Center\|Pharmacyclics LLC.	Leukemia	February 27, 2012	Phase 2
NCT00724971	Pfizer	Lymphoma, B-Cell	July 4, 2008	Phase 1
NCT00691652	OHSU Knight Cancer Institute\|National Cancer Institute (NCI)	Lymphoma	May 2008	Phase 1\|Phase 2
NCT02356159	National Cancer Institute (NCI)\|National Institutes of Health Clinical Center (CC)	Myelodysplastic Syndrome\|Hodgkin´s Lymphoma\|Non-Hodgkin´s Lymphoma\|Acute Leukemia\|Multiple Myeloma	September 24, 2015	Phase 1\|Phase 2
NCT01724021	Hoffmann-La Roche	Diffuse Large B-Cell Lymphoma, Non-Hodgkin´s Lymphoma	December 2012	Phase 3
NCT04285268	Rutgers, The State University of New Jersey\|National Cancer Institute (NCI)	High Grade B-Cell Lymphoma, Not Otherwise Specified\|Recurrent Burkitt Lymphoma\|Recurrent Diffuse Large B-Cell Lymphoma\|Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements\|Refractory Burkitt Lymphoma\|Refractory Diffuse Large B-Cell Lymphoma\|Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements	May 6, 2020	Phase 2
NCT02266888	National Institute of Allergy and Infectious Diseases (NIAID)\|Clinical Trials in Organ Transplantation in Children\|Rho Federal Systems Division, Inc.	Lung Transplant	January 22, 2015	Phase 2
NCT01203930	Gilead Sciences	Chronic Lymphocytic Leukemia (CLL)\|Small Lymphocytic Lymphoma (SLL)	October 2010	Phase 2
NCT00227695	Swiss Group for Clinical Cancer Research	Lymphoma	June 8, 2004	Phase 3
NCT02003222	National Cancer Institute (NCI)\|Canadian Cancer Trials Group	Acute Lymphoblastic Leukemia\|B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative	December 23, 2013	Phase 3
NCT00330252	Dana-Farber Cancer Institute\|Genzyme, a Sanofi Company	Chronic Lymphocytic Leukemia	May 2006	Phase 1
NCT04745728	Peking Union Medical College Hospital	Idiopathic Membranous Nephropathy	April 14, 2021	Phase 3
NCT02569996	Hoffmann-La Roche	Lymphoma, Follicular	July 2005	Phase 3
NCT02652468	University of Wisconsin, Madison	Lymphoma	March 10, 2016	Not Applicable
NCT00734773	Northwestern University\|Pharmacyclics LLC.	Brain and Central Nervous System Tumors\|Lymphoma\|Neurotoxicity	November 2008	Early Phase 1
NCT02728531	Washington University School of Medicine	Mantle Cell Lymphoma	April 18, 2016	Phase 1
NCT04047797	M.D. Anderson Cancer Center\|National Cancer Institute (NCI)	Recurrent Mantle Cell Lymphoma\|Refractory Mantle Cell Lymphoma	August 28, 2019	Phase 2
NCT02446236	Hackensack Meridian Health	Mantle Cell Lymphoma	June 18, 2015	Phase 1
NCT05207358	Institutul Clinic Fundeni	Lupus Nephritis	March 2, 2022	Phase 4
NCT04416451	Memorial Sloan Kettering Cancer Center\|AbbVie	Marginal Zone Lymphoma	May 4, 2021	Phase 2
NCT03967925	Rachel Jones\|GlaxoSmithKline\|Medical Research Council\|Imperial College London\|University College, London\|Newcastle University\|University of Glasgow\|University of Cambridge\|Cambridge University Hospitals NHS Foundation Trust	ANCA Associated Vasculitis\|Granulomatosis With Polyangiitis	February 1, 2019	Phase 2
NCT00299104	Genentech, Inc.\|Hoffmann-La Roche	Rheumatoid Arthritis	January 2006	Phase 3
NCT00169156	Lymphoma Study Association\|Hoffmann-La Roche	Untreated T-cell Angioimmunoblastic Lymphoma	December 2005	Phase 2
NCT03078855	Jonathan Friedberg\|National Institutes of Health (NIH)\|National Cancer Institute (NCI)\|University of Rochester	Follicular Lymphoma\|Small Lymphocytic Lymphoma\|Marginal Zone Lymphoma\|Mucosal-Associated Lymphoid Tissue Lymphoma	September 7, 2017	Phase 3
NCT00210353	International Extranodal Lymphoma Study Group (IELSG)	Lymphoma, Mucosa-Associated Lymphoid Tissue	January 2003	Phase 3
NCT01773616	Imperial College London\|Karolinska Institutet\|Ohio State University\|Dutch Working Party on Systemic Lupus Erythematosus\|EULAR Lupus Nephritis Trial Network Study Group	Systemic Lupus Erythematosus, Lupus Nephritis	April 2015	Phase 3
NCT01594229	AbbVie\|Genentech, Inc.	Non-Hodgkin´s Lymphoma	May 21, 2012	Phase 1
NCT00654732	M.D. Anderson Cancer Center\|National Cancer Institute (NCI)	Classic Hodgkin Lymphoma\|Lugano Classification Stage III Hodgkin Lymphoma AJCC v8\|Lugano Classification Stage IV Hodgkin Lymphoma AJCC v8	March 19, 2008	Phase 2
NCT01429025	Alliance for Clinical Trials in Oncology\|National Cancer Institute (NCI)\|Celgene Corporation	Refractory+Relapsed Indolent Non-Hodgkin Lymphoma	May 2012	Phase 1
NCT02314403	Massachusetts General Hospital	Kidney Failure, Chronic\|Renal Insufficiency	February 2015	Phase 1
NCT02541565	University of Washington\|National Cancer Institute (NCI)	Composite Lymphoma\|Grade 3b Follicular Lymphoma\|Stage I Diffuse Large B-Cell Lymphoma\|Stage I Follicular Lymphoma\|Stage II Diffuse Large B-Cell Lymphoma\|Stage II Follicular Lymphoma\|Stage III Diffuse Large B-Cell Lymphoma\|Stage III Follicular Lymphoma\|Stage IV Diffuse Large B-Cell Lymphoma\|Stage IV Follicular Lymphoma	November 24, 2015	Phase 1
NCT04680052	Incyte Corporation	Follicular Lymphoma\|Marginal Zone Lymphoma	April 15, 2021	Phase 3
NCT00117975	Alliance for Clinical Trials in Oncology\|National Cancer Institute (NCI)	Lymphoma	June 2005	Phase 2
NCT02468791	Mabion SA	Rheumatoid Arthritis	May 2013	Phase 3
NCT00298272	Biogen\|Hoffmann-La Roche\|Genentech, Inc.	Rheumatoid Arthritis	May 2006	Phase 2
NCT00972101	M.D. Anderson Cancer Center	Stem Cell Transplantation\|Leukemia\|Lymphoma\|Pediatric Disorders	September 2009	Phase 1
NCT01153971	Hoffmann-La Roche	Non-Hodgkin´s Lymphoma	July 20, 2005	Phase 2
NCT02055820	Hoffmann-La Roche\|AbbVie	Lymphoma, Non-Hodgkin	November 17, 2013	Phase 1\|Phase 2
NCT01253460	M.D. Anderson Cancer Center\|Cyclacel Pharmaceuticals, Inc.\|National Cancer Institute (NCI)	Leukemia	August 22, 2011	Phase 2
NCT00636155	David Rizzieri\|Eleos, Inc.\|Duke University	Lymphoma, Small Lymphocytic\|Leukemia, Lymphocytic, Chronic	February 2008	Phase 2
NCT00695409	City of Hope Medical Center\|National Cancer Institute (NCI)	Lymphoma	March 18, 2008	Phase 2
NCT02980042	University of Colorado, Denver	Multiple Sclerosis	January 1, 2017	Phase 3
NCT05221645	University of Southampton\|Merck Sharp & Dohme LLC	Diffuse Large B Cell Lymphoma	June 27, 2022	Phase 2
NCT01956695	Institut Curie\|Centre Hospitalier Universitaire, Amiens\|Institut Bergonié\|University Hospital, Clermont-Ferrand\|University Hospital, Lille\|Central Hospital, Nancy, France\|Groupe Hospitalier Pitie-Salpetriere\|Centre Henri Becquerel\|University Hospital, Tours\|Centre Leon Berard\|University Hospital, Grenoble	Lymphoma\|Relapse	September 18, 2013	Phase 2
NCT01737177	Fondazione Italiana Linfomi ONLUS	Mantle Cell Lymphoma	July 31, 2012	Phase 2
NCT01282476	Massachusetts General Hospital\|Dana-Farber Cancer Institute\|Beth Israel Deaconess Medical Center	Diffuse Large B Cell Lymphoma	June 2011	Phase 2
NCT05283720	AbbVie\|Genmab	Non-Hodgkin Lymphoma	June 14, 2022	Phase 2
NCT01059786	National Cancer Institute (NCI)\|National Institutes of Health Clinical Center (CC)	Hairy Cell Leukemia	July 1, 2010	Phase 2
NCT03864185	Nagoya University\|Japan Agency for Medical Research and Development\|Zenyaku Kogyo Co., Ltd.	Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)	March 28, 2019	Phase 2
NCT00261612	Medical University of Vienna	Lymphoma, Mantle-Cell	January 2005	Phase 2
NCT03336333	BeiGene	Chronic Lymphocytic Leukemia\|Small Lymphocytic Lymphoma	November 2, 2017	Phase 3
NCT00020800	Jonsson Comprehensive Cancer Center\|National Cancer Institute (NCI)	Lymphoma	September 2001	Phase 2
NCT02135874	M.D. Anderson Cancer Center\|National Cancer Institute (NCI)	Acute Bilineal Leukemia\|Acute Biphenotypic Leukemia\|Acute Leukemia of Ambiguous Lineage\|Acute Undifferentiated Leukemia\|Mixed Phenotype Acute Leukemia\|Mixed Phenotype Acute Leukemia, B+Myeloid, Not Otherwise Specified\|Mixed Phenotype Acute Leukemia, T+Myeloid, Not Otherwise Specified\|Recurrent Mixed Phenotype Acute Leukemia	October 27, 2014	Phase 2
NCT01534949	Celltrion	Diffuse Large B-Cell Lymphoma	February 2012	Phase 1
NCT02417129	Boehringer Ingelheim	Lymphoma, Non-Hodgkin	April 2015	Phase 3
NCT03121677	Washington University School of Medicine	Follicular Lymphoma	October 16, 2018	Phase 1
NCT00004112	University of Nebraska\|National Cancer Institute (NCI)	Lymphoma	September 1999	Phase 3
NCT03805932	National Cancer Institute (NCI)\|National Institutes of Health Clinical Center (CC)	Hairy Cell Leukemia	October 3, 2019	Phase 1
NCT04061512	University College, London\|Janssen-Cilag Ltd.	Waldenstrom Macroglobulinemia	February 3, 2020	Phase 2\|Phase 3
NCT00807196	Maisonneuve-Rosemont Hospital\|Bayer	Non-Hodgkins Lymphoma	September 2008	Phase 1\|Phase 2
NCT00738374	Hoffmann-La Roche	Lymphocytic Leukemia, Chronic	November 3, 2008	Phase 2
NCT04790903	Hoffmann-La Roche	Lymphoma, Large B-Cell, Diffuse	July 2, 2021	Phase 1
NCT02501473	Immune Design\|Merck Sharp & Dohme LLC	Follicular Low Grade Non-Hodgkin´s Lymphoma	February 3, 2016	Phase 1\|Phase 2
NCT00392691	Swiss Group for Clinical Cancer Research	Lymphoma	October 2006	Phase 1
NCT01926639	Oslo University Hospital\|Norwegian Cancer Society\|Helse Sor-Ost	Follicular Lymphoma	October 2009	Phase 2
NCT00726700	Universität des Saarlandes	Lymphoma	May 2004	Phase 2
NCT02858804	Institute of Hematology & Blood Diseases Hospital	Mantle Cell Lymphoma	January 2016	Phase 4
NCT04245722	Fate Therapeutics	Lymphoma, B-Cell\|Chronic Lymphocytic Leukemia	March 19, 2020	Phase 1
NCT04182204	Hoffmann-La Roche	Diffuse Large B-Cell Lymphoma	February 7, 2020	Phase 3
NCT00012298	National Cancer Institute (NCI)	Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue\|Nodal Marginal Zone B-cell Lymphoma\|Recurrent Grade 1 Follicular Lymphoma\|Recurrent Grade 2 Follicular Lymphoma\|Recurrent Grade 3 Follicular Lymphoma\|Recurrent Marginal Zone Lymphoma\|Recurrent Small Lymphocytic Lymphoma\|Splenic Marginal Zone Lymphoma\|Waldenström Macroglobulinemia	April 2001	Phase 1\|Phase 2
NCT00436280	Eli Lilly and Company	Lymphoma, Large Cell, Diffuse	February 2007	Phase 2
NCT00410982	M.D. Anderson Cancer Center	Leukemia\|Lymphoma\|Myeloma	December 2006	Phase 1
NCT01279616	Nationwide Children´s Hospital	Sickle Cell Disease	September 2010	Phase 2
NCT00855205	University of Cincinnati\|University of Chicago	Sarcoidosis	July 2009	Phase 2
NCT05099471	University of Ulm\|Institute for Medical Informatics, Biometry and Epidemiology, University of Munich\|Zentrum für Klinische Studien Ulm\|AbbVie\|Pfizer\|University Hospital Schleswig-Holstein, Campus Kiel	Waldenstrom Macroglobulinemia	March 2023	Phase 2
NCT00180895	Gustave Roussy, Cancer Campus, Grand Paris\|Hoffmann-La Roche	Burkitt Lymphoma	June 2004	Phase 2
NCT02914938	MEI Pharma, Inc.	Chronic Lymphocytic Leukemia (CLL)\|Small Lymphocytic Lymphoma (SLL)\|Follicular Lymphoma (FL)\|Marginal Zone B Cell Lymphoma\|Diffuse Large B-cell Lymphoma (DLBCL)\|High Grade Non-Hodgkin´s Lymphoma\|Mantle Cell Lymphoma (MCL)	October 2016	Phase 1
NCT01299857	University Hospital, Rouen	Pemphigus	June 2011	Phase 3
NCT00142168	Dana-Farber Cancer Institute\|Beth Israel Deaconess Medical Center\|Brigham and Women´s Hospital\|Celgene Corporation\|Genentech, Inc.	Waldenstrom´s Macroglobulinemia	September 2004	Phase 2
NCT02453087	Hoffmann-La Roche	Non-Hodgkin´s Lymphoma	August 4, 2015	Phase 1
NCT00182650	City of Hope Medical Center\|National Cancer Institute (NCI)	Lymphoma	June 2004	Phase 1
NCT02682641	Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea\|Janssen-Cilag, S.A.	Mantle Cell Lymphoma	May 18, 2016	Phase 2
NCT00385125	University of Magdeburg	Lymphoma, High-Grade	August 2004	Phase 2
NCT00504777	Hoffmann-La Roche	Rheumatoid Arthritis	July 2007	Phase 4
NCT02267915	Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea	Mantle-cell Lymphoma	March 2015	Phase 2
NCT03295383	University Hospital, Rouen	Severe Forms of Mucous Membrane Pemphigoid	July 11, 2019	Phase 3
NCT03571321	University of Chicago\|Incyte Corporation	Acute Lymphoblastic Leukemia\|ALL, Childhood\|ALL	May 28, 2019	Phase 1
NCT00582166	University of Wisconsin, Madison\|Genentech, Inc.	Non-Hodgkin´s Lymphoma	January 25, 2005	Phase 2
NCT01234766	Dartmouth-Hitchcock Medical Center\|Cephalon\|Spectrum Pharmaceuticals, Inc	Lymphoma, Follicular	October 2010	Phase 2
NCT01388959	Hoffmann-La Roche	Non-Hodgkin´s Lymphoma	November 1998	Phase 2
NCT00435955	Azienda Ospedaliera San Giovanni Battista\|University of Turin, Italy\|Gruppo Italiano Trapianto di Midollo Osseo\|Gruppo Italiano Studio Linfomi\|Hoffmann-La Roche	Follicular Lymphoma	March 2000	Phase 3
NCT00892827	Wolfson Medical Center	Advanced Refractory Chronic Lymphocytic Leukemia	April 2009	Phase 2
NCT04673617	Artiva Biotherapeutics, Inc.	Non Hodgkin Lymphoma	March 29, 2021	Phase 1\|Phase 2
NCT03414502	University of Nebraska	Rheumatoid Arthritis	August 2007	Phase 3
NCT04419389	Aprea Therapeutics	Non Hodgkin Lymphoma\|Chronic Lymphocytic Leukemia\|Mantle Cell Lymphoma	March 2, 2021	Phase 1\|Phase 2
NCT00039130	Alliance for Clinical Trials in Oncology\|National Cancer Institute (NCI)	Leukemia\|Lymphoma	May 2002	Phase 2
NCT02951156	Pfizer\|EMD Serono	Diffuse Large B-Cell Lymphoma	December 16, 2016	Phase 3
NCT02086175	Dana-Farber Cancer Institute\|HiberCell, Inc.	Relapsed+Refractory Indolent B Cell Non-Hodgkin Lymphomas	December 2014	Phase 2
NCT01206777	Ohio State University Comprehensive Cancer Center	Indolent or Intermediate Grade B-cell Malignancy	October 2010	Phase 2
NCT01118845	SymBio Pharmaceuticals	Non-Hodgkin´s Lymphoma\|Lymphoma, Large Cell\|Diffuse, Mantle Cell Lymphoma, Lymphoma\|Follicular Lymphoma\|Large B-Cell, Diffuse	April 2010	Phase 2
NCT03258866	Shandong University	Purpura, Thrombocytopenic, Idiopathic\|Immune Thrombocytopenia	January 1, 2010	Phase 4
NCT03520920	BeiGene	Marginal Zone Lymphoma\|Follicular Lymphoma\|Diffuse Large B-Cell Lymphoma	January 4, 2018	Phase 2
NCT01974440	Janssen Research & Development, LLC\|Pharmacyclics LLC.	Lymphoma	January 31, 2014	Phase 3
NCT01539512	Gilead Sciences	Chronic Lymphocytic Leukemia	April 2012	Phase 3
NCT04856137	National Health Research Institutes, Taiwan\|Taipei Veterans General Hospital, Taiwan\|Chang Gung Memorial Hospital\|China Medical University Hospital\|Shin Kong Wu Huo-Shih Memorial Hospital	Refractory Diffuse Large B-cell Lymphoma	May 1, 2021	Phase 1\|Phase 2
NCT05168475	Cambridge University Hospitals NHS Foundation Trust	Giant Cell Arteritis\|Takayasu Arteritis\|Cogan Syndrome\|Relapsing Polychondritis\|Cryoglobulinemic Vasculitis\|IgA Vasculitis\|Polyarteritis Nodosa\|Cutaneous Polyarteritis Nodosa\|Primary Angiitis of Central Nervous System	July 14, 2021	Phase 2
NCT00244127	Zeneus Pharma	Aggressive Non-Hodgkin´s Lymphoma in the Elderly.	October 2002	Phase 2
NCT01661881	Dana-Farber Cancer Institute\|Massachusetts General Hospital	Mantle Cell Lymphoma	August 16, 2012	Phase 2
NCT03930953	Celgene	Lymphoma, Non-Hodgkin	May 20, 2019	Phase 1
NCT04384484	ADC Therapeutics S.A.	Relapsed Diffuse Large B-Cell Lymphoma\|Refractory Diffuse Large B-Cell Lymphoma	September 16, 2020	Phase 3
NCT01451879	University of Florida	Pompe Disease	October 2008
NCT03283202	Celgene	Diffuse B-Cell Lymphoma	October 4, 2017	Phase 1
NCT05532111	RenJi Hospital	Efficacy and Safety	September 1, 2022	Not Applicable
NCT00343447	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins\|National Cancer Institute (NCI)	Leukemia	August 2006	Phase 2
NCT01007292	Astellas Pharma Inc	Non-Hodgkin´s Lymphoma	November 2009	Phase 2
NCT03372837	SymBio Pharmaceuticals	Assess the Efficacy and Safety of SyB L-0501 in Combination With Rituximab in Patients With Recurrent or Relapsed DLBCL	January 15, 2018	Phase 3
NCT00740948	University Hospital, Brest\|Ministry of Health, France	Sjogren´s Disease	March 2008	Phase 2\|Phase 3
NCT01569295	Gilead Sciences	Chronic Lymphocytic Leukemia	June 15, 2012	Phase 3
NCT00089284	Northwestern University\|Robert H. Lurie Cancer Center	Non-Hodgkin´s Lymphoma (NHL)	October 28, 2003	Phase 1\|Phase 2
NCT02776813	Cogent Biosciences, Inc.	Lymphoma	August 2016	Phase 1
NCT02763319	MorphoSys AG\|ICON Clinical Research	Diffuse Large B-cell Lymphoma	June 2016	Phase 2\|Phase 3
NCT03505762	Wake Forest University Health Sciences\|National Cancer Institute (NCI)	B-Cell Non-Hodgkin Lymphoma	July 19, 2018	Phase 2
NCT03558750	Vanderbilt-Ingram Cancer Center\|National Cancer Institute (NCI)\|Bristol-Myers Squibb	Recurrent Central Nervous System Lymphoma\|Recurrent Diffuse Large B-Cell Lymphoma\|Refractory Central Nervous System Lymphoma\|Refractory Diffuse Large B-Cell Lymphoma	June 14, 2018	Phase 1
NCT00695786	M.D. Anderson Cancer Center\|National Cancer Institute (NCI)	Ann Arbor Stage III Grade 1 Follicular Lymphoma\|Ann Arbor Stage III Grade 2 Follicular Lymphoma\|Ann Arbor Stage III Indolent Adult Non-Hodgkin Lymphoma\|Ann Arbor Stage III Marginal Zone Lymphoma\|Ann Arbor Stage III Small Lymphocytic Lymphoma\|Ann Arbor Stage IV Grade 1 Follicular Lymphoma\|Ann Arbor Stage IV Grade 2 Follicular Lymphoma\|Ann Arbor Stage IV Indolent Adult Non-Hodgkin Lymphoma\|Ann Arbor Stage IV Marginal Zone Lymphoma\|Ann Arbor Stage IV Small Lymphocytic Lymphoma	June 10, 2008	Phase 2
NCT00576758	Hoffmann-La Roche	Non-Hodgkin´s Lymphoma	January 2008	Phase 2
NCT02400437	Dana-Farber Cancer Institute\|Millennium Pharmaceuticals, Inc.	Waldenstrom´s Macroglobulinemia	April 2015	Phase 2
NCT04404088	M.D. Anderson Cancer Center\|National Cancer Institute (NCI)	Ann Arbor Stage III Grade 1 Follicular Lymphoma\|Ann Arbor Stage III Grade 2 Follicular Lymphoma\|Ann Arbor Stage III Grade 3 Follicular Lymphoma\|Ann Arbor Stage IV Grade 1 Follicular Lymphoma\|Ann Arbor Stage IV Grade 2 Follicular Lymphoma\|Ann Arbor Stage IV Grade 3 Follicular Lymphoma\|Grade 3a Follicular Lymphoma	July 16, 2020	Phase 2
NCT01332968	Hoffmann-La Roche\|German Low Grade Lymphoma Study Group\|Institute of Cancer Research, United Kingdom	Non-Hodgkin´s Lymphoma	July 6, 2011	Phase 3
NCT03582098	Gilead Sciences	Chronic Lymphocytic Leukaemia	September 12, 2018
NCT00832234	European Myeloma Network\|University of Athens\|University of Roma La Sapienza\|Niguarda Hospital\|University of Turin, Italy\|University of Salamanca\|Hospital Clinic of Barcelona\|Hotel Dieu Hospital\|Erasmus Medical Center\|University Hospital, Toulouse\|IRCCS Policlinico S. Matteo\|Laikο General Hospital, Athens\|Klinikum der Universitaet Muenchen, Grosshadern\|Aalborg University Hospital\|Centre Hospitalier de Lens\|Universitaire Ziekenhuizen KU Leuven\|Theagenio Cancer Hospital\|University of Wuerzburg\|Skane University Hospital\|Sahlgren´s University Hospital	Waldenstroms Macroglobulinemia	September 2006	Phase 2
NCT00169195	Lymphoma Study Association\|Hoffmann-La Roche\|Sanofi-Synthelabo\|Eli Lilly and Company	Diffuse Large Cell Lymphoma	April 2003	Phase 2
NCT00202930	Jean M. Tersak, M.D.\|Genentech, Inc.\|University of Pittsburgh	Neuroblastoma\|Opsoclonus-myoclonus	July 2005	Phase 2
NCT00221325	University of California, San Francisco	Central Nervous System Lymphoma\|Intraocular Lymphoma	April 2007	Phase 1
NCT00010192	National Cancer Institute (NCI)	B-cell Adult Acute Lymphoblastic Leukemia\|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue\|Nodal Marginal Zone B-cell Lymphoma\|Noncontiguous Stage II Adult Burkitt Lymphoma\|Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma\|Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma\|Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma\|Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma\|Noncontiguous Stage II Adult Lymphoblastic Lymphoma\|Noncontiguous Stage II Grade 1 Follicular Lymphoma\|Noncontiguous Stage II Grade 2 Follicular Lymphoma\|Noncontiguous Stage II Grade 3 Follicular Lymphoma\|Noncontiguous Stage II Mantle Cell Lymphoma\|Noncontiguous Stage II Marginal Zone Lymphoma\|Noncontiguous Stage II Small Lymphocytic Lymphoma\|Recurrent Adult Acute Lymphoblastic Leukemia\|Recurrent Adult Burkitt Lymphoma\|Recurrent Adult Diffuse Large Cell Lymphoma\|Recurrent Adult Diffuse Mixed Cell Lymphoma\|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma\|Recurrent Adult Immunoblastic Large Cell Lymphoma\|Recurrent Adult Lymphoblastic Lymphoma\|Recurrent Grade 1 Follicular Lymphoma\|Recurrent Grade 2 Follicular Lymphoma\|Recurrent Grade 3 Follicular Lymphoma\|Recurrent Mantle Cell Lymphoma\|Recurrent Marginal Zone Lymphoma\|Recurrent Small Lymphocytic Lymphoma\|Splenic Marginal Zone Lymphoma\|Stage III Adult Burkitt Lymphoma\|Stage III Adult Diffuse Large Cell Lymphoma\|Stage III Adult Diffuse Mixed Cell Lymphoma\|Stage III Adult Diffuse Small Cleaved Cell Lymphoma\|Stage III Adult Immunoblastic Large Cell Lymphoma\|Stage III Adult Lymphoblastic Lymphoma\|Stage III Grade 1 Follicular Lymphoma\|Stage III Grade 2 Follicular Lymphoma\|Stage III Grade 3 Follicular Lymphoma\|Stage III Mantle Cell Lymphoma\|Stage III Marginal Zone Lymphoma\|Stage III Small Lymphocytic Lymphoma\|Stage IV Adult Burkitt Lymphoma\|Stage IV Adult Diffuse Large Cell Lymphoma\|Stage IV Adult Diffuse Mixed Cell Lymphoma\|Stage IV Adult Diffuse Small Cleaved Cell Lymphoma\|Stage IV Adult Immunoblastic Large Cell Lymphoma\|Stage IV Adult Lymphoblastic Lymphoma\|Stage IV Grade 1 Follicular Lymphoma\|Stage IV Grade 2 Follicular Lymphoma\|Stage IV Grade 3 Follicular Lymphoma\|Stage IV Mantle Cell Lymphoma\|Stage IV Marginal Zone Lymphoma\|Stage IV Small Lymphocytic Lymphoma	December 2000	Phase 1
NCT01549886	Spectrum Pharmaceuticals, Inc	Non-Hodgkin´s Lymphoma	November 2011	Phase 2
NCT00201877	Ohio State University Comprehensive Cancer Center	Non-Hodgkin´s Lymphoma\|Mantle Cell Lymphoma	December 2004	Phase 2
NCT04460248	Ruijin Hospital	Diffuse Large B Cell Lymphoma	July 22, 2020	Phase 2
NCT00244361	National Pediatric Neuroinflammation Organization, Inc.\|Genentech, Inc.	Opsoclonus-myoclonus Syndrome\|Opsoclonus\|Myoclonus\|Ataxia	June 2005	Phase 1\|Phase 2
NCT00384150	Biogen	Lymphoma, Non-Hodgkin´s	November 2007	Phase 3
NCT02303119	The Lymphoma Academic Research Organisation\|Roche Pharma AG	Follicular Lymphoma	February 2, 2015	Phase 3
NCT00169143	Lymphoma Study Association\|Amgen	Untreated CD20-positive Large B-cell Lymphoma	May 2004	Phase 2
NCT00274989	German CLL Study Group\|University of Cologne	Chronic Lymphocytic Leukemia	November 2005	Phase 2
NCT03829566	Northwestern University	Neuromyelitis Optica\|Devic´s Disease\|NMO Spectrum Disorder	November 2019	Phase 2\|Phase 3
NCT00498316	M.D. Anderson Cancer Center\|ViaCell\|National Institutes of Health (NIH)\|National Cancer Institute (NCI)	Myelodysplastic Syndrome\|Leukemia	July 3, 2007	Phase 1
NCT03255096	Hoffmann-La Roche	Diffuse Large B-cell Lymphoma\|High-Grade B-cell Lymphoma	August 28, 2017	Phase 1
NCT01473628	M.D. Anderson Cancer Center\|National Cancer Institute (NCI)	Ann Arbor Stage I Grade 1 Follicular Lymphoma\|Ann Arbor Stage I Grade 2 Follicular Lymphoma\|Ann Arbor Stage II Grade 1 Follicular Lymphoma\|Ann Arbor Stage II Grade 2 Follicular Lymphoma	May 20, 2013	Phase 1\|Phase 2
NCT00005589	EBMT Solid Tumors Working Party\|Lymphoma Trials Office\|National Cancer Institute (NCI)	Lymphoma	October 1999	Phase 3
NCT02733042	Celgene	Lymphoma\|Leukemia, Lymphocytic, Chronic, B-Cell	May 11, 2016	Phase 1\|Phase 2
NCT04235036	Northside Hospital, Inc.\|Pharmacyclics LLC.	Graft Vs Host Disease	December 16, 2019	Phase 2
NCT01900496	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins\|Genentech, Inc.	Lymphoma	June 2014	Phase 1
NCT00625729	Masonic Cancer Center, University of Minnesota\|National Cancer Institute (NCI)	Leukemia\|Lymphoma	January 2008	Phase 1\|Phase 2
NCT01035463	University of Nebraska\|National Cancer Institute (NCI)	Anaplastic Large Cell Lymphoma, ALK-Negative\|Recurrent Anaplastic Large Cell Lymphoma\|Recurrent Mantle Cell Lymphoma\|Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma\|Recurrent Non-Hodgkin Lymphoma\|Recurrent Transformed Non-Hodgkin Lymphoma	November 12, 2009	Phase 1\|Phase 2
NCT00126191	Dana-Farber Cancer Institute\|Beth Israel Deaconess Medical Center\|Brigham and Women´s Hospital	Burkitt Lymphoma\|Non-Hodgkins Lymphoma\|Atypical Burkitt Lymphoma	July 2005	Phase 2
NCT04075292	AstraZeneca	Untreated Chronic Lymphocytic Leukemia	January 20, 2020	Phase 3
NCT01760226	Baylor College of Medicine\|National Cancer Institute (NCI)	Diffuse Large B Cell Lymphoma\|Post Transplant Lymphoproliferative Disorder\|Primary Mediastinal (Thymic) Large B-cell Lymphoma	January 2013	Early Phase 1
NCT00026351	Pharmatech Oncology\|National Cancer Institute (NCI)	Leukemia\|Lymphoma	December 2000	Phase 2
NCT00599170	University of Southern California	Diffuse, Large B-Cell, Lymphoma	January 10, 2008	Phase 2
NCT00086775	Bayer\|National Cancer Institute (NCI)	Leukemia	July 2003	Phase 2
NCT05267054	BeiGene	Relapsed Diffuse Large B-cell Lymphoma\|Refractory Diffuse Large B-cell Lymphoma	April 25, 2022	Phase 1\|Phase 2
NCT00045864	Chiron Corporation	Lymphoma, Non-Hodgkin		Phase 2
NCT01117129	Hoffmann-La Roche	Rheumatoid Arthritis	April 2010	Phase 4
NCT00193440	SCRI Development Innovations, LLC\|Biogen	Non-Hodgkins Lymphoma	April 2002	Phase 2
NCT05351346	Ruijin Hospital	Diffuse Large B Cell Lymphoma	June 1, 2022	Phase 3
NCT00572013	University of Nebraska	Lymphoma	May 1998	Phase 1\|Phase 2
NCT00515554	University of Cologne	Hodgkins Lymphoma	May 2008	Phase 3
NCT01419795	Fred Hutchinson Cancer Center\|National Cancer Institute (NCI)	Adult Nasal Type Extranodal NK+T-cell Lymphoma\|Anaplastic Large Cell Lymphoma\|Angioimmunoblastic T-cell Lymphoma\|Cutaneous B-cell Non-Hodgkin Lymphoma\|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue\|Hepatosplenic T-cell Lymphoma\|Intraocular Lymphoma\|Nodal Marginal Zone B-cell Lymphoma\|Noncutaneous Extranodal Lymphoma\|Peripheral T-cell Lymphoma\|Prolymphocytic Leukemia\|Recurrent Adult Burkitt Lymphoma\|Recurrent Adult Diffuse Large Cell Lymphoma\|Recurrent Adult Diffuse Mixed Cell Lymphoma\|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma\|Recurrent Adult Grade III Lymphomatoid Granulomatosis\|Recurrent Adult Immunoblastic Large Cell Lymphoma\|Recurrent Adult Lymphoblastic Lymphoma\|Recurrent Adult T-cell Leukemia+Lymphoma\|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma\|Recurrent Grade 1 Follicular Lymphoma\|Recurrent Grade 2 Follicular Lymphoma\|Recurrent Grade 3 Follicular Lymphoma\|Recurrent Mantle Cell Lymphoma\|Recurrent Marginal Zone Lymphoma\|Recurrent Mycosis Fungoides+Sezary Syndrome\|Recurrent Small Lymphocytic Lymphoma\|Refractory Chronic Lymphocytic Leukemia\|Refractory Hairy Cell Leukemia\|Small Intestine Lymphoma\|Splenic Marginal Zone Lymphoma\|T-cell Large Granular Lymphocyte Leukemia\|Testicular Lymphoma\|Waldenström Macroglobulinemia	May 2012	Phase 2
NCT00841945	French Innovative Leukemia Organisation	B Cell Lymphoma	April 2005	Phase 3
NCT02040116	Wake Forest University Health Sciences	Multiple Sclerosis	February 2013	Phase 4
NCT01813227	Hackensack Meridian Health\|Onyx Therapeutics, Inc.	Waldenstrom Macroglobulinemia	April 2013	Phase 2
NCT02953509	Gilead Sciences\|The Leukemia and Lymphoma Society	Non Hodgkin Lymphoma	November 21, 2016	Phase 1\|Phase 2
NCT03501459	National University Health System, Singapore	Nephrotic Syndrome	June 2008	Phase 3
NCT01460602	Louisiana State University Health Sciences Center Shreveport\|Millennium Pharmaceuticals, Inc.	Follicular Lymphoma\|Marginal Zone Lymphoma\|Mantle Cell Lymphoma	May 2010	Phase 1\|Phase 2
NCT00141700	University of Michigan Rogel Cancer Center	Lymphoma, Non-Hodgkin´s	March 2003	Phase 2
NCT04542824	Genmab\|AbbVie	Diffuse Large B Cell Lymphoma\|High-grade B-cell Lymphoma\|Primary Mediastinal Large B Cell Lymphoma\|Follicular Lymphoma\|Marginal Zone Lymphoma\|Small Lymphocytic Lymphoma	August 20, 2020	Phase 1\|Phase 2
NCT03719131	Emory University\|Genentech, Inc.	Cutaneous Melanoma, Stage III\|Cutaneous Melanoma, Stage IV\|Stage III Melanoma\|Stage IIIA Skin Melanoma\|Stage IIIB Skin Melanoma\|Stage IIIC Skin Melanoma\|Stage IV Skin Melanoma\|Unresectable Melanoma	June 5, 2019	Phase 2
NCT00057811	Children´s Oncology Group\|National Cancer Institute (NCI)	Childhood Burkitt Lymphoma\|Childhood Diffuse Large Cell Lymphoma\|Childhood Immunoblastic Large Cell Lymphoma\|Stage I Childhood Large Cell Lymphoma\|Stage I Childhood Small Noncleaved Cell Lymphoma\|Stage II Childhood Large Cell Lymphoma\|Stage II Childhood Small Noncleaved Cell Lymphoma\|Stage III Childhood Large Cell Lymphoma\|Stage III Childhood Small Noncleaved Cell Lymphoma\|Stage IV Childhood Large Cell Lymphoma\|Stage IV Childhood Small Noncleaved Cell Lymphoma\|Untreated Childhood Acute Lymphoblastic Leukemia	June 2004	Phase 2
NCT01804712	Stephen Howell, M.D.\|Genentech, Inc.\|University of California, San Diego	Prostate Cancer	July 2013	Early Phase 1
NCT03018626	Nanfang Hospital of Southern Medical University	Lymphoma, Large B-Cell, Diffuse	July 27, 2017	Phase 3
NCT02843061	Fuda Cancer Hospital, Guangzhou\|Shenzhen Hank Bioengineering Institute	B-cell Lymphoma Recurrent	July 1, 2016	Phase 1\|Phase 2
NCT01000610	Hoffmann-La Roche	Rheumatoid Arthritis	March 17, 2008	Phase 4
NCT01381692	National Cancer Institute (NCI)	Recurrent Follicular Lymphoma\|Recurrent Mantle Cell Lymphoma\|Recurrent Marginal Zone Lymphoma\|Recurrent Non-Hodgkin Lymphoma\|Recurrent Small Lymphocytic Lymphoma\|Recurrent Waldenstrom Macroglobulinemia\|Refractory Follicular Lymphoma\|Refractory Mantle Cell Lymphoma\|Refractory Marginal Zone Lymphoma\|Refractory Non-Hodgkin Lymphoma\|Refractory Small Lymphocytic Lymphoma	July 20, 2011	Phase 1\|Phase 2
NCT01479842	Kami Maddocks, MD\|Pharmacyclics LLC.\|Ohio State University Comprehensive Cancer Center	Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue\|Nodal Marginal Zone B-cell Lymphoma\|Recurrent Adult Diffuse Large Cell Lymphoma\|Recurrent Grade 1 Follicular Lymphoma\|Recurrent Grade 2 Follicular Lymphoma\|Recurrent Grade 3 Follicular Lymphoma\|Recurrent Mantle Cell Lymphoma\|Recurrent Marginal Zone Lymphoma\|Splenic Marginal Zone Lymphoma\|Waldenstrom Macroglobulinemia	December 7, 2011	Phase 1
NCT00936546	University Hospital, Ghent	Debilitating Fibrosing Skin Disorders (Localised Scleroderma, Eosinophilic Fasciitis)	June 2009	Phase 2
NCT00244985	Roswell Park Cancer Institute\|Ortho Biotech, Inc.	Lymphoma	September 2005	Phase 1\|Phase 2
NCT02420717	M.D. Anderson Cancer Center\|National Cancer Institute (NCI)	Recurrent B Acute Lymphoblastic Leukemia\|Recurrent Ph-Like Acute Lymphoblastic Leukemia\|Refractory B Acute Lymphoblastic Leukemia\|Refractory Ph-Like Acute Lymphoblastic Leukemia	July 15, 2015	Phase 2
NCT01317901	Aptevo Therapeutics	B-cell Small Lymphocytic Lymphoma Recurrent	May 2011	Phase 1
NCT01542918	James Rubenstein\|Celgene\|Genentech, Inc.\|University of California, San Francisco	Recurrent+Refractory CNS\|Intraocular Lymphoma	December 17, 2012	Phase 1
NCT03418038	Mayo Clinic\|National Cancer Institute (NCI)	Clonal Cytopenia of Undetermined Significance\|High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements\|Recurrent Diffuse Large B-Cell Lymphoma\|Recurrent Hodgkin Lymphoma\|Recurrent Lymphoma\|Refractory Diffuse Large B-Cell Lymphoma\|Refractory Lymphoma	March 23, 2018	Phase 2
NCT00366418	National Heart, Lung, and Blood Institute (NHLBI)\|National Institutes of Health Clinical Center (CC)	Refractory Chronic Lymphocytic Leukemia	August 10, 2006	Phase 1
NCT00101010	M.D. Anderson Cancer Center\|National Cancer Institute (NCI)\|Ortho Biotech, Inc.	Lymphoma	September 2005	Phase 2
NCT02315118	National University Hospital, Singapore\|National University, Singapore	B-Cell Chronic Lymphocytic Leukemia\|Non-Hodgkin´s Lymphoma	December 2014	Phase 1\|Phase 2
NCT01671904	Genentech, Inc.\|AbbVie (prior sponsor, Abbott)	Chronic Lymphocytic Leukemia	January 13, 2014	Phase 1
NCT03579927	M.D. Anderson Cancer Center\|National Cancer Institute (NCI)	CD19 Positive\|Mantle Cell Lymphoma\|Recurrent Diffuse Large B-Cell Lymphoma\|Recurrent Follicular Lymphoma\|Refractory B-Cell Non-Hodgkin Lymphoma\|Refractory Diffuse Large B-Cell Lymphoma\|Refractory Follicular Lymphoma	October 3, 2019	Phase 1\|Phase 2
NCT02689986	Helse Fonna	Cold Agglutinin Disease\|Autoimmune Hemolytic Anemia	January 2013	Phase 2
NCT02703272	Janssen Research & Development, LLC\|Pharmacyclics LLC.	Lymphoma, Non-Hodgkin	July 1, 2016	Phase 3
NCT01754857	University of Wisconsin, Madison\|Celgene Corporation\|Genentech, Inc.	Lymphoid Leukemia\|Small Lymphocytic Lymphoma\|Lymphoma, Non-Hodgkin	November 12, 2013	Phase 2
NCT02670616	Samsung Medical Center	Epstein-Barr Virus-positive Diffuse Large B-cell Lymphoma	May 1, 2016	Phase 2
NCT00541034	Memorial Sloan Kettering Cancer Center\|National Cancer Institute (NCI)\|Astex Pharmaceuticals, Inc.	Leukemia\|Lymphoma	May 2005	Phase 2
NCT00633594	SCRI Development Innovations, LLC\|Millennium Pharmaceuticals, Inc.\|Celgene	Mantle Cell Lymphoma	June 2008	Phase 1\|Phase 2
NCT04640818	Claudio Gobbi\|Merck AG Switzerland\|Ospedale Civico, Lugano	Multiple Sclerosis	December 17, 2020
NCT01955187	Hospital Universitario 12 de Octubre\|Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz\|Hospital Universitario Fundación Alcorcón\|Fundación para la Investigación Biomédica Hospital Universitario 12 de Octubre\|Biobanco REDinREN\|ERA-EDTA\|REDinREN\|Spanish Society of Nephrology\|Fundación de Investigación Biomédica - Hospital Universitario de La Princesa\|University Hospital, Aachen	MEMBRANOUS NEPHROPATHY	January 2014	Phase 3
NCT00347971	ZymoGenetics	Lymphoma, Non-Hodgkin	June 2006	Phase 1
NCT01134575	M.D. Anderson Cancer Center\|Wyeth is now a wholly owned subsidiary of Pfizer	Acute Lymphoblastic Leukemia	June 4, 2010	Phase 2
NCT04022239	M.D. Anderson Cancer Center\|National Cancer Institute (NCI)	Hematopoietic and Lymphoid System Neoplasm	March 13, 2020	Phase 1\|Phase 2
NCT00080847	National Cancer Institute (NCI)	Contiguous Stage II Adult Diffuse Large Cell Lymphoma\|Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma\|Stage III Adult Diffuse Large Cell Lymphoma\|Stage IV Adult Diffuse Large Cell Lymphoma	March 2004	Phase 2
NCT00040950	Jonsson Comprehensive Cancer Center\|National Cancer Institute (NCI)	Lymphoma	March 2002	Phase 1
NCT00006669	Medstar Health Research Institute	Lymphoma	September 1999	Phase 2
NCT01516567	Gustave Roussy, Cancer Campus, Grand Paris\|Children´s Oncology Group	Primary Mediastinal Large B Cell Lymphoma	April 1, 2012	Phase 2
NCT00254163	US Oncology Research\|Astex Pharmaceuticals, Inc.	B-Cell Chronic Lymphocytic Leukemia	December 2003	Phase 3
NCT01973387	Janssen Research & Development, LLC\|Pharmacyclics LLC.	Chronic Lymphocytic Leukemia\|Small Lymphocytic Lymphoma	October 28, 2013	Phase 3
NCT01525836	Shandong University\|The Affiliated Hospital of the Chinese Academy of Military Medical Sciences\|The First Affiliated Hospital of Anhui Medical University\|The First Affiliated Hospital of Dalian Medical University\|Shandong Provincial Hospital\|Shenzhen Second People´s Hospital\|First Hospital of China Medical University	Purpura\|Idiopathic Thrombocytopenic Purpura	May 2011	Phase 3
NCT01697267	Cambridge University Hospitals NHS Foundation Trust\|Arthritis Research UK\|Roche Pharma AG\|Genentech, Inc.\|University of Pennsylvania	Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis\|Microscopic Polyangiitis\|Wegener Granulomatosis	April 2013	Phase 3
NCT05578976	AbbVie\|Genmab	Diffuse Large B-Cell Lymphoma	February 5, 2023	Phase 3
NCT02460276	Lund University Hospital\|Celgene\|Janssen, LP\|Nordic Lymphoma Group	Relapsed+Refractory Mantle Cell Lymphoma	April 2015	Phase 2
NCT00026182	National Cancer Institute (NCI)	Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue\|Nodal Marginal Zone B-cell Lymphoma\|Recurrent Grade 1 Follicular Lymphoma\|Recurrent Grade 2 Follicular Lymphoma\|Recurrent Mantle Cell Lymphoma\|Recurrent Small Lymphocytic Lymphoma\|Splenic Marginal Zone Lymphoma	October 2001	Phase 2
NCT04045028	Genentech, Inc.	Multiple Myeloma\|Non-Hodgkin Lymphoma\|B-Cell Lymphoma	July 22, 2019	Phase 1
NCT00893477	French Innovative Leukemia Organisation\|National Cancer Institute (NCI)	Lymphoma	March 2009	Phase 2
NCT00324831	Favrille\|National Cancer Institute (NCI)	Lymphoma		Phase 3
NCT04843904	Dana-Farber Cancer Institute	Chronic Lymphocytic Leukemia\|Small Lymphocytic Lymphoma	April 14, 2021	Phase 1
NCT01765374	University Hospital, Rouen	Rheumatoid Arthritis	February 2011	Phase 4
NCT01980888	Gilead Sciences	Chronic Lymphocytic Leukemia	February 5, 2014	Phase 3
NCT03979456	Karolinska Institutet	Multiple Sclerosis, Relapsing-Remitting	July 4, 2018	Phase 3
NCT02538926	University of Washington\|National Cancer Institute (NCI)	B Acute Lymphoblastic Leukemia\|B Lymphoblastic Lymphoma\|Recurrent Adult Acute Lymphoblastic Leukemia\|Recurrent B Lymphoblastic Lymphoma\|Recurrent T Lymphoblastic Leukemia+Lymphoma\|Refractory B Lymphoblastic Lymphoma\|Refractory T Lymphoblastic Lymphoma\|T Acute Lymphoblastic Leukemia\|T Lymphoblastic Lymphoma	July 1, 2018	Phase 2
NCT01001780	University of Rochester	Active Chronic Graft Versus Host Disease	August 2009	Phase 2
NCT00006072	National Center for Research Resources (NCRR)\|Genentech, Inc.	Peripheral Neuropathy		Phase 2
NCT00499343	M.D. Anderson Cancer Center\|Bayer	Lymphoma	January 2004	Phase 2
NCT00250926	Dana-Farber Cancer Institute\|Beth Israel Deaconess Medical Center\|Millennium Pharmaceuticals, Inc.	Waldenstrom´s Macroglobulinemia	October 2005	Phase 2
NCT04624906	Sunnybrook Health Sciences Centre\|AstraZeneca	Waldenstrom Macroglobulinemia	March 2, 2021	Phase 2
NCT00983619	MedImmune LLC	B-cell Malignancies\|Cancer	April 16, 2010	Phase 1\|Phase 2
NCT00972478	National Cancer Institute (NCI)	Ann Arbor Stage II Non-Hodgkin Lymphoma\|Ann Arbor Stage III Non-Hodgkin Lymphoma\|Ann Arbor Stage IV Non-Hodgkin Lymphoma	November 15, 2010	Phase 1\|Phase 2
NCT00004040	Hoag Memorial Hospital Presbyterian\|Cancer Biotherapy Research Group	Leukemia\|Multiple Myeloma and Plasma Cell Neoplasm	June 1998	Phase 2
NCT03899337	University of Birmingham\|Bloodwise\|Acerta Pharma, LLC	Richter Syndrome	April 2019	Phase 2
NCT00848328	University of California, Davis\|Celgene	Lymphoma	August 25, 2008	Phase 2
NCT01424982	M.D. Anderson Cancer Center	Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive\|Acute Lymphoblastic Leukemia\|Adult Acute Lymphoblastic Leukemia in Complete Remission\|B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1\|Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive\|Philadelphia Chromosome Positive\|Untreated Adult Acute Lymphoblastic Leukemia	October 5, 2011	Phase 2
NCT01664910	M.D. Anderson Cancer Center\|National Cancer Institute (NCI)	Hematopoietic and Lymphoid Cell Neoplasm	October 29, 2012	Phase 1\|Phase 2
NCT01156909	Haukeland University Hospital	Chronic Fatigue Syndrome\|Myalgic Encephalomyelitis	October 2010	Phase 2
NCT00520130	National Cancer Institute (NCI)\|National Institutes of Health Clinical Center (CC)	Myelodysplastic Syndrome\|Hodgkin´s Lymphoma\|Non-Hodgkin´s Disease\|Acute Leukemia\|Multiple Myeloma	October 30, 2007	Phase 1\|Phase 2
NCT00424749	Fernando Fervenza\|Genentech, Inc.\|Biogen\|National Center for Research Resources (NCRR)\|Mayo Clinic	Churg-Strauss Syndrome	June 2007	Phase 2
NCT01684865	Hoffmann-La Roche	Non-Hodgkin´s Lymphoma	October 22, 2012
NCT02933320	Cancer Research UK\|BioInvent International AB\|Bloodwise	B-cell Lymphoma\|Chronic Lymphocytic Leukaemia\|Waldenström Macroglobulinemia	October 27, 2016	Phase 1\|Phase 2
NCT02729896	Hoffmann-La Roche	Lymphoma	November 9, 2016	Phase 1\|Phase 2
NCT01313611	The Lymphoma Academic Research Organisation	Follicular Lymphoma	February 2011	Phase 2
NCT00851552	Roswell Park Cancer Institute\|Ortho Biotech, Inc.	Lymphoma	January 2009	Phase 2
NCT03593902	Northwestern University	Systemic Sclerosis\|Scleroderma	May 17, 2018	Phase 2\|Phase 3
NCT00059904	Memorial Sloan Kettering Cancer Center\|National Cancer Institute (NCI)	Lymphoma	January 2003	Phase 2
NCT02259348	St. Jude Children´s Research Hospital	Acute Lymphoblastic Leukemia (ALL)\|Acute Myeloid Leukemia (AML)\|Myeloid Sarcoma\|Chronic Myelogenous Leukemia (CML)\|Juvenile Myelomonocytic Leukemia (JMML)\|Myelodysplastic Syndrome (MDS)\|Non-Hodgkin Lymphoma (NHL)	October 2014	Phase 2
NCT01125176	Weill Medical College of Cornell University\|Celgene	Chronic Lymphocytic Leukemia	March 30, 2012	Phase 2
NCT00937131	University College, London	Thrombotic Thrombocytopenic Purpura (TTP)	March 2006	Phase 2
NCT01280682	Nanjing Medical University	Diabetes Mellitus, Type 1	July 2010	Phase 4
NCT00770224	Southwest Oncology Group\|National Cancer Institute (NCI)	Lymphoma	April 2009	Phase 2
NCT03689894	Dartmouth-Hitchcock Medical Center	Chronic Graft-versus-host-disease	April 12, 2019	Phase 1\|Phase 2
NCT01082939	M.D. Anderson Cancer Center\|Bayer	Chronic Lymphocytic Leukemia	December 2002	Phase 2
NCT01514344	Andres J. M. Ferreri\|IRCCS San Raffaele	Ocular Adnexal Mucosa-Associated Lymphoid Tissue Lymphoma	December 2011	Phase 2
NCT03018535	Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia\|University of Bari\|Azienda Ospedaliera Brotzu\|University of Messina\|University of Milan\|Universita di Verona\|University of Chieti\|University of Bologna\|Azienda Sanitaria Locale Roma E\|IRCCS Azienda Ospedaliero-Universitaria di Bologna\|Regione Piemonte\|University of Modena and Reggio Emilia\|University of Pisa\|University of Milano Bicocca\|Humanitas Hospital, Italy\|Azienda Ospedaliera Universitaria Policlinico\|Fondazione Salvatore Maugeri\|University of Bern\|University of Alberta\|Istituto Giannina Gaslini	Glomerulonephritis, Membranous	January 2012	Phase 3
NCT00691015	Barbara Ann Karmanos Cancer Institute\|National Cancer Institute (NCI)	Chronic Myeloproliferative Disorders\|Leukemia\|Lymphoma\|Multiple Myeloma and Plasma Cell Neoplasm\|Myelodysplastic Syndromes\|Myelodysplastic+Myeloproliferative Neoplasms	May 2008	Phase 2
NCT04624958	Sun Yat-sen University	Mantle Cell Lymphoma\|Newly-diagnosed Mantle Cell Lymphoma	December 1, 2020	Phase 2
NCT03949855	National Institute of Allergy and Infectious Diseases (NIAID)\|Immune Tolerance Network (ITN)\|GlaxoSmithKline\|PPD\|Rho Federal Systems Division, Inc.	Membranous Nephropathy\|Nephrotic Syndrome	December 18, 2019	Phase 2
NCT00509379	Gruppo Italiano Multiregionale per lo studio dei Linfomi e delle Leucemie\|Centro di Riferimento per l´Epidemiologia e la Prev. Oncologica Piemonte\|Fondazione Italiana Linfomi ONLUS\|University of Turin, Italy	Lymphoma\|Non-Hodgkin Lymphoma	September 2006	Phase 2
NCT00602836	Mayo Clinic\|National Cancer Institute (NCI)	Leukemia\|Lymphoma	February 2008	Phase 2
NCT01307592	Auxilio Mutuo Cancer Center\|National Cancer Institute (NCI)	Lymphoma	February 2011	Phase 2
NCT03703167	Memorial Sloan Kettering Cancer Center\|Pharmacyclics LLC.	Primary Central Nervous System Lymphoma (PCNSL)\|Secondary Central Nervous System Lymphoma (SCNSL)	January 22, 2019	Phase 1
NCT01539174	Fox Chase Cancer Center\|Genentech, Inc.	Contiguous Stage II Adult Diffuse Large Cell Lymphoma\|Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma\|Stage I Adult Diffuse Large Cell Lymphoma\|Stage III Adult Diffuse Large Cell Lymphoma\|Stage IV Adult Diffuse Large Cell Lymphoma		Phase 2
NCT00278408	German High-Grade Non-Hodgkin´s Lymphoma Study Group	Lymphoma	November 2005	Phase 3
NCT00045877	Chiron Corporation	Lymphoma, Non-Hodgkin		Phase 2\|Phase 3
NCT00301301	Royal Marsden NHS Foundation Trust	Non-Hodgkins Lymphoma
NCT04850495	Yazeed Sawalha\|Ohio State University Comprehensive Cancer Center	Diffuse Large B-Cell Lymphoma\|Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma\|Transformed Marginal Zone Lymphoma to Diffuse Large B-Cell Lymphoma	November 16, 2021	Phase 1
NCT00869323	Masonic Cancer Center, University of Minnesota\|Millennium Pharmaceuticals, Inc.	Lymphoproliferative Disorder	March 2009	Phase 2
NCT00278564	Northwestern University	MYOPATHY	September 2005	Phase 1
NCT00001379	National Cancer Institute (NCI)\|National Institutes of Health Clinical Center (CC)	Lymphomatoid Granulomatosis\|Granulomatosis, Lymphomatoid\|Non-Hodgkins Lymphoma\|Lymphoproliferative Disorder	May 5, 1995	Phase 2
NCT00794820	M.D. Anderson Cancer Center\|Genentech, Inc.	Chronic Lymphocytic Leukemia	December 2003	Phase 2
NCT01969409	University of Alabama at Birmingham\|National Institutes of Health (NIH)	Ambulatory IPF	January 2014	Phase 2
NCT01369849	National Cancer Institute (NCI)	Chronic Lymphocytic Leukemia\|Recurrent Small Lymphocytic Lymphoma\|Refractory Chronic Lymphocytic Leukemia	September 2011	Phase 1\|Phase 2
NCT03777085	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	Diffuse Large B-cell Lymphoma	January 10, 2019	Phase 3
NCT00782821	University of Cincinnati\|Millennium Pharmaceuticals, Inc.\|Genzyme, a Sanofi Company	Kidney Transplantation	September 2008	Phase 4
NCT00080886	University of Nebraska\|National Cancer Institute (NCI)	Lymphoma	May 2002	Phase 2
NCT01415752	Eastern Cooperative Oncology Group\|National Cancer Institute (NCI)	Lymphoma\|Neurotoxicity\|Therapy-related Toxicity	May 22, 2012	Phase 2
NCT00692939	Paul Szabolcs\|University of Pittsburgh	Crohn´s Disease	June 26, 2012	Phase 1\|Phase 2
NCT00722137	Millennium Pharmaceuticals, Inc.\|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.\|Takeda	Mantle Cell Lymphoma	May 1, 2008	Phase 3
NCT02636322	M.D. Anderson Cancer Center\|National Cancer Institute (NCI)	Diffuse Large B-Cell Lymphoma Unclassifiable	March 29, 2016	Phase 2
NCT04555811	Masonic Cancer Center, University of Minnesota	NHL\|Non Hodgkin Lymphoma\|Diffuse Large B Cell Lymphoma\|High-grade B-cell Lymphoma	September 22, 2020	Phase 1
NCT03710772	M.D. Anderson Cancer Center\|National Cancer Institute (NCI)	Mantle Cell Lymphoma	May 1, 2019	Phase 2
NCT02576275	SecuraBio	Indolent Non-Hodgkin´s Lymphoma\|Follicular Lymphoma\|Small Lymphocytic Lymphoma\|Marginal Zone Lymphoma	December 2015	Phase 3
NCT00371904	Hunter and New England Health\|Melbourne Health\|Princess Alexandra Hospital, Brisbane, Australia\|Royal Prince Alfred Hospital, Sydney, Australia\|Auckland City Hospital\|Monash Medical Centre\|Royal Perth Hospital\|Westmead Hospital\|Royal Adelaide Hospital	Kidney Transplantation	April 2006	Phase 2
NCT05575973	Jianfeng Zhou\|CSPC Ouyi Pharmaceutical Co., Ltd.\|Huazhong University of Science and Technology	Diffuse Large B-cell Lymphoma	October 10, 2022	Phase 2
NCT00107614	University of Arkansas	Waldenstrom Macroglobulinemia	November 2002	Phase 2
NCT03864419	Fred Hutchinson Cancer Center	Burkitt Lymphoma\|KSHV-associated Multicentric Castleman Disease\|Diffuse Large B-Cell Lymphoma	October 24, 2019	Phase 1
NCT02367040	Bayer	Lymphoma,Non-Hodgkin	August 3, 2015	Phase 3
NCT00005601	Alliance for Clinical Trials in Oncology\|National Cancer Institute (NCI)	Lymphoma	October 2000	Phase 2
NCT00118209	Alliance for Clinical Trials in Oncology\|National Cancer Institute (NCI)	Large B Cell Lymphoma	May 2005	Phase 3
NCT03970577	Assistance Publique - Hôpitaux de Paris	Minimal Change Nephrotic Syndrome (MCNS)	July 29, 2020	Phase 2
NCT00074282	Eastern Cooperative Oncology Group\|National Cancer Institute (NCI)	Leukemia	December 16, 2004	Phase 2
NCT02213913	University of Chicago\|National Cancer Institute (NCI)	Adult Grade III Lymphomatoid Granulomatosis\|B-cell Chronic Lymphocytic Leukemia\|Contiguous Stage II Adult Diffuse Large Cell Lymphoma\|Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma\|Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma\|Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma\|Contiguous Stage II Grade 1 Follicular Lymphoma\|Contiguous Stage II Grade 2 Follicular Lymphoma\|Contiguous Stage II Grade 3 Follicular Lymphoma\|Contiguous Stage II Mantle Cell Lymphoma\|Contiguous Stage II Marginal Zone Lymphoma\|Contiguous Stage II Small Lymphocytic Lymphoma\|Cutaneous B-cell Non-Hodgkin Lymphoma\|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue\|Intraocular Lymphoma\|Nodal Marginal Zone B-cell Lymphoma\|Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma\|Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma\|Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma\|Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma\|Noncontiguous Stage II Grade 1 Follicular Lymphoma\|Noncontiguous Stage II Grade 2 Follicular Lymphoma\|Noncontiguous Stage II Grade 3 Follicular Lymphoma\|Noncontiguous Stage II Mantle Cell Lymphoma\|Noncontiguous Stage II Marginal Zone Lymphoma\|Noncontiguous Stage II Small Lymphocytic Lymphoma\|Progressive Hairy Cell Leukemia, Initial Treatment\|Small Intestine Lymphoma\|Splenic Marginal Zone Lymphoma\|Stage 0 Chronic Lymphocytic Leukemia\|Stage I Adult Diffuse Large Cell Lymphoma\|Stage I Adult Diffuse Mixed Cell Lymphoma\|Stage I Adult Diffuse Small Cleaved Cell Lymphoma\|Stage I Adult Hodgkin Lymphoma\|Stage I Adult Immunoblastic Large Cell Lymphoma\|Stage I Chronic Lymphocytic Leukemia\|Stage I Grade 1 Follicular Lymphoma\|Stage I Grade 2 Follicular Lymphoma\|Stage I Grade 3 Follicular Lymphoma\|Stage I Mantle Cell Lymphoma\|Stage I Marginal Zone Lymphoma\|Stage I Small Lymphocytic Lymphoma\|Stage II Adult Hodgkin Lymphoma\|Stage II Chronic Lymphocytic Leukemia\|Stage II Small Lymphocytic Lymphoma\|Stage III Adult Diffuse Large Cell Lymphoma\|Stage III Adult Diffuse Mixed Cell Lymphoma\|Stage III Adult Diffuse Small Cleaved Cell Lymphoma\|Stage III Adult Hodgkin Lymphoma\|Stage III Adult Immunoblastic Large Cell Lymphoma\|Stage III Chronic Lymphocytic Leukemia\|Stage III Grade 1 Follicular Lymphoma\|Stage III Grade 2 Follicular Lymphoma\|Stage III Grade 3 Follicular Lymphoma\|Stage III Mantle Cell Lymphoma\|Stage III Marginal Zone Lymphoma\|Stage III Small Lymphocytic Lymphoma\|Stage IV Adult Diffuse Large Cell Lymphoma\|Stage IV Adult Diffuse Mixed Cell Lymphoma\|Stage IV Adult Diffuse Small Cleaved Cell Lymphoma\|Stage IV Adult Hodgkin Lymphoma\|Stage IV Adult Immunoblastic Large Cell Lymphoma\|Stage IV Chronic Lymphocytic Leukemia\|Stage IV Grade 1 Follicular Lymphoma\|Stage IV Grade 2 Follicular Lymphoma\|Stage IV Grade 3 Follicular Lymphoma\|Stage IV Mantle Cell Lymphoma\|Stage IV Marginal Zone Lymphoma\|Stage IV Small Lymphocytic Lymphoma\|Testicular Lymphoma\|Untreated Hairy Cell Leukemia\|Waldenström Macroglobulinemia	July 29, 2014	Phase 1\|Phase 2
NCT00209222	European Mantle Cell Lymphoma Network\|German Low Grade Lymphoma Study Group\|Lymphoma Study Association	Lymphoma, Mantle-Cell	July 2004	Phase 3
NCT02481310	Northwestern University\|National Cancer Institute (NCI)\|Millennium Pharmaceuticals, Inc.	Adult Burkitt Lymphoma\|B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma\|Diffuse Large B-Cell Lymphoma\|MYC Gene Mutation\|Plasmablastic Lymphoma	October 28, 2015	Phase 1\|Phase 2
NCT00529503	Seagen Inc.\|Genentech, Inc.	Lymphoma, Large B-Cell, Diffuse\|Lymphoma, Non-Hodgkin	September 2007	Phase 2
NCT03206671	University Hospital Muenster\|Deutsche Krebshilfe e.V., Bonn (Germany)	Mature B-cell Non-Hodgkin Lymphoma	August 3, 2017	Phase 3
NCT00759798	M.D. Anderson Cancer Center	Chronic Lymphocytic Leukemia\|Leukemia	August 13, 2008	Phase 2
NCT03180723	Assiut University	Membranoproliferative Glomerulonephritis	July 1, 2017	Phase 3
NCT01938001	Celgene	Lymphoma, Non-Hodgkin	November 21, 2013	Phase 3
NCT00550342	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)\|Genentech, Inc.\|Indiana University	Focal Segmental Glomerulosclerosis (FSGS)	January 2008	Phase 2
NCT01613027	Hoffmann-La Roche	Rheumatoid Arthritis	February 2012
NCT00334438	UNC Lineberger Comprehensive Cancer Center\|National Cancer Institute (NCI)	Lymphoma	July 2006	Phase 1
NCT00266227	Genentech, Inc.	Rheumatoid Arthritis	January 2006	Phase 3
NCT00144807	Lymphoma Study Association	Diffuse Large Cell Lymphoma	December 2003	Phase 2
NCT00772655	Charite University, Berlin, Germany	Follicular Lymphoma	October 2007	Phase 2
NCT00327678	Assistance Publique - Hôpitaux de Paris\|Group for Research in Adult Acute Lymphoblastic Leukemia	Leukemia, Lymphocytic	May 2006	Phase 3
NCT00082836	Memorial Sloan Kettering Cancer Center\|National Cancer Institute (NCI)	Lymphoma	December 2004	Not Applicable
NCT00337246	Cancer Research UK\|National Cancer Institute (NCI)	Leukemia	July 2005	Phase 2
NCT04189588	TerSera Therapeutics LLC	Oncology Patients Receiving Chemotherapy	March 25, 2020	Phase 2
NCT00295932	Memorial Sloan Kettering Cancer Center\|National Cancer Institute (NCI)\|Rutgers Cancer Institute of New Jersey\|Columbia University\|Emory University	Leukemia\|Lymphoma	December 13, 2005	Phase 1\|Phase 2
NCT01598558	Sanjiv Sam Gambhir\|Stanford University	Non-Hodgkin´s Lymphoma	January 2012	Not Applicable
NCT05036577	Huashan Hospital	Primary Central Nervous System Lymphoma	October 10, 2021	Phase 1
NCT02257242	Adam Olszewski\|Spectrum Pharmaceuticals, Inc\|Rhode Island Hospital\|The Miriam Hospital\|Brown University	Lymphoma, Non-Hodgkin\|Lymphoma, Follicular\|Lymphoma, Mantle-Cell\|Lymphoma, Small-Cell\|Waldenstrom Macroglobulinemia\|Lymphoma, B-Cell, Marginal Zone	May 10, 2017	Phase 1
NCT00738829	Arbeitsgemeinschaft medikamentoese Tumortherapie\|Celgene Corporation\|Roche Pharma AG	Leukemia, Lymphocytic, Chronic, B-Cell	October 2008	Phase 1\|Phase 2
NCT04835870	The First Affiliated Hospital of Soochow University	Non-GCB+ABC Diffuse Large B-Cell Lymphoma	April 1, 2021	Phase 2
NCT00068315	National Cancer Institute (NCI)	Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue\|Hematopoietic+Lymphoid Cancer\|Nodal Marginal Zone B-cell Lymphoma\|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma\|Recurrent Grade 1 Follicular Lymphoma\|Recurrent Grade 2 Follicular Lymphoma\|Recurrent Mantle Cell Lymphoma\|Recurrent Marginal Zone Lymphoma\|Recurrent Small Lymphocytic Lymphoma\|Refractory Chronic Lymphocytic Leukemia\|Splenic Marginal Zone Lymphoma\|Waldenström Macroglobulinemia	July 2003	Phase 1
NCT00472225	The Korean Society of Hematopoietic Stem Cell Transplantation\|Hoffmann-La Roche	Steroid-Refractory Chronic GVHD	May 2007	Phase 2
NCT02749292	Massachusetts General Hospital	Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis	June 2016	Phase 4
NCT00166439	Academic and Community Cancer Research United\|Mayo Clinic	Lymphoma	March 2005	Phase 2
NCT04025593	Ruijin Hospital	Diffuse Large B Cell Lymphoma	July 17, 2019	Phase 2
NCT03150693	Alliance for Clinical Trials in Oncology\|National Cancer Institute (NCI)	B Acute Lymphoblastic Leukemia	June 1, 2017	Phase 3
NCT00091897	National Institute of Neurological Disorders and Stroke (NINDS)\|National Institutes of Health Clinical Center (CC)	Stiff Person Syndrome	September 2004	Phase 2
NCT00003663	Hoag Memorial Hospital Presbyterian\|Cancer Biotherapy Research Group	Lymphoma	June 1998	Phase 2
NCT00121199	National Cancer Institute (NCI)	Contiguous Stage II Adult Diffuse Large Cell Lymphoma\|Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma\|Stage III Adult Diffuse Large Cell Lymphoma\|Stage IV Adult Diffuse Large Cell Lymphoma	June 2005	Phase 2
NCT02600897	Hoffmann-La Roche	Relapsed or Refractory Follicular Lymphoma, Relapsed or Refractory Diffuse Large B-Cell Lymphoma	March 23, 2016	Phase 1
NCT04974216	The Lymphoma Academic Research Organisation	DLBCL	December 20, 2021	Phase 2
NCT00503425	Hoffmann-La Roche	Rheumatoid Arthritis	June 30, 2005	Phase 3
NCT00602459	National Cancer Institute (NCI)\|Eastern Cooperative Oncology Group\|NCIC Clinical Trials Group\|Southwest Oncology Group	Stage I Chronic Lymphocytic Leukemia\|Stage II Chronic Lymphocytic Leukemia\|Stage III Chronic Lymphocytic Leukemia\|Stage IV Chronic Lymphocytic Leukemia	January 15, 2008	Phase 2
NCT02337985	City of Hope Medical Center\|National Cancer Institute (NCI)	AIDS-Related Burkitt Lymphoma\|AIDS-Related Diffuse Large B-cell Lymphoma\|AIDS-Related Plasmablastic Lymphoma\|AIDS-Related Primary Effusion Lymphoma\|HIV Infection\|AIDS Related Non-Hodgkin Lymphoma	November 20, 2015	Phase 1
NCT02165397	Pharmacyclics LLC.\|Janssen Research & Development, LLC	Waldenström´s Macroglobulinemia	July 7, 2014	Phase 3
NCT03536039	Andres J. M. Ferreri\|AGC Biologics S.p.A.\|IRCCS San Raffaele	Lymphoma, Large B-Cell, Diffuse	January 27, 2016	Phase 2
NCT05388123	Scripps Health	Hairy Cell Leukemia	January 1, 2022	Phase 2
NCT01592292	Hoffmann-La Roche	Rheumatoid Arthritis	November 2011
NCT00049036	National Cancer Institute (NCI)	AIDS-related Diffuse Large Cell Lymphoma\|AIDS-related Immunoblastic Large Cell Lymphoma\|AIDS-related Peripheral+Systemic Lymphoma\|AIDS-related Small Noncleaved Cell Lymphoma	March 2003	Phase 2
NCT02423915	M.D. Anderson Cancer Center\|National Cancer Institute (NCI)\|Cancer Prevention Research Institute of Texas	Leukemia\|Lymphoma	July 30, 2015	Phase 1
NCT00331006	HealthCore-NERI\|National Heart, Lung, and Blood Institute (NHLBI)\|Genentech, Inc.	Hemophilia A	June 2006	Phase 2
NCT00317096	Ludwig-Maximilians - University of Munich	Lymphoma, Follicular\|Lymphoma, Low-Grade\|Lymphoma, Intermediate-Grade	November 1998	Phase 3
NCT01400685	Massachusetts General Hospital\|Dana-Farber Cancer Institute	Chronic Lymphocytic Leukemia\|Small Lymphocytic Lymphoma\|B Chronic Lymphocytic Leukemia	December 2012	Phase 1
NCT00032019	Alliance for Clinical Trials in Oncology\|National Cancer Institute (NCI)	Lymphoma	February 2002	Phase 2
NCT01506414	Ming Hou\|Peking Union Medical College Hospital\|Cancer Institute and Hospital, Chinese Academy of Medical Sciences\|First Affiliated Hospital, Sun Yat-Sen University\|West China Hospital\|Shandong Provincial Hospital\|Wuhan Union Hospital, China\|Zhejiang University\|Shandong University	Purpura\|Idiopathic Thrombocytopenic Purpura	June 2009	Phase 3
NCT00765245	Vanderbilt-Ingram Cancer Center\|National Cancer Institute (NCI)	Lymphoma	October 2008	Phase 2
NCT05025800	M.D. Anderson Cancer Center	Aggressive B-Cell Non-Hodgkin Lymphoma\|Ann Arbor Stage III Grade 2 Follicular Lymphoma\|Ann Arbor Stage III Grade 3 Follicular Lymphoma\|Ann Arbor Stage III Marginal Zone Lymphoma\|Ann Arbor Stage IV Grade 1 Follicular Lymphoma\|Ann Arbor Stage IV Grade 2 Follicular Lymphoma\|Ann Arbor Stage IV Grade 3 Follicular Lymphoma\|Ann Arbor Stage IV Marginal Zone Lymphoma\|Composite Lymphoma\|Indolent B-Cell Non-Hodgkin Lymphoma\|Refractory Aggressive B-Cell Non-Hodgkin Lymphoma\|Refractory Follicular Lymphoma\|Refractory Grade 3b Follicular Lymphoma\|Refractory High Grade B-Cell Lymphoma\|Refractory Mantle Cell Lymphoma\|Refractory Marginal Zone Lymphoma\|Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma\|Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma\|Refractory Transformed Marginal Zone Lymphoma to Diffuse Large B-Cell Lymphoma\|Richter Syndrome	October 13, 2021	Phase 1\|Phase 2
NCT04236141	Hoffmann-La Roche	Diffuse, Large B-Cell, Lymphoma	July 10, 2020	Phase 3
NCT01244958	Frank Behrens\|Johann Wolfgang Goethe University Hospital	Rheumatoid Arthritis	August 2010	Phase 3
NCT00060294	Jonsson Comprehensive Cancer Center\|National Cancer Institute (NCI)	Lymphoma	April 2003	Phase 1
NCT00301821	Alliance for Clinical Trials in Oncology\|National Cancer Institute (NCI)	Lymphoma	January 2006	Phase 2
NCT03545035	Gruppo Italiano Malattie EMatologiche dell´Adulto\|ERIC Group	Chronic Lymphocytic Leukemia	February 6, 2019
NCT03983031	Region Örebro County\|Örebro University, Sweden	Obsessive-Compulsive Disorder\|Treatment Resistant Disorders	August 8, 2019	Phase 1
NCT00617929	Masonic Cancer Center, University of Minnesota	Cancer	January 2008	Phase 2
NCT01164098	George W. Burke\|Genentech, Inc.\|National Institutes of Health (NIH)\|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)\|University of Miami	FSGS\|Proteinuria	February 2012	Phase 3
NCT00790413	Lund University Hospital	Neuroblastoma	August 2005	Early Phase 1
NCT03474744	Christian Buske\|University of Ulm\|SSS International Clinical Research GmbH\|X-act Cologne Clinical Research GmbH\|Zentrum für Klinische Studien Ulm\|Celltrion Healthcare Co., LTD\|Bayer Healthcare LTD	Marginal Zone Lymphoma	December 15, 2019	Phase 2
NCT01902862	Janssen-Cilag G.m.b.H	Lymphoma, Follicular	February 2006	Phase 2
NCT00279305	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)\|National Institute of Allergy and Infectious Diseases (NIAID)\|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)\|American Diabetes Association\|Juvenile Diabetes Research Foundation	Type 1 Diabetes Mellitus	August 2005	Phase 2
NCT02005471	Hoffmann-La Roche\|AbbVie	Chronic Lymphocytic Leukemia	March 17, 2014	Phase 3
NCT00502996	Hoffmann-La Roche	Rheumatoid Arthritis	February 2006	Phase 3
NCT03651518	Assistance Publique - Hôpitaux de Paris	Inflammatory Disease\|Autoimmune Diseases	October 20, 2020	Phase 2
NCT02205333	MedImmune LLC	Advanced Solid Tumors\|Aggressive B-cell Lymphomas	August 13, 2014	Phase 1\|Phase 2
NCT04181489	The First Affiliated Hospital with Nanjing Medical University	EBV-Positive DLBCL, Nos	January 1, 2019	Phase 2
NCT02867553	CHU de Reims	Indolent Cutaneous B Cell Lymphomas	October 2011	Phase 3
NCT05618925	ImmunityBio, Inc.	NonHodgkin´s Lymphoma Refractory	November 15, 2022	Phase 1
NCT01650701	The Lymphoma Academic Research Organisation\|Celgene Corporation	Follicular Lymphoma	February 2012	Phase 3
NCT01491841	Anne Beaven, MD\|CTI BioPharma\|Duke University	Non-Hodgkin´s Lymphoma	November 1, 2011	Phase 1
NCT00396812	National Institute of Allergy and Infectious Diseases (NIAID)\|Autoimmunity Centers of Excellence	Rheumatoid Arthritis	November 2006	Phase 1\|Phase 2
NCT01534884	Celltrion	Rheumatoid Arthritis	February 2012	Phase 1
NCT04481815	Second Affiliated Hospital, School of Medicine, Zhejiang University	PCNSL	October 1, 2020	Phase 2
NCT00994643	Sidney Kimmel Cancer Center at Thomas Jefferson University\|Thomas Jefferson University	High Risk Non-Hodgkin´s Lymphoma	February 5, 2009	Phase 2
NCT00020943	Alliance for Clinical Trials in Oncology\|National Cancer Institute (NCI)	Lymphoma	June 2001	Phase 2
NCT00820469	University Hospital, Toulouse	Renal Transplant\|Autoimmune Diseases	September 2008	Phase 4
NCT05583071	University of Cologne\|Incyte Corporation	Non-Hodgkin Lymphoma	January 2023	Phase 2
NCT01808911	University Hospital, Rouen	Acquired Haemophilia	May 2012	Phase 3
NCT02044822	Gilead Sciences	B-cell Chronic Lymphocytic Leukemia (CLL) With 17p Deletion	August 6, 2014	Phase 2
NCT00090038	Biogen	Non-Hodgkin´s Lymphoma	October 2003	Phase 4
NCT00137995	Lymphoma Study Association	Lymphoma, Large-Cell, Diffuse	June 2003	Phase 3
NCT01088724	A.O. Ospedale Papa Giovanni XXIII	Post-transplant Lymphoproliferative Disease (PTLD)\|Non Burkitt	February 2002	Phase 4
NCT00198978	Johann Wolfgang Goethe University Hospital	Adult Acute Lymphocytic Leukemia	January 2003	Phase 4
NCT00636792	Millennium Pharmaceuticals, Inc.	Follicular Lymphoma	February 2008	Phase 2
NCT00415506	Oregon Health and Science University\|Genentech, Inc.	Scleritis\|Orbital Disease	January 2007	Phase 1\|Phase 2
NCT04216524	M.D. Anderson Cancer Center\|National Cancer Institute (NCI)	Blastic Plasmacytoid Dendritic Cell Neoplasm	May 29, 2020	Phase 2
NCT04268277	University of Ulm\|X-act Cologne Clinical Research GmbH\|Zentrum für Klinische Studien Ulm\|Merck Sharp & Dohme LLC\|Celltrion Healthcare Co., LTD	Marginal Zone Lymphoma	March 1, 2022	Not Applicable
NCT00133991	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins\|National Cancer Institute (NCI)	Leukemia\|Lymphoma	July 2005	Phase 2
NCT04933617	National Cancer Institute (NCI)\|National Institutes of Health Clinical Center (CC)	Burkitt Lymphoma\|High-grade B-cell Lymphoma\|T-cell+Histocyte-rich Large B-cell Lymphoma\|Diffuse Large B-Cell Lymphoma (DLBCL)\|Germinal Center B-cell Type (GCB)	March 24, 2022	Phase 1
NCT01278745	National Institute of Allergy and Infectious Diseases (NIAID)\|National Heart, Lung, and Blood Institute (NHLBI)\|Clinical Trials in Organ Transplantation\|Genentech, Inc.\|Rho Federal Systems Division, Inc.	Cardiac Allograft Vasculopathy\|Heart Transplant Recipients	September 2011	Phase 2
NCT05422066	Li Zhiming\|Antengene Corporation\|Sun Yat-sen University	DLBCL Germinal Center B-Cell Type	July 26, 2022	Phase 2
NCT00041132	Southwest Oncology Group\|National Cancer Institute (NCI)	Lymphoma	September 2002	Phase 2
NCT04494438	Istituto Giannina Gaslini	Idiopathic Nephrotic Syndrome	July 2013	Phase 3
NCT01775631	Bristol-Myers Squibb	B-Cell Malignancies	March 2013	Phase 1
NCT02142335	California Cancer Assocaties for Research & Excellence	Malignant Melanoma of Skin Stage III\|Metastatic Melanoma	March 2014	Phase 2
NCT00119392	Fred Hutchinson Cancer Center\|National Cancer Institute (NCI)	B-cell Chronic Lymphocytic Leukemia\|Nodal Marginal Zone B-cell Lymphoma\|Recurrent Adult Burkitt Lymphoma\|Recurrent Adult Diffuse Large Cell Lymphoma\|Recurrent Adult Diffuse Mixed Cell Lymphoma\|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma\|Recurrent Adult Grade III Lymphomatoid Granulomatosis\|Recurrent Adult Immunoblastic Large Cell Lymphoma\|Recurrent Adult Lymphoblastic Lymphoma\|Recurrent Grade 1 Follicular Lymphoma\|Recurrent Grade 2 Follicular Lymphoma\|Recurrent Grade 3 Follicular Lymphoma\|Recurrent Mantle Cell Lymphoma\|Recurrent Marginal Zone Lymphoma\|Recurrent Small Lymphocytic Lymphoma\|Splenic Marginal Zone Lymphoma\|Waldenström Macroglobulinemia	June 2004	Phase 2
NCT02006706	Hoffmann-La Roche	Rheumatoid Arthritis	August 10, 2006	Phase 3
NCT03934814	AbbVie\|I-Mab Biopharma Co. Ltd.	Solid Tumor\|Lymphoma	April 16, 2019	Phase 1
NCT00411086	M.D. Anderson Cancer Center\|National Cancer Institute (NCI)\|Bayer	Lymphoma	November 2006	Phase 2
NCT01071798	Hoffmann-La Roche	Rheumatoid Arthritis	January 2010
NCT01659099	The Lymphoma Academic Research Organisation\|Hoffmann-La Roche	Diffuse Large B Cell Lymphoma CD20 Positive	September 2012	Phase 3
NCT04337827	Deepa Jagadeesh\|Case Comprehensive Cancer Center	Post-transplant Lymphoproliferative Disorder	September 2, 2020	Phase 2
NCT04021992	Sun Yat-sen University	Lymphoma, Large B-Cell, Diffuse	July 15, 2019	Phase 2
NCT00513747	Alliance for Clinical Trials in Oncology\|National Cancer Institute (NCI)	Leukemia	January 2008	Phase 3
NCT04447716	Thomas Jefferson University\|National Cancer Institute (NCI)	Recurrent B-Cell Non-Hodgkin Lymphoma\|Recurrent Follicular Lymphoma\|Recurrent Indolent Adult Non-Hodgkin Lymphoma\|Recurrent Marginal Zone Lymphoma\|Refractory B-Cell Non-Hodgkin Lymphoma\|Refractory Follicular Lymphoma\|Refractory Indolent Adult Non-Hodgkin Lymphoma\|Refractory Marginal Zone Lymphoma	October 16, 2020	Phase 1
NCT04882163	Celgene	Lymphoma, B-Cell	October 10, 2021	Phase 1\|Phase 2
NCT01075477	Hoffmann-La Roche	Rheumatoid Arthritis	September 2009
NCT00281931	German CLL Study Group	Prolymphocytic Leukemia	September 1999	Phase 2
NCT03671018	Hoffmann-La Roche	B-cell Non-Hodgkin Lymphoma	September 25, 2018	Phase 1\|Phase 2
NCT03579875	Masonic Cancer Center, University of Minnesota	Fanconi Anemia\|Severe Aplastic Anemia\|Myelodysplastic Syndromes	November 13, 2018	Phase 2
NCT00509678	Swedish Medical Center\|Genentech, Inc.	Psoriatic Arthritis	December 2006	Phase 1
NCT01309997	Lee, Stephanie\|National Cancer Institute (NCI)\|Fred Hutchinson Cancer Center	Graft Versus Host Disease\|Systemic Scleroderma	March 2011	Phase 2
NCT05406401	Merck Sharp & Dohme LLC	Lymphoma, Large B-Cell, Diffuse (DLBCL)	July 14, 2022	Phase 2
NCT01964755	University of Miami	Epstein Barr Virus Associated Non Hodgkin´s Lymphoma\|Epstein Barr Virus Associated Hodgkin´s Lymphoma\|Post-Transplant Lymphoproliferative Disease	April 21, 2009	Phase 2
NCT01086540	National Institute of Allergy and Infectious Diseases (NIAID)\|Autoimmunity Centers of Excellence\|Rho Federal Systems Division, Inc.	Systemic Sclerosis-Associated PAH	June 24, 2011	Phase 2
NCT05338190	Assistance Publique - Hôpitaux de Paris\|GlaxoSmithKline	Primary Immune Thrombocytopenia (ITP)	June 1, 2022	Phase 3
NCT01880567	M.D. Anderson Cancer Center\|National Cancer Institute (NCI)	CCND1 Positive\|CCND2 Positive\|CCND3 Positive\|CD20 Positive\|Mantle Cell Lymphoma\|Recurrent Mantle Cell Lymphoma\|Refractory Mantle Cell Lymphoma	July 15, 2013	Phase 2
NCT05494593	Takeda\|Takeda Development Center Americas, Inc.	Mucopolysaccharidosis (MPS)\|Hunter Syndrome	December 9, 2022	Phase 4
NCT01482754	National University Hospital, Singapore	Non Hodgkin Lymphoma	May 2012	Not Applicable
NCT00481832	Stanford University	Lymphoma, Non-Hodgkin	January 2007	Phase 2
NCT02500251	E. Steve Woodle\|GlaxoSmithKline\|University of Cincinnati	Renal Transplant Rejection	June 2015	Phase 1\|Phase 2
NCT00816595	Mayo Clinic\|National Cancer Institute (NCI)	Leukemia\|Lymphoma	February 2009	Phase 2
NCT00112931	University College, London\|Cancer Research UK\|Roche Pharma AG	Lymphoma	September 2004	Phase 3
NCT01526057	Pfizer	Rheumatoid Arthritis	March 20, 2012	Phase 2
NCT00931918	Millennium Pharmaceuticals, Inc.\|Takeda	Non-Germinal B-Cell-like (GCB) Diffuse Large B-cell Lymphoma (DLBCL)	October 2009	Phase 2
NCT01319981	M.D. Anderson Cancer Center\|Spectrum Pharmaceuticals, Inc	Leukemia	March 5, 2013	Phase 2
NCT02053610	Hoffmann-La Roche\|German CLL Study Group\|Genentech, Inc.	Lymphocytic Leukemia, Chronic	December 31, 2009	Phase 3
NCT00204659	University Hospital Tuebingen\|Hoffmann-La Roche	Primary Gastric Diffuse-Large B-Cell Lymphoma	March 2003	Phase 2
NCT00909077	Copenhagen University Hospital at Herlev	Idiopathic Thrombocytopenic Purpura	August 2004	Phase 3
NCT05506410	Zhengzhou University	Newly Diagnosed Mantle Cell Lymphoma	August 12, 2022
NCT00881387	University of Miami	Lymphoma	February 2009	Phase 2
NCT00971763	University College, London	Lymphoma	March 2006	Phase 2
NCT01014208	GlaxoSmithKline	Lymphoma, Large-Cell, Diffuse	March 2010	Phase 3
NCT03194815	University of Cambridge\|University of Oxford	Psychosis\|Autoimmune Encephalitis	November 1, 2017	Phase 2
NCT00363350	University Medical Center Groningen\|Hoffmann-La Roche	Sjogren´s Syndrome	August 2006	Phase 1\|Phase 2
NCT00104858	Fred Hutchinson Cancer Center\|National Cancer Institute (NCI)	Chronic Lymphocytic Leukemia\|Prolymphocytic Leukemia\|Recurrent Small Lymphocytic Lymphoma\|Refractory Chronic Lymphocytic Leukemia\|Stage III Chronic Lymphocytic Leukemia\|Stage III Small Lymphocytic Lymphoma\|Stage IV Chronic Lymphocytic Leukemia\|Stage IV Small Lymphocytic Lymphoma\|T-Cell Large Granular Lymphocyte Leukemia	December 2004	Phase 2
NCT00209209	European Mantle Cell Lymphoma Network\|German Low Grade Lymphoma Study Group\|Lymphoma Study Association\|HOVON - Dutch Haemato-Oncology Association\|Nordic Lymphoma Group	Lymphoma, Mantle-Cell	January 14, 2004	Phase 3
NCT01682616	AbbVie\|Genentech, Inc.	Small Lymphocytic Lymphoma\|Chronic Lymphocytic Leukemia	July 25, 2012	Phase 1
NCT02383589	Hoffmann-La Roche\|Genentech, Inc.	Pemphigus Vulgaris	May 26, 2015	Phase 3
NCT04062448	Janssen Pharmaceutical K.K.	Waldenstrom Macroglobulinemia	September 25, 2019	Phase 2
NCT00033423	University of Alabama at Birmingham\|National Cancer Institute (NCI)	Lymphoma	August 2001	Phase 1
NCT02013817	Hoffmann-La Roche	Lymphocytic Leukemia, Chronic	October 11, 2005	Phase 2
NCT00072592	National Institute of Allergy and Infectious Diseases (NIAID)\|National Institutes of Health Clinical Center (CC)	Wegener´s Granulomatosis	October 2003	Phase 1
NCT00308087	Genzyme, a Sanofi Company\|Sanofi	Lymphoma, Follicular	May 2006	Phase 2
NCT00492050	M.D. Anderson Cancer Center\|Millennium Pharmaceuticals, Inc.	Waldenstrom´s Macroglobulinemia	August 2006	Phase 2
NCT04776850	M.D. Anderson Cancer Center	Beta Thalassemia Major\|Sickle Beta 0 Thalassemia\|Sickle Beta Plus Thalassemia\|Sickle Beta Thalassemia\|Sickle Cell Disease\|Sickle Cell-SS Disease	December 29, 2020	Early Phase 1
NCT01085617	University College, London	Leukemia\|Mucositis\|Oral Complications	December 2010	Phase 3
NCT04585152	Istituto Giannina Gaslini\|Bambino Gesù Hospital and Research Institute	Nephrotic Syndrome Steroid-Dependent	October 15, 2020	Phase 2
NCT00595335	Rebecca Bahn\|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)\|National Center for Research Resources (NCRR)\|Mayo Clinic	Thyroid-associated Ophthalmopathy	April 2008	Phase 2\|Phase 3
NCT04189952	University of Miami\|AstraZeneca	Diffuse Large B Cell Lymphoma\|Chronic Lymphocytic Leukemia\|Small Lymphocytic Leukemia\|Marginal Zone Lymphoma	September 22, 2020	Phase 2
NCT01716442	Seoul National University Childrens Hospital	Steroid Resistant Nephrotic Syndrome\|Steroid Dependent Nephrotic Syndrome	August 2012	Phase 2\|Phase 3
NCT02461290	Hoffmann-La Roche	Follicular Lymphoma	April 2008
NCT03401853	University of Washington\|Merck Sharp & Dohme LLC	Recurrent Diffuse Large B-Cell Lymphoma\|Recurrent Follicular Lymphoma\|Refractory Diffuse Large B-Cell Lymphoma\|Refractory Follicular Lymphoma	March 23, 2018	Phase 2
NCT01318915	National Institute of Allergy and Infectious Diseases (NIAID)\|Immune Tolerance Network (ITN)	Renal Transplant Recipients	July 25, 2011	Early Phase 1
NCT00003150	Eastern Cooperative Oncology Group\|National Cancer Institute (NCI)\|Cancer and Leukemia Group B\|Southwest Oncology Group	Lymphoma	December 1997	Phase 3
NCT00388193	PETHEMA Foundation	Acute Lymphoblastic Leukemia\|Burkitt´s Lymphoma	August 2006	Phase 2
NCT00003280	Swiss Group for Clinical Cancer Research	Lymphoma	January 1998	Phase 3
NCT03518112	M.D. Anderson Cancer Center\|National Cancer Institute (NCI)	Philadelphia Chromosome Negative\|Recurrent B Acute Lymphoblastic Leukemia\|Refractory B Acute Lymphoblastic Leukemia	April 18, 2018	Phase 2
NCT01274182	Sandoz\|Novartis Pharmaceuticals	Rheumatoid Arthritis	January 2011	Phase 1\|Phase 2
NCT00977977	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)\|National Institutes of Health Clinical Center (CC)	Nephrotic Syndrome\|Proteinuria\|Autoimmune Disease\|Glomerular Disease\|Membranous Glomerulonephritis	December 22, 2010	Phase 2
NCT00290498	M.D. Anderson Cancer Center\|Genentech, Inc.	Lymphoma	August 1, 2005	Phase 2
NCT02844322	Institute of Hematology & Blood Diseases Hospital	Waldenström Macroglobulinemia	May 2016	Phase 4
NCT00039195	Memorial Sloan Kettering Cancer Center\|National Cancer Institute (NCI)\|Bristol-Myers Squibb\|Genentech, Inc.	Lymphoma	November 2006	Phase 2
NCT02972840	Acerta Pharma BV\|AstraZeneca	Lymphoma, Mantle Cell	April 5, 2017	Phase 3
NCT00496340	H. Lee Moffitt Cancer Center and Research Institute	Hematologic Malignancies	July 2007	Phase 2
NCT01126541	Hoffmann-La Roche	Rheumatoid Arthritis	September 2006	Phase 3
NCT01224769	Gruppo Italiano Studio Linfomi	Relapsed or Refractory Chronic Lymphoproliferative Disorders	September 2005
NCT03112603	Incyte Corporation	Graft-versus-host Disease (GVHD)	March 7, 2018	Phase 3
NCT03312907	GlaxoSmithKline	Systemic Lupus Erythematosus	March 1, 2018	Phase 3
NCT05115409	Sun Yat-sen University\|Chipscreen Biosciences, Ltd.	Relapsed or Refractory DLBCL	June 1, 2022	Phase 2
NCT03010202	Ostfold Hospital Trust\|Oslo University Hospital\|St. Olavs Hospital\|Helse Stavanger HF\|University Hospital of North Norway\|Haukeland University Hospital\|Odense University Hospital\|Centre Hôpital Universitaire Farhat Hached, Tunisia\|Henri Mondor University Hospital\|University Hospital, Akershus\|Hammersmith hospital, UK\|Cairo University Hospital, Egypt	Purpura, Thrombocytopenic, Idiopathic	December 2016	Phase 3
NCT00452374	M.D. Anderson Cancer Center\|Sanofi	Leukemia	November 2004	Phase 1\|Phase 2
NCT01371630	M.D. Anderson Cancer Center\|National Cancer Institute (NCI)	B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1\|B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative\|Burkitt-Like Lymphoma With 11q Aberration\|High Grade B-Cell Lymphoma With MYC and BCL2 and+or BCL6 Rearrangements\|High Grade B-Cell Lymphoma, Not Otherwise Specified\|Recurrent B Acute Lymphoblastic Leukemia\|Recurrent Burkitt Lymphoma\|Refractory B Acute Lymphoblastic Leukemia\|Refractory Burkitt Lymphoma	August 26, 2011	Phase 1\|Phase 2
NCT01859819	New York Medical College	Diffuse Large Cell Lymphoma\|Burkitt´s Lymphoma\|High Grade B-cell Lymphoma	January 2013	Phase 2
NCT02758925	University Hospital, Caen	Diffuse Large B Cell Lymphoma	June 2016	Phase 2
NCT04799275	National Cancer Institute (NCI)	Ann Arbor Stage III Diffuse Large B-Cell Lymphoma\|Ann Arbor Stage IIX (Bulky) Diffuse Large B-Cell Lymphoma\|Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma\|Diffuse Large B-Cell Lymphoma Activated B-Cell Type\|Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation\|Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type\|Diffuse Large B-Cell Lymphoma, Not Otherwise Specified\|EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified\|Grade 3b Follicular Lymphoma\|HHV8-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified\|High Grade B-Cell Lymphoma With MYC and BCL2 and+or BCL6 Rearrangements\|High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements\|High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements\|High Grade B-Cell Lymphoma, Not Otherwise Specified\|Intravascular Large B-Cell Lymphoma\|Lymphoplasmacytic Lymphoma\|Nodular Lymphocyte Predominant Hodgkin Lymphoma\|Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type\|T-Cell+Histiocyte-Rich Large B-Cell Lymphoma\|Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma\|Transformed Marginal Zone Lymphoma to Diffuse Large B-Cell Lymphoma	March 19, 2021	Phase 2\|Phase 3
NCT00074490	National Cancer Institute (NCI)\|National Institutes of Health Clinical Center (CC)	Lymphoma\|Leukemia\|Myeloproliferative Disorders\|Multiple Myleoma\|Myelodysplastic Syndrome	January 1, 2004	Phase 2
NCT02371096	Gedeon Richter Plc.	Rheumatoid Arthritis		Phase 1
NCT02471911	Weill Medical College of Cornell University\|Karyopharm Therapeutics Inc\|The Leukemia and Lymphoma Society\|FDA Office of Orphan Products Development	Diffuse Large B-Cell Lymphoma	December 11, 2015	Phase 1
NCT01238146	National Cancer Institute (NCI)	Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue\|Nodal Marginal Zone B-cell Lymphoma\|Recurrent Grade 1 Follicular Lymphoma\|Recurrent Grade 2 Follicular Lymphoma\|Recurrent Mantle Cell Lymphoma\|Recurrent Marginal Zone Lymphoma\|Splenic Marginal Zone Lymphoma	October 2010	Phase 1\|Phase 2
NCT00176475	University of Medicine and Dentistry of New Jersey\|National Cancer Institute (NCI)\|Rutgers, The State University of New Jersey	Leukemia\|Lymphoma\|Multiple Myeloma and Plasma Cell Neoplasm	January 2005	Phase 1
NCT00749112	Hospital Universitario Dr. Jose E. Gonzalez	Idiopathic Thrombocytopenic Purpura\|Anemia, Hemolytic, Autoimmune	August 2008	Phase 2\|Phase 3
NCT00201721	Ohio State University Comprehensive Cancer Center\|Astex Pharmaceuticals, Inc.	B-Chronic Lymphocytic Leukemia	July 2002	Phase 2
NCT00150111	Odense University Hospital	Graves´ Disease\|Thyroid Associated Ophthalmopathy	June 2003	Phase 1\|Phase 2
NCT01886872	National Cancer Institute (NCI)	Stage I Chronic Lymphocytic Leukemia\|Stage II Chronic Lymphocytic Leukemia\|Stage III Chronic Lymphocytic Leukemia\|Stage IV Chronic Lymphocytic Leukemia	December 9, 2013	Phase 3
NCT00987493	Swiss Group for Clinical Cancer Research	Lymphoma	September 2009	Phase 1\|Phase 2
NCT04871191	Assistance Publique - Hôpitaux de Paris\|URC-CIC Paris Descartes Necker Cochin	Granulomatosis With Polyangiitis\|Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis	October 2022	Phase 2
NCT05332587	First Affiliated Hospital, Sun Yat-Sen University	Refractory Myasthenia Gravis\|Rituximab	August 1, 2020	Phase 3
NCT02160015	National Cancer Institute (NCI)	Ann Arbor Stage III Small Lymphocytic Lymphoma\|Ann Arbor Stage IV Small Lymphocytic Lymphoma\|Recurrent Chronic Lymphocytic Leukemia\|Recurrent Small Lymphocytic Lymphoma\|Refractory Chronic Lymphocytic Leukemia\|Refractory Small Lymphocytic Lymphoma\|Stage III Chronic Lymphocytic Leukemia\|Stage IV Chronic Lymphocytic Leukemia	May 9, 2014	Phase 1
NCT03615105	Memorial Sloan Kettering Cancer Center	Acute Lymphoid Leukemia (ALL)\|Acute Myeloid Leukemia (AML)\|Chronic Myeloid Leukemia (CML)\|Hodgkin Lymphoma\|Non-Hodgkin Lymphoma\|Chronic Lymphocytic Leukemia	July 25, 2018	Phase 2
NCT05564052	Janssen Research & Development, LLC\|Pharmacyclics LLC.	Lymphoma, Mantle-Cell	December 21, 2022	Phase 2\|Phase 3
NCT00075946	Eastern Cooperative Oncology Group\|National Cancer Institute (NCI)	Lymphoma	November 2003	Phase 3
NCT02623920	University of Arizona	Diffuse Large B Cell Lymphoma\|Mediastinal Large B-cell Lymphoma\|Grey Zone Lymphoma\|High Grade B Cell Lymphoma\|Follicular Lymphoma\|Marginal Zone Lymphoma\|Small Lymphocytic Lymphoma	December 16, 2015	Phase 2
NCT01980654	Pharmacyclics LLC.	Follicular Lymphoma\|B-cell Lymphoma\|Non-Hodgkin´s Lymphoma	December 2013	Phase 2
NCT00062296	Fox Chase Cancer Center\|National Cancer Institute (NCI)	Leukemia\|Lymphoma	March 2003	Phase 2
NCT02197767	Mayo Clinic\|Genentech, Inc.	Fibrillary Glomerulonephritis	November 2014	Phase 2
NCT01013961	ECOG-ACRIN Cancer Research Group\|National Cancer Institute (NCI)\|Eastern Cooperative Oncology Group	Chronic Lymphocytic Leukemia	October 2010	Phase 2
NCT00801632	National Institute of Allergy and Infectious Diseases (NIAID)\|Immune Tolerance Network (ITN)	Kidney Transplantation\|Kidney Failure, Chronic	December 2008	Phase 2
NCT02626455	Bayer	Lymphoma, Non-Hodgkin	January 6, 2016	Phase 3
NCT00216164	Hoosier Cancer Research Network\|Eli Lilly and Company\|Walther Cancer Institute	Lymphoma, B-Cell	April 2005	Phase 2
NCT04525729	CHENNAN\|Dongfang Hospital Affiliated to Tongji University\|Shanghai Pudong New Area People´s Hospital\|Ruijin Hospital North Shanghai Jiao Tong University School of Medicine\|Ningbo Municipal Yinzhou District No.2 Hospital\|Third Affiliated Hospital, Sun Yat-Sen University\|Xiamen Hongai Hospital\|Sir Run Run Shaw Hospital\|Ruijin Hospital	IgA Nephropathy	July 1, 2020	Phase 4
NCT00556699	Genentech, Inc.\|Seagen Inc.	Non-Hodgkin´s Lymphoma	December 2007	Phase 1
NCT03154385	Assistance Publique - Hôpitaux de Paris	Immune Thrombocytopenia	March 13, 2017	Not Applicable
NCT01560117	Arbeitsgemeinschaft medikamentoese Tumortherapie	Follicular T-NHL Lymphoma\|Rituximab Maintenance	January 2004	Phase 2
NCT02059239	Weill Medical College of Cornell University	Hodgkin´s Lymphoma\|Non-Hodgkin´s Lymphoma	June 4, 2014	Phase 1\|Phase 2
NCT04784052	Rajni Agarwal\|Stanford University	Fanconi Anemia	December 7, 2021	Phase 1\|Phase 2
NCT04083066	Mingzhi Zhang\|Zhengzhou University	Primary Central Nervous System Lymphoma	September 5, 2019	Phase 4
NCT05498220	UNC Lineberger Comprehensive Cancer Center\|Genentech, Inc.	Diffuse Large B-cell Lymphoma	October 27, 2022	Phase 2
NCT04323566	Uppsala University Hospital\|Uppsala University	Obsessive-Compulsive Disorder\|Obsessive-Compulsive Behavior\|Schizophrenia\|Delusional Disorder\|Brief Psychotic Disorder\|Schizo Affective Disorder\|Other Psychoses\|Unspecified Psychosis	May 1, 2022	Phase 2
NCT00918723	Fred Hutchinson Cancer Center\|National Cancer Institute (NCI)	Chronic Lymphocytic Leukemia\|Stage I Chronic Lymphocytic Leukemia\|Stage I Small Lymphocytic Lymphoma\|Stage II Chronic Lymphocytic Leukemia\|Stage II Small Lymphocytic Lymphoma\|Stage III Chronic Lymphocytic Leukemia\|Stage III Small Lymphocytic Lymphoma\|Stage IV Chronic Lymphocytic Leukemia\|Stage IV Small Lymphocytic Lymphoma	June 2009	Phase 1\|Phase 2
NCT03736616	Swedish Medical Center\|Acerta Pharma BV	Diffuse Large B Cell Lymphoma	August 16, 2019	Phase 2
NCT01449344	Prof. Dr. M. Dreyling (co-chairman)\|Klinikum der Universitaet Muenchen, Grosshadern\|ClinAssess GmbH\|GELARC Service de Pharmacovigilance, Pierre Benite\|European Mantle Cell Lymphoma Network	Mantle Cell Lymphoma	May 9, 2009	Phase 3
NCT01096992	M.D. Anderson Cancer Center	Leukemia	April 19, 2010	Phase 1\|Phase 2
NCT00645606	University Hospital, Tours\|Roche Pharma AG\|French Innovative Leukemia Organisation	Leukemia	December 2007	Phase 3
NCT00833534	Fred Hutchinson Cancer Center\|National Cancer Institute (NCI)	Leukemia\|Lymphoma	February 2009	Phase 2
NCT05201248	AbbVie\|Genmab	B-Cell Non-Hodgkin Lymphoma	March 10, 2022	Phase 1
NCT01000441	University Hospital, Strasbourg, France	Rheumatoid Arthritis	December 23, 2009	Phase 4
NCT00140660	Lymphoma Study Association\|Amgen	Diffuse Large Cell Lymphoma	December 2003	Phase 3
NCT02141451	Masonic Cancer Center, University of Minnesota	Diffuse Large B Cell Non-Hodgkin Lymphoma	May 2014	Phase 1\|Phase 2
NCT02332941	Washington University School of Medicine	Macular Degeneration	August 2014	Phase 1
NCT05209308	MEI Pharma, Inc.\|Kyowa Kirin, Inc.	CLL	November 2022	Phase 2
NCT05270057	Medical College of Wisconsin	B-cell Lymphoma\|Burkitt Lymphoma	December 2022	Phase 1
NCT00387959	Memorial Sloan Kettering Cancer Center\|National Cancer Institute (NCI)	Leukemia\|Lymphoma	July 2006	Phase 2
NCT00784927	Mayo Clinic\|National Cancer Institute (NCI)	Lymphoma	November 2008	Phase 2
NCT04913103	Czech Lymphoma Study Group	Lymphoma, Mantle-Cell	September 1, 2021	Phase 2
NCT00107380	Southwest Oncology Group\|National Cancer Institute (NCI)	Lymphoma	November 2005	Phase 2
NCT00723658	Southwest Oncology Group\|National Cancer Institute (NCI)	Lymphoma	September 2008	Phase 2
NCT03844061	Hospital for Special Surgery, New York\|GlaxoSmithKline	Systemic Sclerosis	July 29, 2019	Phase 2
NCT04433156	Henan Cancer Hospital	Marginal Zone Lymphoma	April 22, 2020	Phase 2
NCT03527147	Acerta Pharma BV\|AstraZeneca	NHL\|DLBCL\|Non-hodgkin´s Lymphoma\|Diffuse Large B Cell Lymphoma	June 19, 2018	Phase 1
NCT02484053	Baylor College of Medicine	Hematologic Disorders\|Oncologic Disorders\|Rheumatologic Disorders	June 2015	Early Phase 1
NCT01732926	Gilead Sciences	Indolent Non-Hodgkin´s Lymphomas	January 2, 2013	Phase 3
NCT01156922	Haukeland University Hospital	Chronic Fatigue Syndrome\|Myalgic Encephalomyelitis	June 2010	Phase 2
NCT01332994	Hoffmann-La Roche	Rheumatoid Arthritis	March 2011	Phase 3
NCT01056510	Hoffmann-La Roche	Lymphocytic Leukemia, Chronic	March 2010	Phase 4
NCT05453500	University of Washington\|Incyte Corporation	B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative	January 1, 2023	Phase 2
NCT05200312	The First Affiliated Hospital with Nanjing Medical University	Non Hodgkin Lymphoma\|Diffuse Large B Cell Lymphoma	February 1, 2022	Phase 2
NCT00278161	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins\|National Cancer Institute (NCI)	Leukemia\|Lymphoma	January 2005	Phase 2
NCT01713738	Neufeld, Ellis J, MD, PhD\|Genentech, Inc.\|Biogen\|Glaser Pediatric Research Network\|Terrana ITP Research Fund	Idiopathic Thrombocytopenic Purpura (ITP)\|Immune Thrombocytopenic Purpura (ITP)	May 2003	Phase 1\|Phase 2
NCT02329080	International Extranodal Lymphoma Study Group (IELSG)	Diffuse Large B-cell Lymphoma	December 2014	Phase 2
NCT05057468	Assiut University	Primary Autoimmune Hemolytic Anemia	October 20, 2021	Phase 3
NCT01419561	National Cancer Institute (NCI)\|National Institutes of Health Clinical Center (CC)	KSHV Inflammatory Cytokine Syndrome (KICS)\|KSHV\|HHV-8	September 8, 2011	Phase 2
NCT02532192	M.D. Anderson Cancer Center\|Spectrum Pharmaceuticals, Inc	Lymphoma	December 2015	Phase 1
NCT02819726	Archigen Biotech Limited	Rheumatoid Arthritis	October 11, 2016	Phase 1
NCT02398240	Mitchell Cairo\|New York Medical College	Hodgkin Lymphoma	May 2015	Phase 2
NCT00199004	Johann Wolfgang Goethe University Hospital	Adult Acute Lymphocytic Leukemia	April 2004	Phase 4
NCT05508009	Alice Bertaina\|Stanford University	SIOD With CKD Stage 3 Through 5\|Cystinosis With CKD Stage 3 Through 5\|FSGS With CKD Stage 3 Through 5\|SLE Nephritis With CKD Stage 3 Through 5	October 2022	Phase 1\|Phase 2
NCT04224571	Chinese University of Hong Kong\|Shanghai Children´s Medical Center	Acute Lymphoblastic Leukemia, in Relapse	September 14, 2018	Phase 2
NCT04256252	Tang-Du Hospital	Neuromyelitis Optica Spectrum Disorder	April 2014	Phase 4
NCT00662948	PETHEMA Foundation\|GELCAB\|Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea	Lymphoma	December 2008	Phase 2
NCT00064116	NCIC Clinical Trials Group\|Canadian Cancer Trials Group	Lymphoma	May 8, 2001	Phase 3
NCT04136756	Nektar Therapeutics	Multiple Myeloma\|Non-Hodgkin Lymphoma\|Indolent Non-Hodgkin Lymphoma	October 7, 2019	Phase 1
NCT01421667	Seagen Inc.	Lymphoma, B-Cell\|Lymphoma, Large B-Cell, Diffuse\|Lymphoma, Non-Hodgkin\|Lymphoma, T-Cell	August 2011	Phase 2
NCT00268983	GlaxoSmithKline	Lymphoma, Non-Hodgkin	October 2004	Phase 3
NCT00718549	Hoffmann-La Roche	Lymphocytic Leukemia, Chronic	July 21, 2009	Phase 3
NCT01702961	Baylor College of Medicine\|The Methodist Hospital Research Institute\|Center for Cell and Gene Therapy, Baylor College of Medicine	Lymphoma\|Hodgkin´s Disease	June 2002	Not Applicable
NCT01649856	Hoffmann-La Roche	Lymphoma, Large B-Cell, Diffuse	August 24, 2012	Phase 3
NCT00794638	SymBio Pharmaceuticals	Non-Hodgkin´s Lymphoma\|Diffuse Large B-Cell Lymphoma\|Mantle Cell Lymphoma\|Follicular Lymphoma	November 2008	Phase 1
NCT05063513	European Society for Blood and Marrow Transplantation\|EULAR	REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUS	July 2009	Phase 2\|Phase 3
NCT02628405	Academic and Community Cancer Research United\|National Cancer Institute (NCI)	Recurrent B-Cell Non-Hodgkin Lymphoma\|Recurrent Diffuse Large B-Cell Lymphoma\|Recurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma\|Recurrent Transformed Non-Hodgkin Lymphoma\|Refractory B-Cell Non-Hodgkin Lymphoma\|Refractory Diffuse Large B-Cell Lymphoma\|Refractory Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma\|Refractory Transformed Non-Hodgkin Lymphoma	May 20, 2016	Phase 1\|Phase 2
NCT00169208	Lymphoma Study Association	Follicular Lymphoma	April 2001	Phase 2
NCT00168740	Biogen	Low-Grade or Follicular B-Cell Non-Hodgkin´s Lymphoma	April 1995	Phase 3
NCT02486952	Hoffmann-La Roche\|Serbian Lymphoma Group	Lymphoma, Lymphoma, Large B-Cell, Diffuse, Non-Hodgkin´s Lymphoma, Lymphoma, Non Hodgkin, Relapsed or Refractory Diffuse Large B-Cell Lymphoma	August 2005
NCT01765842	Fundación Pública Andaluza Progreso y Salud\|Ministry of Health, Spain\|Andalusian Network for Design and Translation of Advanced Therapies	Lupus Nephritis	November 2012	Phase 3
NCT00098670	National Cancer Institute (NCI)	B-cell Chronic Lymphocytic Leukemia\|Stage I Chronic Lymphocytic Leukemia\|Stage II Chronic Lymphocytic Leukemia\|Stage III Chronic Lymphocytic Leukemia\|Stage IV Chronic Lymphocytic Leukemia	October 2004	Phase 2
NCT01609023	Hoffmann-La Roche	Lymphocytic Leukemia, Chronic	April 2012
NCT00012051	Commissie Voor Klinisch Toegepast Onderzoek\|National Cancer Institute (NCI)	Lymphoma	September 2000	Phase 3
NCT01734057	Shandong University\|The Affiliated Hospital of the Chinese Academy of Military Medical Sciences\|Anhui Medical University\|The First Affiliated Hospital of Dalian Medical University\|Shandong Provincial Hospital\|Shenzhen Second People´s Hospital\|China Medical University, China\|Zhejiang Provincial Hospital of TCM	Purpura\|Idiopathic Thrombocytopenic Purpura	July 2012	Phase 3
NCT00243412	Genentech, Inc.	Rheumatoid Arthritis	August 2005	Phase 2
NCT04752163	M.D. Anderson Cancer Center	Hematopoietic and Lymphoid Cell Neoplasm\|Recurrent Acute Lymphoblastic Leukemia\|Recurrent Acute Myeloid Leukemia\|Recurrent Chronic Myelomonocytic Leukemia\|Recurrent Myelodysplastic Syndrome\|Refractory Acute Lymphoblastic Leukemia\|Refractory Acute Myeloid Leukemia\|Refractory Chronic Myelomonocytic Leukemia\|Refractory Myelodysplastic Syndrome	March 25, 2021	Phase 1\|Phase 2
NCT02204982	SecuraBio	Follicular Lymphoma	September 2014	Phase 3
NCT00278421	German High-Grade Non-Hodgkin´s Lymphoma Study Group	Lymphoma	November 2005	Phase 3
NCT04155840	University of Washington\|Bayer	Lymphoid Leukemia\|Non-Hodgkin´s Lymphoma\|Chronic Lymphocytic Leukemia\|Small Lymphocytic Lymphoma	January 31, 2020	Phase 2
NCT03019640	M.D. Anderson Cancer Center\|National Cancer Institute (NCI)	Mantle Cell Lymphoma\|Recurrent Diffuse Large B-Cell Lymphoma\|Recurrent Follicular Lymphoma\|Recurrent Indolent Adult Non-Hodgkin Lymphoma\|Refractory Diffuse Large B-Cell Lymphoma\|Refractory Follicular Lymphoma\|Refractory Indolent Adult Non-Hodgkin Lymphoma	October 10, 2017	Phase 2
NCT02258529	Gilead Sciences	Follicular Lymphoma\|Small Lymphocytic Lymphoma	September 14, 2015	Phase 2
NCT00281983	German CLL Study Group	Chronic Lymphocytic Leukemia	June 2000	Phase 1\|Phase 2
NCT03804372	Gruppo Italiano Malattie EMatologiche dell´Adulto	Large-B-cell Diffuse Lymphoma\|Chronic Lymphoid Leukemia	July 7, 2020	Phase 2
NCT01810588	Weill Medical College of Cornell University	Hematologic Malignancies	October 16, 2012	Phase 2
NCT01072240	Hoffmann-La Roche	Lymphocytic Leukemia, Chronic	September 2009
NCT03758989	University of Rochester	DLBCL	May 8, 2019	Phase 2
NCT00210340	International Extranodal Lymphoma Study Group (IELSG)	Lymphoma, B Cell		Phase 1
NCT02735876	Acerta Pharma BV	Mantle Cell Lymphoma	May 2016	Phase 3
NCT02366663	City of Hope Medical Center\|National Cancer Institute (NCI)	Recurrent Diffuse Large B-Cell Lymphoma\|Refractory Diffuse Large B-Cell Lymphoma	January 2015	Phase 3
NCT02257567	Hoffmann-La Roche	Lymphoma	October 15, 2014	Phase 1\|Phase 2
NCT02049541	Kami Maddocks, MD\|Novartis\|Ohio State University Comprehensive Cancer Center	Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue\|Nodal Marginal Zone B-cell Lymphoma\|Recurrent Grade 1 Follicular Lymphoma\|Recurrent Grade 2 Follicular Lymphoma\|Recurrent Grade 3 Follicular Lymphoma\|Recurrent Mantle Cell Lymphoma\|Recurrent Marginal Zone Lymphoma\|Splenic Marginal Zone Lymphoma\|Waldenström Macroglobulinemia	July 21, 2014	Phase 1
NCT02320292	Mayo Clinic\|National Cancer Institute (NCI)	Ann Arbor Stage I Grade 1 Follicular Lymphoma\|Ann Arbor Stage I Grade 2 Follicular Lymphoma\|Ann Arbor Stage II Grade 1 Contiguous Follicular Lymphoma\|Ann Arbor Stage II Grade 1 Non-Contiguous Follicular Lymphoma\|Ann Arbor Stage II Grade 2 Contiguous Follicular Lymphoma\|Ann Arbor Stage II Grade 2 Non-Contiguous Follicular Lymphoma\|Ann Arbor Stage III Grade 1 Follicular Lymphoma\|Ann Arbor Stage III Grade 2 Follicular Lymphoma\|Ann Arbor Stage IV Grade 1 Follicular Lymphoma\|Ann Arbor Stage IV Grade 2 Follicular Lymphoma	February 11, 2015	Phase 3
NCT02451111	Swiss Group for Clinical Cancer Research\|Nordic Lymphoma Group	Follicular Lymphoma	November 6, 2015	Phase 2
NCT05280626	Innovent Biologics (Suzhou) Co. Ltd.	Diffuse Large B-Cell Lymphoma	March 25, 2022	Phase 2
NCT00498368	Mayo Clinic\|Ohio State University\|Stanford University\|University of North Carolina, Chapel Hill\|Columbia University\|Genentech, Inc.\|Biogen	IgA Nephropathy	February 2009	Phase 4
NCT03023046	University of Washington\|National Cancer Institute (NCI)	Acute Lymphoblastic Leukemia\|Lymphoblastic Lymphoma	February 23, 2017	Phase 2
NCT03366272	Universität des Saarlandes\|Bristol-Myers Squibb\|Lymphoma Study Association\|University of Leipzig	Lymphoma, Non-Hodgkin	December 5, 2017	Phase 2\|Phase 3
NCT00536978	M.D. Anderson Cancer Center	Lymphoma\|Leukemia	September 2007	Phase 2
NCT00078598	Corixa Corporation	Non-Hodgkin´s Lymphoma	April 2004	Phase 3
NCT02077166	Pharmacyclics LLC.\|Janssen Research & Development, LLC\|Celgene Corporation	Relapsed Diffuse Large B-Cell Lymphoma\|Refractory Diffuse Large B-Cell Lymphoma	March 13, 2014	Phase 1\|Phase 2
NCT03746223	Peking Union Medical College Hospital	Primary Intraocular Lymphoma	November 15, 2018	Phase 2
NCT03424122	Incyte Corporation	B-cell Lymphoma	July 2, 2018	Phase 1
NCT01136395	University of Giessen\|Heidelberg University\|German Cancer Research Center\|Astellas Pharma US, Inc.\|Novartis	Kidney Transplantation\|Rituximab (RTx)\|Living Donors\|Immunology\|Virus	January 2010	Phase 2
NCT00052923	Eastern Cooperative Oncology Group\|National Cancer Institute (NCI)\|Cancer and Leukemia Group B	Lymphoma	March 2003	Phase 3
NCT00877006	Teva Branded Pharmaceutical Products R&D, Inc.	Non-Hodgkin´s Lymphoma\|Mantle Cell Lymphoma	April 30, 2009	Phase 3
NCT01103388	M.D. Anderson Cancer Center\|Genentech, Inc.	Non-Hodgkin´s Lymphoma	August 2003	Phase 3
NCT04154787	Novartis Pharmaceuticals\|Novartis	Glomerulonephritis, Membranous	November 23, 2019	Phase 2
NCT04594798	University of Rochester\|Genentech, Inc.	DLBCL\|Lymphoma, B-Cell	September 20, 2021	Phase 2
NCT00255593	Karolinska University Hospital	Renal Transplantation	November 2005	Phase 1
NCT01279902	Asan Medical Center	Diffuse Large B-cell Lymphoma	August 2010	Phase 2
NCT01812005	Ohio State University Comprehensive Cancer Center\|Millennium Pharmaceuticals, Inc.	Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue\|Nodal Marginal Zone B-cell Lymphoma\|Recurrent Adult Burkitt Lymphoma\|Recurrent Adult Diffuse Large Cell Lymphoma\|Recurrent Grade 1 Follicular Lymphoma\|Recurrent Grade 2 Follicular Lymphoma\|Recurrent Grade 3 Follicular Lymphoma\|Recurrent Mantle Cell Lymphoma\|Recurrent Marginal Zone Lymphoma\|Splenic Marginal Zone Lymphoma\|Waldenström Macroglobulinemia	May 21, 2013	Phase 2
NCT00400764	Genentech, Inc.\|Amgen	Non-Hodgkin´s Lymphoma	June 2006	Phase 1\|Phase 2
NCT00505895	M.D. Anderson Cancer Center	Multiple Myeloma	January 2002	Phase 2
NCT04915482	Institute of Hematology & Blood Diseases Hospital	Immune Thrombocytopenia (ITP)\|Autoantibodies\|Evan Syndrome\|Connective Tissue Diseases	June 6, 2021	Phase 4
NCT01832922	Dartmouth-Hitchcock Medical Center\|National Cancer Institute (NCI)	Chronic Lymphocytic Leukemia\|Small Lymphocytic Lymphoma	April 2013	Phase 1
NCT03795571	The First Affiliated Hospital with Nanjing Medical University	Diffuse Large B-cell Lymphoma Recurrent\|Diffuse Large B Cell Lymphoma Refractory	January 1, 2019	Phase 1
NCT00299182	M.D. Anderson Cancer Center\|Amgen	Lymphoma	March 2006	Phase 1\|Phase 2
NCT03193866	Karolinska Institutet\|Patient-Centered Outcomes Research Institute\|Kaiser Foundation Research Institute	Relapsing-remitting Multiple Sclerosis	June 2, 2017
NCT01691898	Genentech, Inc.	Follicular Lymphoma\|Diffuse Large B-Cell Lymphoma	September 27, 2012	Phase 1\|Phase 2
NCT00771602	M.D. Anderson Cancer Center\|Genzyme, a Sanofi Company	Chronic Lymphocytic Leukemia\|Leukemia	August 2008	Phase 2
NCT03949062	Ruijin Hospital	Diffuse Large B Cell Lymphoma	March 13, 2019	Phase 2
NCT05553496	Ain Shams University	Pharmacological Action	September 25, 2022	Phase 2\|Phase 3
NCT00551239	CTI BioPharma	Leukemia\|Lymphoma	August 2007	Phase 3
NCT00788606	Royal Marsden NHS Foundation Trust\|Hoffmann-La Roche	Non-Hodgkin´s Lymphoma\|B-cell Lymphoma	May 2008	Phase 2
NCT01116232	Barbara Ann Karmanos Cancer Institute\|National Cancer Institute (NCI)	Chronic Myeloproliferative Disorders\|Graft Versus Host Disease\|Leukemia\|Lymphoma\|Lymphoproliferative Disorder\|Multiple Myeloma and Plasma Cell Neoplasm\|Myelodysplastic Syndromes\|Myelodysplastic+Myeloproliferative Neoplasms	August 2010	Phase 2
NCT01470196	Dana-Farber Cancer Institute\|Amgen	Waldenstrom´s Macroglobulinemia	October 2011	Phase 2
NCT00701129	Genzyme, a Sanofi Company\|Sanofi	Pompe Disease\|Glycogen Storage Disease Type II	October 2009	Phase 4
NCT01086631	National Eye Institute (NEI)\|National Institutes of Health Clinical Center (CC)	Autoimmune Disease	January 22, 2010	Phase 1
NCT01303887	University of Liverpool\|Liverpool University Hospitals NHS Foundation Trust\|Cancer Research UK\|Roche Pharma AG	Follicular Lymphoma	October 2009	Phase 3
NCT03259503	M.D. Anderson Cancer Center\|National Cancer Institute (NCI)	Recurrent Diffuse Large B-Cell Lymphoma\|Recurrent T-Cell Non-Hodgkin Lymphoma\|Refractory Diffuse Large B-Cell Lymphoma\|Refractory Hodgkin Lymphoma\|Refractory T-Cell Non-Hodgkin Lymphoma	September 13, 2019	Phase 1
NCT04127578	Prevail Therapeutics\|Eli Lilly and Company	Parkinson Disease	January 3, 2020	Phase 1\|Phase 2
NCT02442648	E. Steve Woodle\|Amgen\|University of Cincinnati	Transplants and Implants	December 2014	Phase 1
NCT00432653	Charite University, Berlin, Germany\|Hoffmann-La Roche	Ankylosing Spondylitis	March 2007	Phase 2\|Phase 3
NCT01625741	Cliniques universitaires Saint-Luc- Université Catholique de Louvain	Chronic Lymphocytic Leukemia	July 2012	Phase 2
NCT00294632	M.D. Anderson Cancer Center\|Celgene Corporation	Lymphoma	February 2006	Phase 1\|Phase 2
NCT01439750	Milton S. Hershey Medical Center	Mantle Cell Lymphoma	May 2012	Phase 1
NCT00048737	M.D. Anderson Cancer Center\|Biogen	Lymphoma\|Leukemia	October 2002	Phase 1\|Phase 2
NCT04464798	Celgene	Lymphoma	November 11, 2020	Phase 1
NCT00372892	Hamilton Health Sciences Corporation\|Hoffmann-La Roche\|McMaster University	Purpura, Thrombocytopenic, Idiopathic	September 2006	Phase 2
NCT01748084	Assistance Publique - Hôpitaux de Paris	Systemic Sclerosis	April 9, 2013	Phase 2\|Phase 3
NCT00670358	Mayo Clinic\|National Cancer Institute (NCI)	Lymphoma	August 25, 2008	Phase 1\|Phase 2
NCT02481297	M.D. Anderson Cancer Center\|Bristol-Myers Squibb	Leukemia\|Chronic Lymphocytic Leukemia\|Lymphocytic Leukemia	June 23, 2015	Phase 2
NCT00965289	Nantes University Hospital\|French Innovative Leukemia Organisation\|Hoffmann-La Roche	B-Cell Lymphoma	April 2002	Phase 2
NCT01445535	National Cancer Institute (NCI)\|National Institutes of Health Clinical Center (CC)	T-Cell Peripheral Lymphoma\|Gamma Delta Hepatosplenic T-Cell Lymphoma\|Subcutaneous Panniculitis-Like T-Cell Lymphoma\|NK T-Cell Lymphoma	January 13, 2009	Phase 1
NCT00064246	National Cancer Institute (NCI)	Post-transplant Lymphoproliferative Disorder\|Recurrent Adult Burkitt Lymphoma\|Recurrent Adult Diffuse Large Cell Lymphoma\|Stage III Adult Burkitt Lymphoma\|Stage III Adult Diffuse Large Cell Lymphoma\|Stage IV Adult Burkitt Lymphoma\|Stage IV Adult Diffuse Large Cell Lymphoma\|Waldenström Macroglobulinemia	July 2003	Phase 1\|Phase 2
NCT00003716	Stanford University	Lymphoma	March 1998	Phase 2
NCT01524068	University of Pittsburgh	Idiopathic Pulmonary Fibrosis	September 2012	Phase 2
NCT00136396	Dana-Farber Cancer Institute\|Brigham and Women´s Hospital	Graft vs Host Disease	January 2004	Phase 1\|Phase 2
NCT03609593	Nicole Lamanna\|Columbia University	Chronic Lymphocytic Leukemia	November 12, 2018	Phase 2
NCT00074165	OHSU Knight Cancer Institute\|National Cancer Institute (NCI)	Brain and Central Nervous System Tumors\|Drug+Agent Toxicity by Tissue+Organ\|Lymphoma\|Thrombocytopenia	January 2003	Phase 2
NCT01127841	Grupo Oncológico para el Tratamiento y el Estudio de los Linfomas	Follicular Non-Hodgking´s Lymphoma Refractory or Relapsed After Treatment With R-chemotherapy in First Line.	July 2009	Phase 2
NCT04404283	Seagen Inc.	Diffuse Large B-cell Lymphoma	August 20, 2020	Phase 3
NCT00031642	University of Nebraska\|Biogen	Lymphoma	January 2002	Phase 1\|Phase 2
NCT02514772	Sandoz\|Hexal AG	Rheumatoid Arthritis	July 2015	Phase 3
NCT01015248	Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea	MALT LYMPHOMA	May 2009	Phase 2
NCT00005089	Southwest Oncology Group\|National Cancer Institute (NCI)	Lymphoma	April 2000	Phase 2
NCT00060346	Eastern Cooperative Oncology Group\|National Cancer Institute (NCI)	Lymphoma	June 2004	Phase 2
NCT00004889	Jonsson Comprehensive Cancer Center\|Genentech, Inc.	Lymphoma	December 1999	Phase 2
NCT05329090	Hopital Foch\|Ministry of Health, France	IgA Vasculitis	March 11, 2022	Phase 3
NCT00842595	French Innovative Leukemia Organisation	Diffuse Large B-Cell Lymphoma	December 2003	Phase 2
NCT02390362	Nationwide Children´s Hospital\|Emory University\|Children´s Healthcare of Atlanta\|Genentech, Inc.\|The NephCure Foundation	Frequent Relapsing Nephrotic Syndrome\|Steroid Dependent Nephrotic Syndrome	January 2015	Phase 3
NCT04400994	The University of Hong Kong	Pemphigus	June 20, 2020	Phase 2
NCT01209130	Genentech, Inc.	Non-Hodgkin´s Lymphoma, Chronic Lymphocytic Leukemia	October 2010	Phase 1
NCT01009970	Fondazione Italiana Linfomi ONLUS	Diffuse Large B-Cell Lymphoma	May 2010	Phase 2
NCT00201682	John Byrd\|Ohio State University Comprehensive Cancer Center	Chronic Lymphocytic Leukemia\|Small Lymphocytic Lymphoma	October 2002	Phase 1\|Phase 2
NCT00087425	National Institute on Aging (NIA)\|National Cancer Institute (NCI)	Leukemia\|Lymphoma	July 2004	Phase 2
NCT00307593	Assistance Publique - Hôpitaux de Paris	Wegener´s Granulomatosis\|Churg-Strauss Syndrome\|Microscopic Polyangiitis	May 2004	Not Applicable
NCT05596786	University Hospital, Tours	Lung Diseases	December 15, 2022	Phase 3
NCT01326702	National Cancer Institute (NCI)	Adult B Acute Lymphoblastic Leukemia\|Adult Nasal Type Extranodal NK+T-Cell Lymphoma\|Adult Solid Neoplasm\|Anaplastic Large Cell Lymphoma\|Angioimmunoblastic T-Cell Lymphoma\|Chronic Lymphocytic Leukemia\|Cutaneous B-Cell Non-Hodgkin Lymphoma\|Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue\|Hepatosplenic T-Cell Lymphoma\|Intraocular Lymphoma\|Lymphomatous Involvement of Non-Cutaneous Extranodal Site\|Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma\|Nodal Marginal Zone Lymphoma\|Recurrent Adult Acute Lymphoblastic Leukemia\|Recurrent Adult Burkitt Lymphoma\|Recurrent Adult Diffuse Large Cell Lymphoma\|Recurrent Adult Diffuse Mixed Cell Lymphoma\|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma\|Recurrent Adult Grade III Lymphomatoid Granulomatosis\|Recurrent Adult Hodgkin Lymphoma\|Recurrent Adult Immunoblastic Lymphoma\|Recurrent Adult Lymphoblastic Lymphoma\|Recurrent Adult T-Cell Leukemia+Lymphoma\|Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma\|Recurrent Grade 1 Follicular Lymphoma\|Recurrent Grade 2 Follicular Lymphoma\|Recurrent Grade 3 Follicular Lymphoma\|Recurrent Mantle Cell Lymphoma\|Recurrent Marginal Zone Lymphoma\|Recurrent Mycosis Fungoides and Sezary Syndrome\|Recurrent Small Lymphocytic Lymphoma\|Refractory Chronic Lymphocytic Leukemia\|Refractory Hairy Cell Leukemia\|Refractory Plasma Cell Myeloma\|Small Intestinal Lymphoma\|Splenic Marginal Zone Lymphoma\|Testicular Lymphoma\|Waldenstrom Macroglobulinemia	July 2011	Phase 1\|Phase 2
NCT01338103	Rabin Medical Center\|Leumit Health Services	Pemphigus	January 2010	Not Applicable
NCT03189836	Cogent Biosciences, Inc.	Lymphoma	October 4, 2017	Phase 1
NCT05004064	University College, London\|AstraZeneca	Mantle Cell Lymphoma	January 1, 2023	Phase 2
NCT01729104	M.D. Anderson Cancer Center\|Celgene\|Onyx Therapeutics, Inc.	Lymphoma	April 25, 2013	Phase 1
NCT00299130	Genentech, Inc.\|Hoffmann-La Roche	Rheumatoid Arthritis	October 2005	Phase 3
NCT00462345	Hoffmann-La Roche	Rheumatoid Arthritis	June 2007	Phase 4
NCT02113007	SCRI Development Innovations, LLC\|Genentech, Inc.	Primary Central Nervous System Lymphoma	July 2014	Phase 2
NCT00577993	M.D. Anderson Cancer Center\|Genentech, Inc.	Lymphoma	March 16, 1998	Phase 3
NCT02433795	Seoul National University Hospital\|Gyeongsang National University Hospital\|Korea Cancer Center Hospital\|Seoul National University Boramae Hospital\|Hallym University Medical Center\|Inje University\|Gangnam Severance Hospital\|Chonbuk National University Hospital\|Chungnam National University\|The Catholic University of Korea\|Wonju Severance Christian Hospital\|Gachon University Gil Medical Center\|Seoul National University Bundang Hospital	Marginal Zone B-cell Lymphoma	May 2015	Phase 2
NCT03630042	University College, London\|Merck Sharp & Dohme LLC	Waldenstrom Macroglobulinemia	September 6, 2019	Phase 2
NCT01829568	National Cancer Institute (NCI)\|Celgene Corporation	Ann Arbor Stage II Grade 1 Contiguous Follicular Lymphoma\|Ann Arbor Stage II Grade 1 Non-Contiguous Follicular Lymphoma\|Ann Arbor Stage II Grade 2 Contiguous Follicular Lymphoma\|Ann Arbor Stage II Grade 2 Non-Contiguous Follicular Lymphoma\|Ann Arbor Stage II Grade 3 Contiguous Follicular Lymphoma\|Ann Arbor Stage II Grade 3 Non-Contiguous Follicular Lymphoma\|Ann Arbor Stage III Grade 1 Follicular Lymphoma\|Ann Arbor Stage III Grade 2 Follicular Lymphoma\|Ann Arbor Stage III Grade 3 Follicular Lymphoma\|Ann Arbor Stage IV Grade 1 Follicular Lymphoma\|Ann Arbor Stage IV Grade 2 Follicular Lymphoma\|Ann Arbor Stage IV Grade 3 Follicular Lymphoma	June 21, 2013	Phase 1
NCT04224493	Epizyme, Inc.	Relapsed+Refractory Follicular Lymphoma	December 19, 2019	Phase 3
NCT01848132	Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea\|Janssen-Cilag, S.A.	Diffuse, Large B-Cell, Lymphoma	October 3, 2013	Phase 2
NCT02533401	Hoffmann-La Roche	Lymphocytic Leukemia, Chronic	February 2006	Phase 2
NCT04989491	University Hospital, Strasbourg, France	Epstein-Barr Virus Infections	December 1, 2021	Phase 4
NCT01592981	University College, London	Waldenstrom´s Macroglobulinaemia	January 2013	Phase 2
NCT01609010	Hoffmann-La Roche\|Nordic Lymphoma Group	Lymphoma	October 2002	Phase 3
NCT00265915	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins\|National Cancer Institute (NCI)	Leukemia	July 2005	Phase 2
NCT01095172	Guy´s and St Thomas´ NHS Foundation Trust\|Astellas Pharma Europe Ltd.	Function of Renal Transplant	November 2010	Phase 4
NCT00510887	Duke University\|Millennium Pharmaceuticals, Inc.	Lymphoma, Follicular	January 2007	Phase 2
NCT00472849	M.D. Anderson Cancer Center\|Sanofi	Richter´s Transformation\|Leukemia	May 2007	Phase 1\|Phase 2
NCT02162771	Celltrion	Lymphoma, Follicular	July 14, 2014	Phase 3
NCT00453102	University of Miami	Marginal Zone Lymphoma	February 2006	Phase 2
NCT00904722	M.D. Anderson Cancer Center\|CureTech Ltd	Lymphoma	January 2010	Phase 2
NCT05409066	AbbVie\|Genmab	Follicular Lymphoma (FL)	September 20, 2022	Phase 3
NCT01510184	Spectrum Pharmaceuticals, Inc	Diffuse Large B-cell Lymphoma\|Follicle Center Lymphoma	April 19, 2012	Phase 3
NCT00546377	Memorial Sloan Kettering Cancer Center\|National Cancer Institute (NCI)	Leukemia\|Lymphoma	July 2005	Phase 1\|Phase 2
NCT00963534	Lund University Hospital\|Mundipharma Pte Ltd.\|Celgene\|Roche Pharma AG	Mantle Cell Lymphoma	September 2009	Phase 1\|Phase 2
NCT01030900	National Cancer Institute (NCI)\|National Institutes of Health Clinical Center (CC)	Hodgkin Lymphoma\|Diffuse Large B-Cell Lymphoma	October 22, 2009	Phase 2
NCT04458610	M.D. Anderson Cancer Center\|National Cancer Institute (NCI)	Chronic Lymphocytic Leukemia+Small Lymphocytic Lymphoma	May 26, 2020	Phase 2
NCT04129710	Second Affiliated Hospital, School of Medicine, Zhejiang University\|Ruijin Hospital\|The First Affiliated Hospital of Nanchang University\|Fujian Medical University Union Hospital\|RenJi Hospital\|Shanghai Tong Ren Hospital\|Shandong Provincial Hospital\|Cancer Hospital of Guangxi Medical University\|Sir Run Run Shaw Hospital\|Taizhou Hospital of Zhejiang Province affiliated to Wenzhou Medical University\|Ningbo Medical Center Lihuili Hospital\|Yinzhou Hospital Affiliated to Medical School of Ningbo University\|Zhejiang University	Recurrent+RefractoryPrimary Central Nervous System Lymphoma (PCNSL)	January 1, 2020	Phase 2
NCT00656084	US Oncology Research\|Eli Lilly and Company	Relapsed or Refractory Mantle Cell Lymphoma (MCL)	December 2004	Phase 2
NCT05139017	Merck Sharp & Dohme LLC	DLBCL\|Diffuse Large B-Cell Lymphoma	January 14, 2022	Phase 2\|Phase 3
NCT05581030	H. Lee Moffitt Cancer Center and Research Institute\|Servier	Acute Lymphoblastic Leukemia	September 16, 2022	Phase 1
NCT01811368	Joseph Tuscano\|Spectrum Pharmaceuticals, Inc\|University of California, Davis	Refractory Non Hodgkin Lymphoma\|Relapsed Non Hodgkin Lymphoma	March 12, 2013	Phase 2
NCT02692248	Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea\|Janssen-Cilag, S.A.	Diffuse Large B-Cell Lymphoma	April 7, 2016	Phase 2
NCT00093769	Jonsson Comprehensive Cancer Center\|National Cancer Institute (NCI)	Lymphoma	August 2004	Phase 2
NCT00261547	Massachusetts General Hospital\|Genentech, Inc.	Chronic Rejection\|Kidney Insufficiency	December 2005	Phase 1\|Phase 2
NCT04666038	Loxo Oncology, Inc.\|Eli Lilly and Company	Chronic Lymphocytic Leukemia\|Small Lymphocytic Lymphoma	March 9, 2021	Phase 3
NCT03315923	Isfahan University of Medical Sciences	Secondary Progressive Multiple Sclerosis	December 1, 2017	Phase 2\|Phase 3
NCT00060671	CTI BioPharma	Lymphoma, Follicular\|Lymphoma, Mixed-Cell, Follicular\|Lymphoma, Small Cleaved-Cell, Follicular\|Lymphoma, Low-Grade	January 2005	Phase 3
NCT01318317	City of Hope Medical Center\|National Cancer Institute (NCI)	Recurrent Grade 1 Follicular Lymphoma\|Recurrent Grade 2 Follicular Lymphoma\|Recurrent Grade 3 Follicular Lymphoma\|Recurrent Mantle Cell Lymphoma\|Recurrent Non-Hodgkin Lymphoma	September 19, 2011	Phase 1\|Phase 2
NCT01370772	French Innovative Leukemia Organisation\|Roche Pharma AG	B-cell Chronic Lymphocytic Leukemia CLL	May 2011	Phase 2
NCT01144364	Hoffmann-La Roche	Non-Hodgkin´s Lymphoma	January 19, 2004	Phase 3
NCT01509300	Asan Medical Center	Acute Leukemia\|Myelodysplastic Syndrome\|Solid Tumors	January 2012	Phase 1\|Phase 2
NCT02792699	Amgen	Arthritis, Rheumatoid	May 17, 2016	Phase 3
NCT03232307	M.D. Anderson Cancer Center\|National Cancer Institute (NCI)	CCND1 Positive\|CD20-Positive Neoplastic Cells Present\|Mantle Cell Lymphoma	July 1, 2019	Phase 2
NCT02296775	Dr. Reddy´s Laboratories Limited	Rheumatoid Arthritis	November 2014	Phase 1\|Phase 2
NCT00895661	Massachusetts General Hospital\|Dana-Farber Cancer Institute\|Brigham and Women´s Hospital\|Genentech, Inc.	B-cell Lymphoma\|Indolent B-cell Lymphoma	July 2009	Phase 2
NCT00958256	M.D. Anderson Cancer Center\|Millennium Pharmaceuticals, Inc.	Mantle Cell Lymphoma\|Lymphoma	August 2009	Phase 2
NCT04998669	Juan P. Alderuccio, MD\|ADC Therapeutics S.A.\|University of Miami	Follicular Lymphoma	February 11, 2022	Phase 2
NCT02855359	Seagen Inc.	Diffuse, Large B-Cell, Lymphoma\|Follicular Lymphoma, Grade 3b\|Transformed Lymphoma + DLBCL	August 2016	Phase 2
NCT00080925	National Institutes of Health Clinical Center (CC)\|National Cancer Institute (NCI)	Chronic Myeloproliferative Disorders\|Leukemia\|Lymphoma\|Multiple Myeloma and Plasma Cell Neoplasm\|Myelodysplastic Syndromes\|Myelodysplastic+Myeloproliferative Neoplasms	February 2004	Phase 1
NCT01994382	Alexion Pharmaceuticals\|Portola Pharmaceuticals	Follicular Lymphoma (FL+Indolent NHL)\|Aggressive NHL (a NHL)\|Chronic Lymphocytic Leukemia (CLL) + Small Lymphocytic Lymphoma (SLL)\|T-cell Lymphoma (PTCL and CTCL)\|B-cell Non Hodgkin Lymphoma (NHL)	August 30, 2013	Phase 1\|Phase 2
NCT05455697	University of Washington	Diffuse Large B-Cell Lymphoma\|Grade 3b Follicular Lymphoma\|High Grade B-Cell Lymphoma	December 15, 2022	Phase 1\|Phase 2
NCT02589145	M.D. Anderson Cancer Center\|Celgene Corporation	Lymphoma	June 22, 2016	Phase 1\|Phase 2
NCT04002401	Kite, A Gilead Company\|Gilead Sciences	Refractory Large B-cell Lymphoma	November 5, 2019	Phase 2
NCT01045928	Case Comprehensive Cancer Center	Adult Non-Hodgkin Lymphoma\|Adult Grade III Lymphomatoid Granulomatosis\|Contiguous Stage II Adult Burkitt Lymphoma\|Contiguous Stage II Adult Diffuse Large Cell Lymphoma\|Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma\|Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma\|Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma\|Contiguous Stage II Adult Lymphoblastic Lymphoma\|Contiguous Stage II Grade 1 Follicular Lymphoma\|Contiguous Stage II Grade 2 Follicular Lymphoma\|Contiguous Stage II Grade 3 Follicular Lymphoma\|Contiguous Stage II Mantle Cell Lymphoma\|Contiguous Stage II Marginal Zone Lymphoma\|Contiguous Stage II Small Lymphocytic Lymphoma\|Cutaneous B-cell Non-Hodgkin Lymphoma\|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue\|Nodal Marginal Zone B-cell Lymphoma\|Noncontiguous Stage II Adult Burkitt Lymphoma\|Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma\|Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma\|Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma\|Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma\|Noncontiguous Stage II Adult Lymphoblastic Lymphoma\|Noncontiguous Stage II Grade 1 Follicular Lymphoma\|Noncontiguous Stage II Grade 2 Follicular Lymphoma\|Noncontiguous Stage II Grade 3 Follicular Lymphoma\|Noncontiguous Stage II Mantle Cell Lymphoma\|Noncontiguous Stage II Marginal Zone Lymphoma\|Noncontiguous Stage II Small Lymphocytic Lymphoma\|Recurrent Adult Burkitt Lymphoma\|Recurrent Adult Diffuse Large Cell Lymphoma\|Recurrent Adult Diffuse Mixed Cell Lymphoma\|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma\|Recurrent Adult Grade III Lymphomatoid Granulomatosis\|Recurrent Adult Immunoblastic Large Cell Lymphoma\|Recurrent Adult Lymphoblastic Lymphoma\|Recurrent Grade 1 Follicular Lymphoma\|Recurrent Grade 2 Follicular Lymphoma\|Recurrent Grade 3 Follicular Lymphoma\|Recurrent Mantle Cell Lymphoma\|Recurrent Marginal Zone Lymphoma\|Recurrent Small Lymphocytic Lymphoma\|Splenic Marginal Zone Lymphoma\|Stage I Adult Burkitt Lymphoma\|Stage I Adult Diffuse Large Cell Lymphoma\|Stage I Adult Diffuse Mixed Cell Lymphoma\|Stage I Adult Diffuse Small Cleaved Cell Lymphoma\|Stage I Adult Immunoblastic Large Cell Lymphoma\|Stage I Adult Lymphoblastic Lymphoma\|Stage I Grade 1 Follicular Lymphoma\|Stage I Grade 2 Follicular Lymphoma\|Stage I Grade 3 Follicular Lymphoma\|Stage I Mantle Cell Lymphoma\|Stage I Marginal Zone Lymphoma\|Stage I Small Lymphocytic Lymphoma\|Stage III Adult Burkitt Lymphoma\|Stage III Adult Diffuse Large Cell Lymphoma\|Stage III Adult Diffuse Mixed Cell Lymphoma\|Stage III Adult Diffuse Small Cleaved Cell Lymphoma\|Stage III Adult Immunoblastic Large Cell Lymphoma\|Stage III Adult Lymphoblastic Lymphoma\|Stage III Grade 1 Follicular Lymphoma\|Stage III Grade 2 Follicular Lymphoma\|Stage III Grade 3 Follicular Lymphoma\|Stage III Mantle Cell Lymphoma\|Stage III Marginal Zone Lymphoma\|Stage III Small Lymphocytic Lymphoma\|Stage IV Adult Burkitt Lymphoma\|Stage IV Adult Diffuse Large Cell Lymphoma\|Stage IV Adult Diffuse Mixed Cell Lymphoma\|Stage IV Adult Diffuse Small Cleaved Cell Lymphoma\|Stage IV Adult Immunoblastic Large Cell Lymphoma\|Stage IV Adult Lymphoblastic Lymphoma\|Stage IV Grade 1 Follicular Lymphoma\|Stage IV Grade 2 Follicular Lymphoma\|Stage IV Grade 3 Follicular Lymphoma\|Stage IV Mantle Cell Lymphoma\|Stage IV Marginal Zone Lymphoma\|Stage IV Small Lymphocytic Lymphoma\|Waldenstrom Macroglobulinemia	January 2010	Phase 1
NCT03384277	Zhang Lei\|Qilu Hospital of Shandong University\|Tianjin First Central Hospital\|The Second Affiliated Hospital of Kunming Medical University\|Henan Cancer Hospital\|Institute of Hematology & Blood Diseases Hospital	Acquired Hemophilia A	October 26, 2017	Phase 3
NCT01230788	Emory University	Leukemia\|Acute Lymphoblastic Leukemia\|ALL	September 2010	Not Applicable
NCT01027000	Alliance for Clinical Trials in Oncology\|National Cancer Institute (NCI)\|Genentech, Inc.\|Biologics, Inc.	Leukemia\|Lymphoma	February 2010	Phase 2
NCT00553943	Lymphoma Study Association	Lymphoma, Non-Hodgkin\|Diffuse Large B-cell Lymphoma	July 2007	Phase 2
NCT05622201	Region Örebro County	Schizophrenia Spectrum and Other Psychotic Disorders	January 15, 2023	Phase 2
NCT00135499	Lymphoma Study Association\|Fondation ARC	Lymphoma, Large-Cell, Diffuse	October 16, 2001	Phase 3
NCT01125293	Dana-Farber Cancer Institute\|Novartis\|Millennium Pharmaceuticals, Inc.	Waldenstrom´s Macroglobulinemia	April 2010	Phase 1\|Phase 2
NCT00758693	University of Kentucky\|Cephalon	Chronic Lymphocytic Leukemia	October 2008	Phase 2
NCT01004991	Weill Medical College of Cornell University\|Celgene	Diffuse Large B Cell Lymphoma	January 2010	Phase 1\|Phase 2
NCT00697996	Stanford University\|Genentech and Biogen IDEC	Kidney Transplantation	June 2005	Phase 2\|Phase 3
NCT01199575	University of California, San Diego\|Celgene Corporation	Chronic Lymphocytic Leukemia\|CLL	August 2010	Phase 2
NCT01042509	Hospital Universitario Dr. Jose E. Gonzalez	Graft vs Host Disease	October 2009	Not Applicable
NCT03352765	Memorial Sloan Kettering Cancer Center	Lymphoma	November 20, 2017	Phase 1
NCT00980395	University of Arizona\|National Cancer Institute (NCI)	Lymphoma\|Mantle Cell Lymphoma\|Indolent Lymphoma\|SLL	July 7, 2009	Phase 2
NCT01842386	National Institute of Allergy and Infectious Diseases (NIAID)\|National Institutes of Health Clinical Center (CC)	Pulmonary Alveolar Proteinosis (PAP)\|Severe Mucocutaneous Candidiasis	April 29, 2014	Phase 1
NCT00038844	M.D. Anderson Cancer Center	Lymphoma\|Leukemia	June 2001	Not Applicable
NCT03495960	International Extranodal Lymphoma Study Group (IELSG)	Primary Central Nervous System Lymphoma	June 15, 2019	Phase 2
NCT00151320	Weill Medical College of Cornell University\|Millennium Pharmaceuticals, Inc.	Non-Hodgkin´s Lymphoma	January 2004	Phase 1\|Phase 2
NCT04622579	Guangdong Provincial People´s Hospital\|Guangzhou First People´s Hospital\|Foshan First People´s Hospital\|Huizhou Municipal Central Hospital\|Shantou Central Hospital	Diffuse Large B Cell Lymphoma\|Age Over 80 Years	October 23, 2020	Phase 2
NCT04759586	National Cancer Institute (NCI)	Primary Mediastinal (Thymic) Large B-Cell Lymphoma	June 7, 2021	Phase 3
NCT03530462	First Affiliated Hospital of Zhejiang University	Cognitive Impairment\|Autoimmune Encephalitis	April 7, 2017
NCT00310128	AIDS Malignancy Consortium\|National Cancer Institute (NCI)	AIDS-related Lymphoma\|Adult Non-Hodgkin´s Lymphoma\|Anaplastic Large Cell Lymphoma	February 2006	Phase 2
NCT02611323	Hoffmann-La Roche	Non-Hodgkin´s Lymphoma	March 9, 2016	Phase 1
NCT02753647	Ruijin Hospital	Diffuse Large B-cell Lymphoma	April 2016	Phase 2
NCT01029730	SCRI Development Innovations, LLC\|Millennium Pharmaceuticals, Inc.\|Cephalon	Lymphoma	March 2010	Phase 2
NCT04496037	Imperial College London\|University of Cambridge\|Viapath LLP	Transplant; Complication, Rejection	September 1, 2020
NCT03620903	Christian Buske\|University of Ulm\|ClinAssess\|Zentrum für Klinische Studien Ulm\|Hoffmann-La Roche\|Johnson & Johnson	Waldenstrom Macroglobulinemia	September 11, 2019	Phase 2
NCT04758975	Paolo Ghia\|IRCCS San Raffaele	Chronic Lymphocytic Leukemia (CLL)	June 1, 2022	Phase 2
NCT01271010	Hoffmann-La Roche	Lymphocytic Leukemia, Chronic	June 17, 2011	Phase 4
NCT04121403	Oslo University Hospital\|University of Oslo\|Göteborg University\|Sykehuset Ostfold\|Sykehuset Telemark\|Vestre Viken Hospital Trust\|Sorlandet Hospital HF\|Helse Stavanger HF\|Sykehuset Innlandet HF\|Sykehuset i Vestfold HF\|Helse Forde\|University Hospital of North Norway\|St. Olavs Hospital	Relapsing Multiple Sclerosis\|Multiple Sclerosis	October 16, 2019	Phase 3
NCT02677155	Oslo University Hospital\|Norwegian Cancer Society\|Merck Sharp & Dohme LLC	Follicular Lymphoma	January 2016	Phase 2
NCT01448096	Chonbuk National University Hospital\|Consortium for Improving Survival of Lymphoma	Large B Cell Diffuse Lymphoma	August 2011	Phase 2
NCT02420938	M.D. Anderson Cancer Center\|Bristol-Myers Squibb	Leukemia	July 2015	Phase 2
NCT00003963	Jonsson Comprehensive Cancer Center\|National Cancer Institute (NCI)\|Genentech, Inc.	Lymphoma	May 1999	Phase 2
NCT00446251	University of Washington\|Genentech, Inc.	Kidney Failure, Chronic\|Diabetic Nephropathies\|Glomerulonephritis, IGA\|Hypertension, Renal	December 2006	Phase 2
NCT00126243	French National Agency for Research on AIDS and Viral Hepatitis\|Hoffmann-La Roche	AIDS Related Lymphoma	January 1999	Phase 2
NCT00259805	California Pacific Medical Center Research Institute\|Genentech, Inc.	Chronic Focal Encephalitis\|Rasmussen´s Encephalitis	January 2005	Phase 1
NCT02265731	AbbVie\|Genentech, Inc.	Non-Hodgkin Lymphoma (NHL)\|Multiple Myeloma (MM)\|Chronic Lymphocytic Leukemia (CLL)\|Small Lymphocytic Lymphoma (SLL)\|Acute Myeloid Leukemia (AML)	September 22, 2014	Phase 1\|Phase 2
NCT00003204	National Cancer Institute (NCI)	Stage III Grade 1 Follicular Lymphoma\|Stage III Grade 2 Follicular Lymphoma\|Stage III Grade 3 Follicular Lymphoma\|Stage III Small Lymphocytic Lymphoma\|Stage IV Grade 1 Follicular Lymphoma\|Stage IV Grade 2 Follicular Lymphoma\|Stage IV Grade 3 Follicular Lymphoma\|Stage IV Small Lymphocytic Lymphoma	March 1998	Phase 3
NCT02571842	Chulalongkorn University	Recurrent IgA Nephropathy	January 2012	Phase 4
NCT03524235	Noah Merin\|Miltenyi Biomedicine GmbH\|Teva Branded Pharmaceutical Products R&D, Inc.\|Cedars-Sinai Medical Center	Multiple Myeloma\|CLL\|Chronic Lymphocytic Leukemia\|Lymphoma\|Hodgkin Lymphoma	July 18, 2018	Phase 1
NCT00720876	City of Hope Medical Center\|National Cancer Institute (NCI)\|Merck Sharp & Dohme LLC	Lymphoma	July 23, 2008	Phase 2
NCT01392716	Hoffmann-La Roche	Non-Hodgkin´s Lymphoma	October 1997	Phase 2
NCT00525876	M.D. Anderson Cancer Center	Lymphoma	January 2005	Not Applicable
NCT00450385	University of Miami	Lymphoma	April 24, 2007	Phase 2
NCT00193505	SCRI Development Innovations, LLC\|Biogen	Non-Hodgkins Lymphoma	October 2003	Phase 2
NCT01461928	Hoffmann-La Roche	Non-Hodgkin´s Lymphoma	December 20, 2011	Phase 3
NCT03136497	Hackensack Meridian Health\|Janssen Scientific Affairs, LLC\|Genentech, Inc.	Relapsed Diffuse Large B-Cell Lymphoma\|Refractory Diffuse Large B-Cell Lymphoma	September 5, 2017	Phase 1
NCT02950155	Fredrik Piehl\|Karolinska Institutet	Generalized Myasthenia Gravis	October 16, 2016	Phase 3
NCT01178216	Stanley Jordan, MD\|Genentech, Inc.\|Cedars-Sinai Medical Center	End Stage Renal Disease	September 2013	Phase 1\|Phase 2
NCT00405340	Mayo Clinic\|Genentech, Inc.	Membranous Nephropathy	October 2006	Early Phase 1
NCT04113226	Centre Hospitalier Universitaire, Amiens\|cimiez hospital Nice\|Institut Bergonié\|groupe hospitalier public sud de l´oise\|Henri Mondor University Hospital\|Centre Henri Becquerel\|Hôpital Charles Foix\|Saint-Louis Hospital, Paris, France	Chemotherapy\|Diffuse Large B-Cell Lymphoma (DLBCL), Nos\|Elderly	July 26, 2021	Phase 2
NCT00476515	Massachusetts General Hospital\|Biogen\|Genentech, Inc.	Kidney Insufficiency	March 2007	Phase 1
NCT00003554	The Cleveland Clinic\|National Cancer Institute (NCI)	Multiple Myeloma and Plasma Cell Neoplasm	November 1998	Phase 2
NCT00439556	M.D. Anderson Cancer Center\|National Cancer Institute (NCI)	CD20 Positive\|Hematopoietic and Lymphoid Cell Neoplasm\|Lymphocytic Neoplasm\|Lymphoma	February 13, 2007	Phase 2
NCT03135262	Hoffmann-La Roche	Follicular Lymphoma\|Lymphoma, Large B-Cell, Diffuse	June 15, 2017	Phase 1\|Phase 2
NCT00562965	Pfizer\|UCB Pharma	Lymphoma, Follicular	November 2007	Phase 3
NCT02199184	M.D. Anderson Cancer Center\|National Cancer Institute (NCI)	AIDS-Related Burkitt Lymphoma\|Atypical Burkitt+Burkitt-Like Lymphoma\|High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements\|High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements\|Recurrent Acute Lymphoblastic Leukemia\|Recurrent Burkitt Lymphoma\|Refractory Acute Lymphoblastic Leukemia\|Refractory Burkitt Lymphoma	January 14, 2015	Phase 2
NCT04679012	Weill Medical College of Cornell University\|Genentech, Inc.	Richter Syndrome\|Chronic Lymphocytic Leukemia	September 24, 2021	Phase 2
NCT05287984	Institute of Hematology & Blood Diseases Hospital	Chronic Lymphocytic Leukemia\|Small Lymphocytic Lymphoma\|Newly Diagnosed	March 22, 2022	Phase 2
NCT04361409	China Medical University Hospital	Head and Neck Squamous Carcinoma	May 2013	Phase 1
NCT02093026	Hoffmann-La Roche\|Genentech, Inc.	Rheumatoid Arthritis	August 2002	Phase 2
NCT01263704	Hoffmann-La Roche	Lymphocytic Leukemia, Chronic	July 17, 2011	Phase 2
NCT01641952	Hoffmann-La Roche	Rheumatoid Arthritis	October 2011
NCT04518475	Institute of Hematology & Blood Diseases Hospital\|The Second Affiliated Hospital of Kunming Medical University\|Henan Cancer Hospital\|Tianjin Medical University Second Hospital\|The First Affiliated Hospital of Xiamen University\|Nantong University	Primary Immune Thrombocytopenia (ITP)	August 10, 2020	Phase 4
NCT00199082	Nicola Goekbuget\|Goethe University	Burkitt´s Lymphoma\|Burkitt´s Leukemia\|Mediastinal Neoplasms\|Lymphoblastic Lymphoma\|Large Cell Anaplastic Lymphoma	July 2002	Phase 4
NCT00974792	Cancer Research UK\|National Cancer Institute (NCI)	Lymphoma	January 2006	Phase 2
NCT00711828	Mayo Clinic\|National Cancer Institute (NCI)	Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue\|Nodal Marginal Zone Lymphoma\|Recurrent Grade 1 Follicular Lymphoma\|Recurrent Grade 2 Follicular Lymphoma\|Recurrent Mantle Cell Lymphoma\|Recurrent Small Lymphocytic Lymphoma\|Refractory Chronic Lymphocytic Leukemia\|Splenic Marginal Zone Lymphoma\|Waldenstrom Macroglobulinemia	August 2008	Phase 2
NCT00004260	Mayo Clinic\|National Cancer Institute (NCI)	Lymphoma	October 1999	Phase 1
NCT00424151	Silkiss, Rona Z., M.D., FACS\|Lauer, Simeon, M.D.\|Reier, Alice M.D.\|Coleman, Morton M.D.	Graves´ Dysthyroid Ophthalmopathy\|Thyroid Related Orbitopathy	December 2006	Phase 1\|Phase 2
NCT00867529	Fred Hutchinson Cancer Center\|American Cancer Society, Inc.\|National Cancer Institute (NCI)	B-cell Adult Acute Lymphoblastic Leukemia\|B-cell Childhood Acute Lymphoblastic Leukemia\|B-cell Chronic Lymphocytic Leukemia\|Childhood Burkitt Lymphoma\|Childhood Diffuse Large Cell Lymphoma\|Childhood Immunoblastic Large Cell Lymphoma\|Cutaneous B-cell Non-Hodgkin Lymphoma\|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue\|Intraocular Lymphoma\|Nodal Marginal Zone B-cell Lymphoma\|Post-transplant Lymphoproliferative Disorder\|Recurrent Adult Acute Lymphoblastic Leukemia\|Recurrent Adult Burkitt Lymphoma\|Recurrent Adult Diffuse Large Cell Lymphoma\|Recurrent Adult Diffuse Mixed Cell Lymphoma\|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma\|Recurrent Adult Grade III Lymphomatoid Granulomatosis\|Recurrent Adult Hodgkin Lymphoma\|Recurrent Adult Immunoblastic Large Cell Lymphoma\|Recurrent Adult Lymphoblastic Lymphoma\|Recurrent Childhood Acute Lymphoblastic Leukemia\|Recurrent Childhood Grade III Lymphomatoid Granulomatosis\|Recurrent Childhood Large Cell Lymphoma\|Recurrent Childhood Lymphoblastic Lymphoma\|Recurrent Childhood Small Noncleaved Cell Lymphoma\|Recurrent Grade 1 Follicular Lymphoma\|Recurrent Grade 2 Follicular Lymphoma\|Recurrent Grade 3 Follicular Lymphoma\|Recurrent Mantle Cell Lymphoma\|Recurrent Marginal Zone Lymphoma\|Recurrent Small Lymphocytic Lymphoma\|Recurrent+Refractory Childhood Hodgkin Lymphoma\|Refractory Chronic Lymphocytic Leukemia\|Refractory Hairy Cell Leukemia\|Small Intestine Lymphoma\|Splenic Marginal Zone Lymphoma\|Testicular Lymphoma\|Waldenström Macroglobulinemia	February 2009	Phase 2
NCT02158091	Dana-Farber Cancer Institute\|Secura Bio, Inc.	Chronic Lymphocytic Leukemia	June 27, 2014	Phase 1\|Phase 2
NCT01268033	University Hospital, Limoges\|Hoffmann-La Roche	Childhood Idiopathic Nephrotic Syndrome	December 2010	Phase 2\|Phase 3
NCT00003820	Ranjana Advani\|Genentech, Inc.\|Stanford University	Lymphoma\|Hodgkin Lymphoma (Category)\|Nodular Lymphocyte Predominant Hodgkin Lymphoma	January 1999	Phase 2
NCT02911142	National Cancer Institute (NCI)\|National Institutes of Health Clinical Center (CC)	Primary Effusion Lymphoma\|B-Cell Neoplasm	July 3, 2017	Phase 1\|Phase 2
NCT01381705	ECOG-ACRIN Cancer Research Group\|National Cancer Institute (NCI)\|Eastern Cooperative Oncology Group	Lymphoma	February 6, 2012
NCT00384553	University of Magdeburg	Non-Hodgkin´s Lymphoma	June 2004	Phase 1\|Phase 2
NCT00575406	Arbeitsgemeinschaft medikamentoese Tumortherapie	Diffuse Large B-Cell Lymphoma	December 2007	Phase 2
NCT01808599	International Extranodal Lymphoma Study Group (IELSG)	MALT Lymphoma	December 2013	Phase 2
NCT00001337	National Cancer Institute (NCI)\|National Institutes of Health Clinical Center (CC)	Diffuse Large B-Cell Lymphoma (DLBCL)\|Primary Mediastinal Large B-cell Lymphoma\|Burkitt Lymphoma\|Anaplastic Large-Cell Lymphoma\|Gray Zone Lymphoma	May 8, 1993	Phase 2
NCT03783403	Celgene	Neoplasms	February 1, 2019	Phase 1
NCT01267812	City of Hope Medical Center\|National Cancer Institute (NCI)	Contiguous Stage II Mantle Cell Lymphoma\|Noncontiguous Stage II Mantle Cell Lymphoma\|Recurrent Mantle Cell Lymphoma\|Stage I Mantle Cell Lymphoma\|Stage III Mantle Cell Lymphoma\|Stage IV Mantle Cell Lymphoma	October 3, 2011	Phase 2
NCT00532129	Hoffmann-La Roche	Lymphocytic Leukemia, Chronic	November 2007	Phase 2
NCT00664521	Merck KGaA, Darmstadt, Germany	Rheumatoid Arthritis	March 2008	Phase 2
NCT03169790	ImmunityBio, Inc.	Non Hodgkin Lymphoma	December 2017	Phase 1\|Phase 2
NCT00003397	University of Maryland, Baltimore\|University of Maryland Greenebaum Cancer Center	Lymphoma	September 1998	Phase 2
NCT00028665	Case Comprehensive Cancer Center\|National Cancer Institute (NCI)	Lymphoma	June 2000	Phase 2
NCT02394119	Istituto Giannina Gaslini	Nephrotic Syndrome	June 2015	Phase 2
NCT00896519	French Innovative Leukemia Organisation\|National Cancer Institute (NCI)	Lymphoma	March 2009	Phase 2
NCT00098774	Alliance for Clinical Trials in Oncology\|National Cancer Institute (NCI)	Lymphoma	October 2004	Phase 2
NCT00005592	University of Alabama at Birmingham\|National Cancer Institute (NCI)\|Biogen	Lymphoma	November 1999	Phase 2
NCT00244855	Fred Hutchinson Cancer Center\|National Cancer Institute (NCI)	Contiguous Stage II Grade 1 Follicular Lymphoma\|Contiguous Stage II Grade 2 Follicular Lymphoma\|Contiguous Stage II Marginal Zone Lymphoma\|Cutaneous B-cell Non-Hodgkin Lymphoma\|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue\|Nodal Marginal Zone B-cell Lymphoma\|Noncontiguous Stage II Grade 1 Follicular Lymphoma\|Noncontiguous Stage II Grade 2 Follicular Lymphoma\|Noncontiguous Stage II Marginal Zone Lymphoma\|Recurrent Grade 1 Follicular Lymphoma\|Recurrent Grade 2 Follicular Lymphoma\|Recurrent Marginal Zone Lymphoma\|Splenic Marginal Zone Lymphoma\|Stage I Grade 1 Follicular Lymphoma\|Stage I Grade 2 Follicular Lymphoma\|Stage I Marginal Zone Lymphoma\|Stage III Grade 1 Follicular Lymphoma\|Stage III Grade 2 Follicular Lymphoma\|Stage III Marginal Zone Lymphoma\|Stage IV Grade 1 Follicular Lymphoma\|Stage IV Grade 2 Follicular Lymphoma\|Stage IV Marginal Zone Lymphoma\|Waldenstrom Macroglobulinemia	May 2004	Phase 2
NCT00552461	East Carolina University\|Genentech, Inc.	Pulmonary Alveolar Proteinosis\|Primary Disease	January 2007	Phase 2
NCT00428142	NCIC Clinical Trials Group\|Canadian Cancer Trials Group	Lymphoma	December 2006	Phase 2
NCT03267433	ECOG-ACRIN Cancer Research Group\|National Cancer Institute (NCI)\|Eastern Cooperative Oncology Group	CD20 Positive\|Mantle Cell Lymphoma	August 29, 2017	Phase 3
NCT04323748	New York Medical College	Immune Thrombocytopenic Purpura	February 24, 2021	Phase 1
NCT02900976	Children´s Oncology Group\|National Cancer Institute (NCI)	EBV-Related Post-Transplant Lymphoproliferative Disorder\|Monomorphic Post-Transplant Lymphoproliferative Disorder\|Polymorphic Post-Transplant Lymphoproliferative Disorder\|Recurrent Monomorphic Post-Transplant Lymphoproliferative Disorder\|Recurrent Polymorphic Post-Transplant Lymphoproliferative Disorder\|Refractory Monomorphic Post-Transplant Lymphoproliferative Disorder\|Refractory Polymorphic Post-Transplant Lymphoproliferative Disorder	March 6, 2017	Phase 2
NCT01805037	Northwestern University\|Seagen Inc.	Adult Grade III Lymphomatoid Granulomatosis\|Adult Nasal Type Extranodal NK+T-cell Lymphoma\|Anaplastic Large Cell Lymphoma\|Angioimmunoblastic T-cell Lymphoma\|Contiguous Stage II Adult Burkitt Lymphoma\|Contiguous Stage II Adult Diffuse Large Cell Lymphoma\|Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma\|Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma\|Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma\|Contiguous Stage II Adult Lymphoblastic Lymphoma\|Contiguous Stage II Grade 1 Follicular Lymphoma\|Contiguous Stage II Grade 2 Follicular Lymphoma\|Contiguous Stage II Grade 3 Follicular Lymphoma\|Contiguous Stage II Mantle Cell Lymphoma\|Contiguous Stage II Marginal Zone Lymphoma\|Contiguous Stage II Small Lymphocytic Lymphoma\|Cutaneous B-cell Non-Hodgkin Lymphoma\|Epstein-Barr Virus Infection\|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue\|Hepatosplenic T-cell Lymphoma\|Intraocular Lymphoma\|Nodal Marginal Zone B-cell Lymphoma\|Noncontiguous Stage II Adult Burkitt Lymphoma\|Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma\|Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma\|Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma\|Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma\|Noncontiguous Stage II Adult Lymphoblastic Lymphoma\|Noncontiguous Stage II Grade 1 Follicular Lymphoma\|Noncontiguous Stage II Grade 2 Follicular Lymphoma\|Noncontiguous Stage II Grade 3 Follicular Lymphoma\|Noncontiguous Stage II Mantle Cell Lymphoma\|Noncontiguous Stage II Marginal Zone Lymphoma\|Noncontiguous Stage II Small Lymphocytic Lymphoma\|Noncutaneous Extranodal Lymphoma\|Peripheral T-cell Lymphoma\|Post-transplant Lymphoproliferative Disorder\|Progressive Hairy Cell Leukemia, Initial Treatment\|Recurrent Adult Burkitt Lymphoma\|Recurrent Adult Diffuse Mixed Cell Lymphoma\|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma\|Recurrent Adult Grade III Lymphomatoid Granulomatosis\|Recurrent Adult Hodgkin Lymphoma\|Recurrent Adult Immunoblastic Large Cell Lymphoma\|Recurrent Adult Lymphoblastic Lymphoma\|Recurrent Adult T-cell Leukemia+Lymphoma\|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma\|Recurrent Grade 1 Follicular Lymphoma\|Recurrent Grade 2 Follicular Lymphoma\|Recurrent Grade 3 Follicular Lymphoma\|Recurrent Mantle Cell Lymphoma\|Recurrent Marginal Zone Lymphoma\|Recurrent Mycosis Fungoides+Sezary Syndrome\|Recurrent Small Lymphocytic Lymphoma\|Refractory Hairy Cell Leukemia\|Small Intestine Lymphoma\|Splenic Marginal Zone Lymphoma\|Stage I Adult Burkitt Lymphoma\|Stage I Adult Diffuse Large Cell Lymphoma\|Stage I Adult Diffuse Mixed Cell Lymphoma\|Stage I Adult Diffuse Small Cleaved Cell Lymphoma\|Stage I Adult Hodgkin Lymphoma\|Stage I Adult Immunoblastic Large Cell Lymphoma\|Stage I Adult Lymphoblastic Lymphoma\|Stage I Adult T-cell Leukemia+Lymphoma\|Stage I Cutaneous T-cell Non-Hodgkin Lymphoma\|Stage I Grade 1 Follicular Lymphoma\|Stage I Grade 2 Follicular Lymphoma\|Stage I Grade 3 Follicular Lymphoma\|Stage I Mantle Cell Lymphoma\|Stage I Marginal Zone Lymphoma\|Stage I Small Lymphocytic Lymphoma\|Stage IA Mycosis Fungoides+Sezary Syndrome\|Stage IB Mycosis Fungoides+Sezary Syndrome\|Stage II Adult Hodgkin Lymphoma\|Stage II Adult T-cell Leukemia+Lymphoma\|Stage II Cutaneous T-cell Non-Hodgkin Lymphoma\|Stage IIA Mycosis Fungoides+Sezary Syndrome\|Stage IIB Mycosis Fungoides+Sezary Syndrome\|Stage III Adult Burkitt Lymphoma\|Stage III Adult Diffuse Large Cell Lymphoma\|Stage III Adult Diffuse Mixed Cell Lymphoma\|Stage III Adult Diffuse Small Cleaved Cell Lymphoma\|Stage III Adult Hodgkin Lymphoma\|Stage III Adult Immunoblastic Large Cell Lymphoma\|Stage III Adult Lymphoblastic Lymphoma\|Stage III Adult T-cell Leukemia+Lymphoma\|Stage III Cutaneous T-cell Non-Hodgkin Lymphoma\|Stage III Grade 1 Follicular Lymphoma\|Stage III Grade 2 Follicular Lymphoma\|Stage III Grade 3 Follicular Lymphoma\|Stage III Mantle Cell Lymphoma\|Stage III Marginal Zone Lymphoma\|Stage III Small Lymphocytic Lymphoma\|Stage IIIA Mycosis Fungoides+Sezary Syndrome\|Stage IIIB Mycosis Fungoides+Sezary Syndrome\|Stage IV Adult Burkitt Lymphoma\|Stage IV Adult Diffuse Large Cell Lymphoma\|Stage IV Adult Diffuse Mixed Cell Lymphoma\|Stage IV Adult Diffuse Small Cleaved Cell Lymphoma\|Stage IV Adult Hodgkin Lymphoma\|Stage IV Adult Immunoblastic Large Cell Lymphoma\|Stage IV Adult Lymphoblastic Lymphoma\|Stage IV Adult T-cell Leukemia+Lymphoma\|Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma\|Stage IV Grade 1 Follicular Lymphoma\|Stage IV Grade 2 Follicular Lymphoma\|Stage IV Grade 3 Follicular Lymphoma\|Stage IV Mantle Cell Lymphoma\|Stage IV Marginal Zone Lymphoma\|Stage IV Small Lymphocytic Lymphoma\|Stage IVA Mycosis Fungoides+Sezary Syndrome\|Stage IVB Mycosis Fungoides+Sezary Syndrome\|T-cell Large Granular Lymphocyte Leukemia\|Testicular Lymphoma\|Untreated Hairy Cell Leukemia\|Waldenström Macroglobulinemia	March 5, 2013	Phase 1\|Phase 2
NCT01573533	Mayo Clinic\|University Health Network, Toronto\|National Institutes of Health (NIH)\|Genentech, Inc.\|Rush University Medical Center\|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Primary Focal Segmental Glomerulosclerosis	October 2013	Phase 2
NCT00490529	Ronald Levy\|National Institutes of Health (NIH)\|Stanford University	Lymphoma, Mantle-Cell	August 2009	Phase 2
NCT01856192	National Cancer Institute (NCI)	Ann Arbor Stage II Diffuse Large B-Cell Lymphoma\|Ann Arbor Stage III Diffuse Large B-Cell Lymphoma\|Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma	August 27, 2013	Phase 2
NCT00229619	National Heart, Lung, and Blood Institute (NHLBI)\|National Institutes of Health Clinical Center (CC)	Anemia, Aplastic\|Red-Cell Aplasia, Pure\|Anemia, Diamond-Blackfan	September 2005	Phase 2
NCT00787969	Alliance for Clinical Trials in Oncology\|National Cancer Institute (NCI)	Lymphoma	April 2009	Phase 1
NCT02097745	Hoffmann-La Roche\|Biogen	Rheumatoid Arthritis	June 2004	Phase 3
NCT00974233	University of Wisconsin, Madison\|Celgene Corporation	Chronic Lymphocytic Leukemia\|Small Lymphocytic Lymphoma	October 2009	Phase 2
NCT01974518	Uprety Shraddha\|Postgraduate Institute of Medical Education and Research	Pemphigus	November 2013	Phase 3
NCT00068250	Radiation Therapy Oncology Group\|National Cancer Institute (NCI)\|NRG Oncology	Brain and Central Nervous System Tumors\|Lymphoma	July 2003	Phase 1\|Phase 2
NCT01224093	Hoffmann-La Roche	Lymphocytic Leukemia, Chronic	October 2010
NCT01058239	Massachusetts General Hospital\|Dana-Farber Cancer Institute\|Brigham and Women´s Hospital\|Beth Israel Deaconess Medical Center\|Millennium Pharmaceuticals, Inc.	Post-transplant Lymphoproliferative Disease\|Solid Organ Transplant\|Stem Cell Transplant (Bone Marrow Transplant)\|Epstein Barr Virus Infections	November 2011	Phase 2
NCT02253264	Johns Hopkins University	Primary Progressive Multiple Sclerosis\|Secondary Progressive Multiple Sclerosis	November 2014	Phase 1
NCT01662102	Spectrum Pharmaceuticals, Inc	Follicular Lymphoma	December 11, 2012	Phase 3
NCT02971982	The First Affiliated Hospital of Soochow University	Treatment	October 2016	Phase 1\|Phase 2
NCT02889523	The Lymphoma Academic Research Organisation\|Epizyme, Inc.	Lymphoma\|DLBCL\|Follicular Lymphoma	October 2016	Phase 1\|Phase 2
NCT02060656	Royal Marsden NHS Foundation Trust\|Celgene Corporation	Diffuse Large B-Cell Lymphoma	September 2013	Phase 2
NCT00293475	OHSU Knight Cancer Institute\|National Cancer Institute (NCI)\|Oregon Health and Science University	Central Nervous System Lymphoma	October 14, 2005	Phase 1\|Phase 2
NCT03443570	Shandong University\|The Affiliated Hospital of Qingdao University\|Yantai Yuhuangding Hospital	Immune Thrombocytopenia\|Purpura, Thrombocytopenic, Idiopathic	March 1, 2018	Phase 3
NCT02960646	M.D. Anderson Cancer Center\|National Cancer Institute (NCI)	Acute Lymphoblastic Leukemia\|Acute Myeloid Leukemia\|Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome\|Aplastic Anemia\|Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive\|Chronic Myelomonocytic Leukemia\|Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive\|Lymphoblastic Lymphoma\|Myelodysplastic Syndrome\|Myeloproliferative Neoplasm\|Plasma Cell Myeloma\|Recurrent Chronic Lymphocytic Leukemia+Small Lymphocytic Lymphoma\|Recurrent Hodgkin Lymphoma\|Recurrent Non-Hodgkin Lymphoma\|Recurrent Plasma Cell Myeloma\|Therapy-Related Myelodysplastic Syndrome	January 18, 2017	Phase 1
NCT01350232	Sidney Kimmel Cancer Center at Thomas Jefferson University\|National Heart, Lung, and Blood Institute (NHLBI)\|Thomas Jefferson University	Sickle Cell Anemia\|Sickle Cell-hemoglobin C Disease\|Sickle Cell-β0-thalassemia	September 2009	Not Applicable
NCT02280525	M.D. Anderson Cancer Center\|The Leukemia and Lymphoma Society\|Celgene Corporation	Leukemia	March 5, 2015	Phase 1
NCT04914741	Peter MacCallum Cancer Centre, Australia\|Hoffmann-La Roche	Diffuse Large B Cell Lymphoma\|High-grade B-cell Lymphoma	June 29, 2021	Phase 1\|Phase 2
NCT00863187	Rambam Health Care Campus\|Technion, Israel Institute of Technology	Lymphoma	February 2009	Not Applicable
NCT00521014	Memorial Sloan Kettering Cancer Center\|National Cancer Institute (NCI)	Lymphoma	October 2007	Phase 2
NCT00772668	University of Miami	Lymphoma\|Follicular Lymphoma\|Marginal Zone Lymphoma	September 25, 2009	Not Applicable
NCT00058227	National Cancer Institute (NCI)	B-cell Chronic Lymphocytic Leukemia\|Contiguous Stage II Grade 1 Follicular Lymphoma\|Contiguous Stage II Grade 2 Follicular Lymphoma\|Contiguous Stage II Mantle Cell Lymphoma\|Contiguous Stage II Marginal Zone Lymphoma\|Contiguous Stage II Small Lymphocytic Lymphoma\|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue\|Nodal Marginal Zone B-cell Lymphoma\|Noncontiguous Stage II Grade 1 Follicular Lymphoma\|Noncontiguous Stage II Grade 2 Follicular Lymphoma\|Noncontiguous Stage II Mantle Cell Lymphoma\|Noncontiguous Stage II Marginal Zone Lymphoma\|Noncontiguous Stage II Small Lymphocytic Lymphoma\|Progressive Hairy Cell Leukemia, Initial Treatment\|Recurrent Grade 1 Follicular Lymphoma\|Recurrent Grade 2 Follicular Lymphoma\|Recurrent Mantle Cell Lymphoma\|Recurrent Marginal Zone Lymphoma\|Recurrent Small Lymphocytic Lymphoma\|Refractory Chronic Lymphocytic Leukemia\|Refractory Hairy Cell Leukemia\|Splenic Marginal Zone Lymphoma\|Stage I Chronic Lymphocytic Leukemia\|Stage I Grade 1 Follicular Lymphoma\|Stage I Grade 2 Follicular Lymphoma\|Stage I Mantle Cell Lymphoma\|Stage I Marginal Zone Lymphoma\|Stage I Small Lymphocytic Lymphoma\|Stage II Chronic Lymphocytic Leukemia\|Stage III Chronic Lymphocytic Leukemia\|Stage III Grade 1 Follicular Lymphoma\|Stage III Grade 2 Follicular Lymphoma\|Stage III Mantle Cell Lymphoma\|Stage III Marginal Zone Lymphoma\|Stage III Small Lymphocytic Lymphoma\|Stage IV Chronic Lymphocytic Leukemia\|Stage IV Grade 1 Follicular Lymphoma\|Stage IV Grade 2 Follicular Lymphoma\|Stage IV Mantle Cell Lymphoma\|Stage IV Marginal Zone Lymphoma\|Stage IV Small Lymphocytic Lymphoma\|Untreated Hairy Cell Leukemia\|Waldenström Macroglobulinemia	April 2003	Phase 1
NCT00695097	University of California, San Francisco\|Genentech, Inc.	Renal Transplant Rejection	August 2004	Not Applicable
NCT00140582	Lymphoma Study Association\|HOVON - Dutch Haemato-Oncology Association\|German Low Grade Lymphoma Study Group\|Australasian Leukaemia and Lymphoma Group\|Institute of Cancer Research, United Kingdom	Follicular Lymphoma	December 2004	Phase 3
NCT00578305	Hoffmann-La Roche	Rheumatoid Arthritis	November 2007	Phase 3
NCT00003658	Memorial Sloan Kettering Cancer Center\|National Cancer Institute (NCI)	Leukemia\|Lymphoma	September 1998	Phase 2
NCT03790293	University Hospital, Rouen	Autoimmune Diseases	December 2019	Phase 3
NCT00436904	Mayo Clinic\|National Cancer Institute (NCI)	Leukemia	December 2004	Phase 2
NCT03791827	Xiqiang Dang\|The Children´s Hospital Affiliated to Suzhou University\|Shandong Provincial Hospital\|Guizhou Provincial People´s Hospital\|LanZhou University\|The First Affiliated Hospital of Inner Mongolia Medical College\|People´s Hospital of Zhangjiajie\|Puyang Oilfield General Hospital\|The First Affiliated Hospital of Anhui Medical University\|Guizhou Maternal and Child Health Care Hospital\|The Second Affiliated Hospital & Yuying Children´s Hospital of Wenzhou Medical University\|Shenzhen Children´s Hospital\|The Second Affiliated Hospital of Harbin Medical University\|Yichang Central People´s Hospital\|Xian Children´s Hospital\|Wuhan Children´s Hospital, Tongji Medical College, Huazhong University of Science & Technology\|The First People´s Hospital of Yunnan\|The First Affiliated Hospital of Xiamen University\|The First Affiliated Hospital of Xinxiang Medical College\|Shanxi Provincial Maternity and Children´s Hospital\|Liaocheng People´s Hospital\|Fujian Provincial Hospital\|First Affiliated Hospital of Guangxi Medical University\|Second Hospital of Lanzhou University\|Guangzhou First People´s Hospital\|The Second Hospital of Shandong University\|Children´s Hospital of Hebei Province\|Beijing Children´s Hospital\|Zhengzhou Children´s Hospital\|The Children´s Hospital of Chongqing Medical University\|Wuxi Children´s Hospital\|The Children´s Hospital of Fudan University\|Shanghai Children´s Medical Center\|Qilu Children´s Hospital of Shandong University\|Second Xiangya Hospital of Central South University	Lupus Nephritis\|Children\|Steroid\|Immunosuppressive Treatment	December 1, 2018
NCT02007044	M.D. Anderson Cancer Center\|National Cancer Institute (NCI)	Prolymphocytic Leukemia\|Recurrent Chronic Lymphocytic Leukemia\|Recurrent Small Lymphocytic Lymphoma	December 6, 2013	Phase 2
NCT00005631	Memorial Sloan Kettering Cancer Center\|National Cancer Institute (NCI)	Lymphoma	November 1999	Phase 2
NCT01780454	Massachusetts General Hospital	End Stage Renal Disease	March 2013	Phase 1\|Phase 2
NCT04494503	Ascentage Pharma Group Inc.	Chronic Lymphocytic Leukemia\|Small Lymphocytic Lymphoma	August 31, 2020	Phase 1\|Phase 2
NCT04274257	Tokyo University\|Japan Agency for Medical Research and Development\|Zenyaku Kogyo Co., Ltd.	Scleroderma, Systemic\|Skin Sclerosis\|Lung Fibrosis\|Autoimmune Diseases\|Collagen Diseases	December 4, 2017	Phase 2\|Phase 3
NCT00230035	National Institute of Allergy and Infectious Diseases (NIAID)	Systemic Lupus Erythematosus	September 2005	Phase 2
NCT00254410	M.D. Anderson Cancer Center\|OSI Pharmaceuticals\|Genentech, Inc.	Chronic Lymphocytic Leukemia	March 14, 2005	Phase 2
NCT02115997	Hoffmann-La Roche	Wegener´s Granulomatosis or Microscopic Polyangiitis	July 6, 2015	Phase 4
NCT00736450	University of Nebraska\|National Cancer Institute (NCI)\|Genta Incorporated	Contiguous Stage II Adult Diffuse Large Cell Lymphoma\|Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma\|Stage I Adult Diffuse Large Cell Lymphoma\|Stage III Adult Diffuse Large Cell Lymphoma\|Stage IV Adult Diffuse Large Cell Lymphoma	July 2008	Not Applicable
NCT00860457	Georgetown University\|Celgene Corporation	Chronic Lymphocytic Leukemia	February 2008	Phase 2
NCT00564512	French Innovative Leukemia Organisation	Leukemia	November 2007	Phase 3
NCT01576588	Prof. Dr. Med. Laimonas Griskevicius\|Vilnius University	B-Cell Chronic Lymphocytic Leukemia	October 2011	Phase 2
NCT05533164	Sint Maartenskliniek\|ZonMw: The Netherlands Organisation for Health Research and Development\|Dutch Arthritis Association	Polymyalgia Rheumatica	January 2023	Phase 3
NCT04421560	Dana-Farber Cancer Institute\|Merck Sharp & Dohme LLC	Primary Central Nervous System Lymphoma\|Recurrent Cancer	August 1, 2020	Phase 1\|Phase 2
NCT01686321	University of Göttingen\|Roche Pharma AG\|Mundipharma Research GmbH & Co KG	Aggressive Lymphoma	July 4, 2012	Phase 2
NCT03899103	Nilratan Sircar Medical College\|Heidelberg University	Steroid-Dependent Nephrotic Syndrome	May 15, 2019	Phase 3
NCT00612612	National Cancer Institute (NCI)	B-cell Chronic Lymphocytic Leukemia\|Leukemia\|Prolymphocytic Leukemia\|Refractory Chronic Lymphocytic Leukemia\|Stage I Chronic Lymphocytic Leukemia\|Stage II Chronic Lymphocytic Leukemia\|Stage III Chronic Lymphocytic Leukemia\|Stage IV Chronic Lymphocytic Leukemia	January 2008	Phase 1
NCT00097188	Genentech, Inc.	Multiple Sclerosis	December 2004	Phase 2
NCT05364424	Hoffmann-La Roche	Diffuse Large B-Cell Lymphoma (DLBCL)	November 4, 2022	Phase 1
NCT02251964	Human Adams\|Amsterdam UMC, location VUmc\|St. Antonius Hospital	Lung Diseases, Interstitial\|Pneumonitis, Interstitial	September 2014	Phase 2\|Phase 3
NCT04246359	Huiqiang Huang\|Sun Yat-sen University	Lymphoma, B-Cell	January 15, 2020	Phase 2
NCT01889069	Hoffmann-La Roche	Lymphoma	July 31, 2013	Phase 3
NCT04127747	Second Affiliated Hospital, School of Medicine, Zhejiang University	Autoimmune Diseases	August 18, 2020	Phase 4
NCT02556866	Assistance Publique - Hôpitaux de Paris	Cryoglobulinemia\|Systemic Vasculitis	July 17, 2015	Phase 2
NCT00553501	Alliance for Clinical Trials in Oncology\|National Cancer Institute (NCI)	Lymphoma	March 2008	Phase 2
NCT01200758	Hoffmann-La Roche	Non-Hodgkin´s Lymphoma	February 15, 2011	Phase 3
NCT03994783	Imperial College London\|Cambridge University Hospitals NHS Foundation Trust\|National Institute for Health Research, United Kingdom\|Kidney Cancer UK	Kidney Transplant Rejection\|Antibody-mediated Rejection	July 17, 2019	Phase 3
NCT00210379	International Extranodal Lymphoma Study Group (IELSG)	Lymphoma, B Cell	November 2000	Phase 2
NCT00517049	Genentech, Inc.	Non-Hodgkin´s Lymphoma	March 2008	Phase 2
NCT01107951	Hospital Universitario Dr. Jose E. Gonzalez	Immune Thrombocytopenic Purpura	April 2010	Phase 2
NCT01097057	Fred Hutchinson Cancer Center\|National Cancer Institute (NCI)	Non-Hodgkin Lymphoma	November 9, 2010	Phase 2
NCT00324467	British Columbia Cancer Agency\|Hoffmann-La Roche	Lymphoma, Non-Hodgkin\|Advanced Stage Diffuse Large B-Cell Non-Hodgkin´s Lymphoma	August 2006	Phase 2
NCT02284984	Leiden University Medical Center\|Dutch Kidney Foundation\|ZonMw: The Netherlands Organisation for Health Research and Development	Lupus Erythematosus, Systemic	March 2014	Phase 2
NCT00863369	City of Hope Medical Center\|National Cancer Institute (NCI)	Lymphoma	June 29, 2005	Phase 1\|Phase 2
NCT04974996	ADC Therapeutics S.A.	Diffuse Large B-Cell Lymphoma	February 1, 2022	Phase 1
NCT00774202	Weill Medical College of Cornell University\|Biogen\|Genentech, Inc.	Immune Thrombocytopenic Purpura	November 2003	Phase 2\|Phase 3
NCT01307267	Pfizer	Lymphoma, Non-Hodgkin\|Lymphoma, Follicular\|Lymphoma, Large B-Cell, Diffuse\|Carcinoma, Non-Small-Cell Lung\|Carcinoma, Renal Cell\|Carcinoma, Squamous Cell of Head and Neck\|Malignant Melanoma	June 21, 2011	Phase 1
NCT02316613	Hoffmann-La Roche	Follicular Lymphoma	February 2007
NCT02693210	Hoffmann-La Roche	Rheumatoid Arthritis	February 2001	Phase 2
NCT00581776	University of Wisconsin, Madison	Mantle Cell Lymphoma	May 2005	Phase 2
NCT02990286	University Hospital, Tours	Lung Disease, Interstitial	January 20, 2017	Phase 3
NCT01213095	Dong-A University Hospital	Lymphoma	September 2010	Phase 2
NCT00393107	Gruppo Italiano Studio Linfomi	Follicular Lymphoma	March 2000	Phase 2
NCT01613599	Genentech, Inc.	Granulomatosis With Polyangiitis\|Microscopic Polyangiitis	June 20, 2012
NCT00333008	The Alvin and Lois Lapidus Cancer Institute\|Ortho Biotech Products, L.P.	Diffuse Large B Cell Lymphoma\|Lymphoma, Non-Hodgkin	May 2006	Phase 2
NCT03943901	University of Wisconsin, Madison\|Medical College of Wisconsin	Diffuse Large B Cell Lymphoma\|DLBCL\|Cancer	February 16, 2021	Phase 2
NCT04669171	Enterome	Follicular Lymphoma\|Marginal Zone Lymphoma	July 5, 2021	Phase 1\|Phase 2
NCT00286325	Duke University\|Genentech, Inc.	Bullous Pemphigoid	March 2005	Phase 1\|Phase 2
NCT00072007	Swiss Group for Clinical Cancer Research	Leukemia	June 2002	Phase 2
NCT00949988	University of California, San Diego\|Bristol-Myers Squibb	Chronic Lymphocytic Leukemia	May 2009	Phase 1\|Phase 2
NCT02951728	Ruijin Hospital	Diffuse Large B Cell Lymphoma	October 2016	Phase 1\|Phase 2
NCT02228512	National Cancer Institute (NCI)\|National Institutes of Health Clinical Center (CC)	Large Cell Lymphoma Arising in KSHV-associated Multicentric Castleman Disease\|Primary Effusion Lymphoma	August 15, 2014	Phase 1\|Phase 2
NCT00389818	AIDS Malignancy Consortium\|National Cancer Institute (NCI)\|The Emmes Company, LLC	Lymphoma	January 2007	Phase 2
NCT04663347	Genmab\|AbbVie	Diffuse Large B-Cell Lymphoma\|Follicular Lymphoma	November 16, 2020	Phase 1\|Phase 2
NCT02438982	Nilratan Sircar Medical College	Nephrotic Syndrome	May 8, 2015	Phase 3
NCT00968331	University of Bologna	Diffuse Large B-cell Lymphoma	March 2009	Phase 2
NCT00477815	Mayo Clinic\|National Cancer Institute (NCI)	Multiple Myeloma and Plasma Cell Neoplasm	May 31, 2005	Phase 1
NCT01567475	The Lymphoma Academic Research Organisation	Non-Hodgkin´s Lymphomas	December 2011	Phase 1
NCT00939328	Southwest Oncology Group\|National Cancer Institute (NCI)	Leukemia	September 2009	Phase 2
NCT00136552	Lymphoma Study Association	Lymphoma	May 2000	Phase 3
NCT00069966	Theradex\|National Cancer Institute (NCI)	Lymphoma	April 2003	Phase 2
NCT03984448	National Cancer Institute (NCI)	Diffuse Large B-Cell Lymphoma\|Diffuse Large B-Cell Lymphoma, Not Otherwise Specified\|Double-Expressor Lymphoma\|EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified\|High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements\|High Grade B-Cell Lymphoma, Not Otherwise Specified\|Neoplastic Cells With Double Expression of MYC and BCL2 Proteins Present\|Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma	August 7, 2019	Phase 2\|Phase 3
NCT00989352	University Hospital Freiburg\|Universitätsklinikum Köln\|Ludwig-Maximilians - University of Munich\|University Hospital Heidelberg\|University Hospital Ulm	Primary Non Hodgkin Lymphoma of the Central Nervous System	September 2009	Phase 2
NCT01390441	Merck Sharp & Dohme LLC	Rheumatoid Arthritis	July 2011	Phase 1
NCT00038623	M.D. Anderson Cancer Center\|Biogen	Lymphoma, Mantle-Cell	April 2002	Phase 2
NCT00085696	Millennium Pharmaceuticals, Inc.	B-Cell Lymphoma\|Follicular Lymphoma\|Marginal Lymphoma	May 2004	Phase 2
NCT00147966	University of California, San Diego\|Genentech, Inc.	Rheumatoid Arthritis	June 2008	Phase 2
NCT00824135	St. Jude Children´s Research Hospital\|Genzyme, a Sanofi Company	Hematologic Malignancies	January 2009	Phase 1
NCT00927797	Heidelberg University\|Diakonie Krankenhaus Schwäbisch Hall, Germany\|Ludwig-Maximilians - University of Munich\|Klinikum am Plattenwald, Bad Friedrichshall, Germany\|Diakonie-Klinikum Stuttgart\|Gemeinschaftspraxis Porowski & Koniczek, Heilbronn, Germany\|Universitätsmedizin Mannheim	Immunocytoma+Morbus Waldenström\|B-Cell Non-Hodgkin´s Lymphoma\|B-Cell Chronic Lymphocytic Leukemia	February 2005	Phase 2
NCT00642655	Cedars-Sinai Medical Center\|Genentech, Inc.\|Biogen	Kidney Transplant	September 2005	Phase 1\|Phase 2
NCT00496873	M.D. Anderson Cancer Center\|Astex Pharmaceuticals, Inc.\|Pharmatech	Lymphoma	June 2005	Phase 2
NCT02705638	Mayo Clinic\|Celgene Corporation	Immunoglobulin G Subclass 4 Related Disease\|IgG4-related Disease\|Autoimmune Pancreatitis\|IgG4-related Sclerosing Cholangitis\|Retroperitoneal Fibrosis	April 2016	Phase 1
NCT01118234	Arbeitsgemeinschaft medikamentoese Tumortherapie\|Roche Pharma AG	Chronic Lymphocytic Leukemia	December 2009	Phase 3
NCT00086203	Point Therapeutics\|FDA Office of Orphan Products Development	Chronic Lymphocytic Leukemia		Phase 2
NCT02624986	Hoffmann-La Roche	Non-Hodgkin´s Lymphoma	December 23, 2015	Phase 1\|Phase 2
NCT00473551	M.D. Anderson Cancer Center	Leukemia\|Lymphoma\|Myeloma	May 2007	Phase 1
NCT03072199	Papworth Hospital NHS Foundation Trust	Ischemic Heart Disease\|Myocardial Infarction\|Inflammation	June 1, 2017	Phase 1\|Phase 2
NCT02699892	Hoffmann-La Roche	Rheumatoid Arthritis	October 2007
NCT00369681	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins\|National Cancer Institute (NCI)	Lymphoma	May 2006	Phase 2
NCT00087529	Genentech, Inc.	Multiple Sclerosis	June 2004	Phase 2\|Phase 3
NCT05533125	Sint Maartenskliniek\|Dutch Arthritis Association\|ZonMw: The Netherlands Organisation for Health Research and Development	Polymyalgia Rheumatica	January 2023	Phase 3
NCT00282308	Genentech, Inc.	Rheumatoid Arthritis	January 23, 2006	Phase 2
NCT01076556	National Cancer Institute (NCI)	Chronic Lymphocytic Leukemia\|Prolymphocytic Leukemia\|Recurrent Small Lymphocytic Lymphoma\|Refractory Chronic Lymphocytic Leukemia\|Stage I Chronic Lymphocytic Leukemia\|Stage I Small Lymphocytic Lymphoma\|Stage II Chronic Lymphocytic Leukemia\|Stage II Small Lymphocytic Lymphoma\|Stage III Chronic Lymphocytic Leukemia\|Stage III Small Lymphocytic Lymphoma\|Stage IV Chronic Lymphocytic Leukemia\|Stage IV Small Lymphocytic Lymphoma	April 2010	Phase 1
NCT05514015	First Affiliated Hospital, Sun Yat-Sen University	Idiopathic Membranous Nephropathy	August 25, 2022	Phase 4
NCT03349346	Gilead Sciences	Diffuse Large B-Cell Lymphoma\|Mediastinal B-cell Lymphoma	June 2019	Phase 1
NCT01212094	National Institute of Neurological Disorders and Stroke (NINDS)\|National Institutes of Health Clinical Center (CC)	Multiple Sclerosis	September 2010	Phase 1\|Phase 2
NCT04115631	ECOG-ACRIN Cancer Research Group\|National Cancer Institute (NCI)\|Eastern Cooperative Oncology Group	Liver Lymphoma\|Mantle Cell Lymphoma	October 3, 2019	Phase 2
NCT00809341	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins\|Genentech, Inc.	Non-Hodgkin´s Lymphoma	January 2009	Phase 2
NCT01996865	Celgene	Lymphoma, Non-Hodgkin	April 1, 2014	Phase 3
NCT02663518	Pfizer	Hematologic Malignancies\|Solid Tumor	January 31, 2016	Phase 1
NCT00137969	Genentech, Inc.	Lupus Erythematosus, Systemic	May 10, 2005	Phase 2\|Phase 3
NCT02293109	Mehrdad Abedi, MD\|Amgen\|University of California, Davis	Contiguous Stage II Adult Lymphoblastic Lymphoma\|Noncontiguous Stage II Adult Lymphoblastic Lymphoma\|Stage I Adult Lymphoblastic Lymphoma\|Stage III Adult Lymphoblastic Lymphoma\|Stage IV Adult Lymphoblastic Lymphoma\|Untreated Adult Acute Lymphoblastic Leukemia	December 17, 2015	Phase 1
NCT03036904	Weill Medical College of Cornell University\|Genentech, Inc.\|Massachusetts General Hospital\|M.D. Anderson Cancer Center	Diffuse Large B-Cell Lymphoma\|High Grade B-Cell Lymphoma	February 6, 2017	Phase 1
NCT00275054	German CLL Study Group	Chronic Lymphocytic Leukemia	October 2005	Phase 3
NCT00183989	University of Southern California	Mantle Cell Lymphoma	August 2000	Phase 2
NCT00004039	Hoag Memorial Hospital Presbyterian\|Cancer Biotherapy Research Group	Lymphoma	June 1998	Phase 2
NCT01124526	Asociacion Espanola de Hematologia y Hemoterapia	Non Hodgkin Lymphoma	September 2004	Phase 4
NCT03578198	Seoul National University Hospital\|Hallym University Medical Center\|Kyunghee University Medical Center\|Gyeongsang National University Hospital	CD20-positive Non-Hodgkin Lymphoma	November 8, 2018	Phase 2
NCT00057343	Biogen	Non-Hodgkin´s Lymphoma	March 2003	Phase 3
NCT01700946	St. Jude Children´s Research Hospital\|Cookies for Kids´ Cancer\|Assisi Foundation	Recurrent B-Cell Childhood Acute Lymphoblastic Leukemia\|Recurrent Childhood B-Lymphoblastic Lymphoma	April 15, 2013	Phase 2
NCT00845104	Fred Hutchinson Cancer Research Center+University of Washington Cancer Consortium\|Fred Hutchinson Cancer Center	B-cell Chronic Lymphocytic Leukemia\|Refractory Chronic Lymphocytic Leukemia	January 2009	Phase 2
NCT01073163	Cephalon\|Teva Branded Pharmaceutical Products R&D, Inc.	Non-Hodgkin´s Lymphoma\|Mantle Cell Lymphoma	February 2010	Phase 3
NCT03422523	University Hospital Southampton NHS Foundation Trust\|Hoffmann-La Roche	Diffuse Large B Cell Lymphoma\|Relapsed Diffuse Large B-Cell Lymphoma\|Refractory Diffuse Large B-Cell Lymphoma	May 9, 2018	Phase 2
NCT01670084	Mayo Clinic	B-cell Adult Acute Lymphoblastic Leukemia\|Blastic Phase Chronic Myelogenous Leukemia\|Chronic Myelogenous Leukemia, BCR-ABL1 Positive\|Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia\|Untreated Adult Acute Lymphoblastic Leukemia	December 2012	Phase 2
NCT01399372	Radiation Therapy Oncology Group\|National Cancer Institute (NCI)\|NRG Oncology	Chemotherapeutic Agent Toxicity\|Cognitive+Functional Effects\|Lymphoma\|Neurotoxicity\|Radiation Toxicity	September 2011	Phase 2
NCT00006436	National Cancer Institute (NCI)\|National Institutes of Health Clinical Center (CC)	Lymphoma, AIDS-related\|Lymphoma, Large B-Cell, Diffuse	January 29, 2001	Phase 2
NCT00401817	Weill Medical College of Cornell University	Untreated Mantle Cell Lymphoma	November 2007	Phase 2
NCT00004031	Southwest Oncology Group\|National Cancer Institute (NCI)\|Cancer and Leukemia Group B\|Eastern Cooperative Oncology Group\|NCIC Clinical Trials Group	Lymphoma	July 1997	Phase 3
NCT02970318	Acerta Pharma BV	Chronic Lymphocytic Leukemia	February 2, 2017	Phase 3
NCT05504603	The First Affiliated Hospital of Soochow University	Untreated Mantle Cell Lymphoma	July 27, 2020	Phase 2
NCT03456466	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	Non-hodgkin´s Lymphoma	May 1, 2017	Phase 1\|Phase 2
NCT00416923	University of California, San Francisco	Brain and Central Nervous System Tumors\|Lymphoma	August 2002	Phase 1
NCT02789397	Medical College of Wisconsin	Granulomatous and Lymphocytic Interstitial Lung Disease	May 2, 2016	Phase 2
NCT03147612	M.D. Anderson Cancer Center	Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive\|Acute Lymphoblastic Leukemia\|Acute Myeloid Leukemia With BCR-ABL1\|Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive\|Recurrent Acute Lymphoblastic Leukemia\|Refractory Acute Lymphoblastic Leukemia	February 8, 2018	Phase 2
NCT00992446	Fred Hutchinson Cancer Center\|National Cancer Institute (NCI)	Adult Diffuse Large B-Cell Lymphoma\|B-Cell Non-Hodgkin Lymphoma\|Follicular Lymphoma\|Mantle Cell Lymphoma\|Non-Hodgkin Lymphoma\|T-Cell Non-Hodgkin Lymphoma	September 2, 2010	Phase 2
NCT01032122	Medical University of Vienna	Metastatic Melanoma	October 2007	Phase 1
NCT02099292	Georg Hess, MD\|Roche Pharma AG\|Klinikum Frankfurt Höchst\|Johannes Gutenberg University Mainz	Relapsed Non-Hodgkin-Lymphoma	May 2001	Phase 2
NCT00555542	Chinese University of Hong Kong	Rheumatoid Arthritis	July 2006	Phase 2
NCT02983097	Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH\|Celgene\|Amgen	Diffuse Large B-cell Lymphoma (DLBCL)\|Follicular Lymphoma Grade III (FL III�)\|Mantle Cell Lymphoma (MCL), Blastoid Variant\|Burkitt Lymphoma (BL)\|Aggressive Marginal Zone Lymphoma (MZL)	November 2010	Phase 1\|Phase 2
NCT04824092	MorphoSys AG	Diffuse Large B-cell Lymphoma	May 11, 2021	Phase 3
NCT00003757	Swiss Group for Clinical Cancer Research	Leukemia	February 1998	Phase 2
NCT02137681	Shandong University	Immune Thrombocytopenia	May 2014	Phase 3
NCT01010061	Hoffmann-La Roche\|German CLL Study Group\|Genentech, Inc.	Lymphocytic Leukemia, Chronic	December 21, 2009	Phase 3
NCT00783367	Abramson Cancer Center of the University of Pennsylvania	Follicular Lymphoma\|Marginal Zone B-Cell Lymphoma\|MALT Lymphoma\|Lymphoma of Mucosa-Associated Lymphoid Tissue\|Lymphoma, Small Lymphocytic\|Waldenstrom Macroglobulinemia\|Mantle-Cell Lymphoma	July 2008	Phase 2
NCT04796922	Incyte Corporation	Follicular Lymphoma ( FL)\|Marginal Zone Lymphoma (MZL)	December 30, 2022	Phase 3
NCT00648037	Memorial Sloan Kettering Cancer Center	Hodgkin´s Disease\|Leukemia\|Myelodysplastic Syndrome\|Non-Hodgkin´s Lymphoma	March 2008	Not Applicable
NCT00502853	Hoffmann-La Roche	Rheumatoid Arthritis	October 25, 2007	Phase 4
NCT04285567	Hoffmann-La Roche	Chronic Lymphocytic Leukemia (CLL)	May 28, 2020	Phase 3
NCT01719159	Anders Svenningsson\|Västerbotten County Council, Sweden\|Umeå University	Progressive Multiple Sclerosis	November 2009	Phase 2
NCT02187133	University of California, San Francisco\|National Comprehensive Cancer Network	Lymphoma, Non-Hodgkin\|Lymphoma	May 5, 2015	Phase 1
NCT00397800	Technical University of Munich	Lymphoma	June 2005	Phase 1\|Phase 2
NCT04516655	Fudan University	Central Nervous System Lymphoma	September 1, 2020	Phase 2
NCT00856245	University of Kansas Medical Center	Non-Hodgkins Lymphoma	February 2009	Phase 2
NCT04502706	Gilead Sciences	Non-hodgkin Lymphoma	November 17, 2020	Phase 1
NCT00344149	Ostfold Hospital Trust\|Oslo University Hospital\|South-Eastern Regional Health Authority	Immune Thrombocytopenia (ITP)	June 2006	Phase 3
NCT03054259	University of Leeds	Systemic Lupus Erythematosus Arthritis	September 21, 2017	Phase 2
NCT01584388	Massachusetts General Hospital\|Genentech, Inc.	Retroperitoneal Fibrosis\|Autoimmune Pancreatitis\|Sialadenitis\|Pseudotumor	April 2012	Phase 1\|Phase 2
NCT02867566	Innovent Biologics (Suzhou) Co. Ltd.	Diffuse, Large B-Cell, Lymphoma	August 22, 2016	Phase 3
NCT00180882	Gustave Roussy, Cancer Campus, Grand Paris	Burkitt Lymphoma	October 2004	Phase 3
NCT01829958	Memorial Sloan Kettering Cancer Center	Non Hodgkin Lymphoma (NHL)\|Diffuse Large B-cell Lymphoma (DLBCL)	April 2013	Not Applicable
NCT02180711	Acerta Pharma BV\|AstraZeneca	Non Hodgkin Lymphoma	December 29, 2014	Phase 1
NCT01466153	MedImmune LLC	Chronic Lymphocytic Leukemia (CLL)	February 7, 2012	Phase 2
NCT00578565	Eric Matteson\|Genentech, Inc.\|National Center for Research Resources (NCRR)\|Mayo Clinic	Rheumatoid Arthritis\|Interstitial Pneumonia	May 2007	Phase 3
NCT00504751	Weill Medical College of Cornell University\|Millennium Pharmaceuticals, Inc.	Non-Hodgkin´s Lymphoma	May 2007	Phase 2
NCT00504504	M.D. Anderson Cancer Center\|Genentech, Inc.	Lymphoma	March 2001	Phase 2
NCT00812669	Cancer Trials Ireland	Leukemia	August 2008	Phase 2
NCT00007865	University of Nebraska\|National Cancer Institute (NCI)	Lymphoma	September 2000	Phase 2
NCT00849355	Asociacion Doctor Peset Para el Estudio de la Hematología\|Cephalon\|Pivotal S.L.	No Hodgkin B Lymphoma	August 2008	Phase 2
NCT00073957	Beth Israel Deaconess Medical Center	Lymphoma	December 2003	Phase 2
NCT01321541	CTI BioPharma	Diffuse Large B-cell Lymphoma\|de Novo DLBCL\|DLBCL Transformed From Indolent Lymphoma\|Follicular Grade 3 Lymphoma	April 20, 2011	Phase 3
NCT04214626	Henan Cancer Hospital	Diffuse Large B Cell Lymphoma	January 2, 2020	Phase 2
NCT02456207	Sinocelltech Ltd.	B-cell Non Hodgkin´s Lymphoma	May 2015	Phase 2
NCT02945215	Innovent Biologics (Suzhou) Co. Ltd.	B-Cell Lymphoma	December 13, 2016	Phase 1
NCT00186628	Stanford University\|The Leukemia and Lymphoma Society\|National Cancer Institute (NCI)	Leukemia, Mast-Cell\|Mantle-cell Lymphoma	June 2005	Phase 2
NCT05265975	Antengene Corporation	Diffuse Large B-cell Lymphoma\|Indolent Non-Hodgkin Lymphoma	April 7, 2022	Phase 1\|Phase 2
NCT00545714	Hoffmann-La Roche	Leukemia, Lymphocytic, Chronic, B-Cell	November 21, 2007	Phase 2
NCT02343536	Celgene	Lymphoma, Large B-Cell, Diffuse\|Lymphoma, Follicular	April 29, 2015	Phase 1
NCT00134082	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins\|National Cancer Institute (NCI)	Lymphoma	November 2005	Phase 1\|Phase 2
NCT01066598	University Health Network, Toronto\|Hoffmann-La Roche	Graft Versus Host Disease	May 2010	Phase 2
NCT04934579	Second Affiliated Hospital, School of Medicine, Zhejiang University	Primary Central Nervous System Lymphoma	January 1, 2020	Phase 2
NCT00381810	Genentech, Inc.	Lupus Erythematosus, Systemic	June 22, 2006	Phase 3
NCT00963703	University of Manitoba\|Hoffmann-La Roche	Rheumatoid Arthritis	December 2007	Not Applicable
NCT00058461	National Cancer Institute (NCI)	B-cell Childhood Acute Lymphoblastic Leukemia\|Childhood Burkitt Lymphoma\|Childhood Diffuse Large Cell Lymphoma\|Childhood Immunoblastic Large Cell Lymphoma\|L3 Childhood Acute Lymphoblastic Leukemia\|Recurrent Childhood Acute Lymphoblastic Leukemia\|Recurrent Childhood Large Cell Lymphoma\|Recurrent Childhood Lymphoblastic Lymphoma\|Recurrent Childhood Small Noncleaved Cell Lymphoma	November 2003	Phase 2
NCT02382575	Nilratan Sircar Medical College	Nephrotic Syndrome	March 15, 2015	Phase 4
NCT00261118	Royal Liverpool University Hospital\|Hoffmann-La Roche\|University of Liverpool	Ulcerative Colitis	April 2004	Phase 2\|Phase 3
NCT00647049	University Hospital Freiburg\|University Hospital Tuebingen	Primary Non Hodgkin Lymphoma of the Central Nervous System	January 2007	Phase 2
NCT04578639	Haukeland University Hospital\|University Hospital, Akershus\|Oslo University Hospital\|Helse Stavanger HF\|St. Olavs Hospital\|University Hospital of North Norway	Relapsing Remitting Multiple Sclerosis	November 2, 2020	Phase 3
NCT04578613	Beijing InnoCare Pharma Tech Co., Ltd.	Chronic Lymphocytic Leukemia\|Small Lymphocytic Lymphoma	January 8, 2021	Phase 3
NCT00867087	Pfizer\|UCB Pharma	Lymphoma, B-Cell	June 8, 2009	Phase 2
NCT00028717	Commissie Voor Klinisch Toegepast Onderzoek\|National Cancer Institute (NCI)	Lymphoma	February 2001	Phase 3
NCT00477412	M.D. Anderson Cancer Center\|National Cancer Institute (NCI)	Mantle Cell Lymphoma	April 3, 2007	Phase 1\|Phase 2
NCT03980379	Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.	CD20 Positive B Cell NHL	December 18, 2018	Phase 1
NCT05299164	Institute of Hematology & Blood Diseases Hospital\|CSPC Ouyi Pharmaceutical Co., Ltd.	Non Hodgkin Lymphoma	May 15, 2022	Phase 1
NCT01622439	Lund University Hospital\|Valcuria	Diffuse Large B-cell Lymphoma	June 2012	Phase 1\|Phase 2
NCT00238368	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins\|National Cancer Institute (NCI)	Lymphoma	February 2004	Phase 2
NCT03569995	Won Seog Kim\|Celltrion\|Samsung Medical Center	Primary CNS Lymphoma	November 30, 2018	Phase 2
NCT00350545	Stanford University	Graft vs Host Disease	August 2006	Not Applicable
NCT02198248	Chiba University	Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis\|Microscopic Polyangiitis\|Wegener Granulomatosis	October 2014	Phase 4
NCT00930514	Hoffmann-La Roche	Lymphoma, Follicular	September 2009	Phase 1
NCT02194374	M.D. Anderson Cancer Center\|CLL Global Research Foundation Alliance	Leukemia	January 2015	Phase 1
NCT01871675	SCRI Development Innovations, LLC\|Infinity Pharmaceuticals, Inc.	Lymphoma\|Chronic Lymphocytic Leukemia\|Non-Hodgkin Lymphoma\|T-cell Lymphoma	May 2013	Phase 1
NCT02428751	Wenqi Jiang\|Sun Yat-sen University	Lymphoma, Large B-Cell, Diffuse	September 2015	Phase 3
NCT00788684	AbbVie\|Genentech, Inc.	CD20-Positive Lymphoid Malignancies\|Chronic Lymphoid Leukemia\|Hematological Malignancies\|Non-Hodgkin´s Lymphoma	July 21, 2009	Phase 1
NCT00784589	University Hospital, Rouen	Pemphigus Disease	July 2009	Phase 3
NCT00311129	Genzyme, a Sanofi Company\|Sanofi	Lymphoma, Low-Grade	December 2005	Phase 2
NCT03500731	Paul Szabolcs\|University of Pittsburgh	Idiopathic Pulmonary Fibrosis\|Emphysema or COPD	April 19, 2018	Phase 1\|Phase 2
NCT01779167	Weill Medical College of Cornell University\|Celgene Corporation	Waldenstrom Macroglobulinemia	June 2012	Phase 2
NCT04431635	Big Ten Cancer Research Consortium\|Bayer\|Bristol-Myers Squibb\|University of Michigan	Indolent Lymphoma	June 15, 2020	Phase 1
NCT01144754	Stanford University	Lymphoma\|Non-Hodgkin´s Lymphoma	February 2009
NCT04980222	Hoffmann-La Roche	Lymphoma	March 22, 2022	Phase 2
NCT03274375	Assistance Publique - Hôpitaux de Paris	Anti-NMDAR Encephalitis	June 23, 2021	Phase 2
NCT04002947	National Cancer Institute (NCI)\|National Institutes of Health Clinical Center (CC)	Non-Hodgkin´s Lymphoma\|Diffuse Large B-Cell Lymphoma\|DLBCL\|NHL	August 5, 2019	Phase 2
NCT02381899	Czech CLL Study Group	Chronic Lymphocytic Leukemia	September 2014
NCT00536341	SCRI Development Innovations, LLC\|Celgene Corporation\|Genentech, Inc.	Chronic Lymphocytic Leukemia	January 2008	Phase 1\|Phase 2
NCT02898259	Brian Hill\|The Cleveland Clinic\|Case Comprehensive Cancer Center	B Cell Lymphoma\|Lymphoma	February 20, 2017	Phase 1\|Phase 2
NCT02136511	Gilead Sciences	Chronic Lymphocytic Leukemia (CLL)
NCT02240407	University of Florida\|Lacerta Therapeutics	Pompe Disease	October 17, 2017	Phase 1
NCT04138875	Yale University	PTLD\|Lymphoid Tumor\|Hematopoietic+Lymphoid Cancer\|Plasmacytic Hyperplasia PTLD\|Infectious Mononucleosis\|Florid Follicular Hyperplasia PTLD\|Polymorphic PTLD\|Monomorphic PTLD\|Classical Hodgkin Lymphoma Type PTLD	January 2022	Phase 2
NCT04542629	Assiut University	Refractory Epilepsy	October 1, 2020	Phase 4
NCT01665768	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins\|Novartis Pharmaceuticals	CD20&addition;, B-cell Lymphomas\|Mantle Cell Lymphoma\|Non-Mantle Cell Low Grade B Cell Lymphomas (SLL+CLL)\|Transformed Lymphoma+DLBCL+PMBCL\|Hodgkin´s Disease\|Gray Zone Lymphoma	September 2012	Phase 2
NCT01397825	Millennium Pharmaceuticals, Inc.\|Takeda	Diffuse Large B-Cell Lymphoma\|Transformed Follicular Lymphoma\|Mantle Cell Lymphoma\|Burkitt´s Lymphoma	August 9, 2011	Phase 1\|Phase 2
NCT00106184	University of Pittsburgh\|National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)\|Genentech, Inc.\|Biogen	Myositis\|Dermatomyositis\|Polymyositis\|Juvenile Dermatomyositis	March 2006	Phase 2
NCT00854321	Kuopio University Hospital	Rheumatoid Arthritis	November 2004
NCT01695941	National Cancer Institute (NCI)	Recurrent B-Cell Non-Hodgkin Lymphoma\|Recurrent Mantle Cell Lymphoma\|Refractory B-Cell Non-Hodgkin Lymphoma\|Refractory Mantle Cell Lymphoma	August 31, 2012	Phase 1
NCT03225924	The Lymphoma Academic Research Organisation	DLBCL	July 26, 2017	Phase 1\|Phase 2
NCT04402580	Istituto Giannina Gaslini\|Bambino Gesù Hospital and Research Institute	Nephrotic Syndrome Steroid-Dependent	July 1, 2019	Phase 2
NCT00072514	Fred Hutchinson Cancer Center\|National Cancer Institute (NCI)	Adult Nasal Type Extranodal NK+T-cell Lymphoma\|Anaplastic Large Cell Lymphoma\|Angioimmunoblastic T-cell Lymphoma\|Cutaneous B-cell Non-Hodgkin Lymphoma\|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue\|Hepatosplenic T-cell Lymphoma\|Intraocular Lymphoma\|Nodal Marginal Zone B-cell Lymphoma\|Noncutaneous Extranodal Lymphoma\|Peripheral T-cell Lymphoma\|Recurrent Adult Burkitt Lymphoma\|Recurrent Adult Diffuse Large Cell Lymphoma\|Recurrent Adult Diffuse Mixed Cell Lymphoma\|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma\|Recurrent Adult Grade III Lymphomatoid Granulomatosis\|Recurrent Adult Hodgkin Lymphoma\|Recurrent Adult Immunoblastic Large Cell Lymphoma\|Recurrent Adult Lymphoblastic Lymphoma\|Recurrent Adult T-cell Leukemia+Lymphoma\|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma\|Recurrent Grade 1 Follicular Lymphoma\|Recurrent Grade 2 Follicular Lymphoma\|Recurrent Grade 3 Follicular Lymphoma\|Recurrent Mantle Cell Lymphoma\|Recurrent Marginal Zone Lymphoma\|Recurrent Mycosis Fungoides+Sezary Syndrome\|Recurrent Small Lymphocytic Lymphoma\|Small Intestine Lymphoma\|Splenic Marginal Zone Lymphoma\|Testicular Lymphoma\|Waldenstrom Macroglobulinemia	August 2003	Phase 2
NCT00655837	Seagen Inc.\|Genentech, Inc.	Lymphoma, Large B-Cell, Diffuse\|Lymphoma, Non-Hodgkin	April 2008	Phase 1
NCT00460109	Alliance for Clinical Trials in Oncology\|National Cancer Institute (NCI)	Lymphoma	April 2008	Phase 2
NCT00468442	National Institute of Allergy and Infectious Diseases (NIAID)\|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Type 1 Diabetes Mellitus	November 2006	Phase 2
NCT02031419	Celgene	Lymphoma, Large B-Cell, Diffuse	December 18, 2013	Phase 1
NCT01851551	Acrotech Biopharma Inc.	Non-Hodgkin´s Lymphoma\|Diffuse Large B-cell Lymphoma\|Mantle Cell Lymphoma	September 2001	Phase 1\|Phase 2
NCT00006721	Southwest Oncology Group\|National Cancer Institute (NCI)\|Cancer and Leukemia Group B\|Eastern Cooperative Oncology Group	Lymphoma	March 2001	Phase 3
NCT00142116	Steven P. Treon, MD, PhD\|Dana-Farber Cancer Institute\|Massachusetts General Hospital\|Beth Israel Deaconess Medical Center\|Brigham and Women´s Hospital\|Cape Cod Hospital	Waldenstrom´s Macroglobulinemia\|Lymphoplasmacytic Lymphoma	May 2003	Phase 2
NCT04058470	Huiqiang Huang\|Sun Yat-sen University	Diffuse Large B Cell Lymphoma\|High-grade B-cell Lymphoma\|Follicular Lymphoma Grade IIIb\|Transformed Lymphoma\|EBV-Positive DLBCL, Nos\|ALK-Positive Anaplastic Large Cell Lymphoma	April 24, 2020	Phase 1\|Phase 2
NCT02296918	Acerta Pharma BV	Chronic Lymphocytic Leukemia\|Small Lymphocytic Lymphoma\|Prolymphocytic Leukemia	December 22, 2014	Phase 1
NCT02157181	Jurgen Barth\|University of Giessen	Hairy Cell Leukemia (HCL)	June 2004	Phase 2
NCT00656812	Arbeitsgemeinschaft medikamentoese Tumortherapie\|Hoffmann-La Roche\|Lipomed	Lymphoma of Mucosa-Associated Lymphoid Tissue	May 2008	Phase 2
NCT04074330	Takeda	Lymphoma, Non-Hodgkin	October 15, 2019	Phase 1\|Phase 2
NCT01238692	Sarit Assouline\|Quebec Clinical Research Organization in Cancer\|Novartis\|Hoffmann-La Roche\|Jewish General Hospital	Diffuse Large B Cell Lymphoma	November 2010	Phase 2
NCT02260934	National Institute of Allergy and Infectious Diseases (NIAID)\|Immune Tolerance Network (ITN)	Lupus Nephritis	July 9, 2015	Phase 2
NCT01307605	Swiss Group for Clinical Cancer Research	Lymphoma	February 9, 2011	Phase 2
NCT00590447	Charite University, Berlin, Germany	PTLD\|Posttransplant Lymphoproliferative Disorder	December 2006	Phase 2
NCT00003356	University of Rochester\|National Cancer Institute (NCI)	Lymphoma	November 1997	Phase 1\|Phase 2
NCT02853370	International Extranodal Lymphoma Study Group (IELSG)	Marginal Zone B-cell Lymphoma	July 2012	Phase 2
NCT05624554	Merck Sharp & Dohme LLC	Chronic Lymphocytic Leukemia\|Small Lymphocytic Leukemia	December 22, 2022	Phase 3
NCT01047072	Fred Hutchinson Cancer Research Center+University of Washington Cancer Consortium\|National Cancer Institute (NCI)\|Fred Hutchinson Cancer Center	Systemic Scleroderma		Phase 2
NCT01144403	Hoffmann-La Roche	Diffuse Large B-Cell Lymphoma	June 2010	Phase 2
NCT01983969	M.D. Anderson Cancer Center	Advanced Cancers\|Lymphoma	November 7, 2013	Phase 1\|Phase 2
NCT00992030	Fondazione Michelangelo	Hodgkin Lymphoma	September 2009	Phase 3
NCT01729806	National Cancer Institute (NCI)	CD20 Positive\|Recurrent B-Cell Non-Hodgkin Lymphoma\|Refractory B-Cell Non-Hodgkin Lymphoma	November 19, 2012	Phase 1
NCT03069248	Sunnybrook Health Sciences Centre	Follicular Lymphoma	June 1, 2000	Phase 2
NCT01197560	Celgene	Diffuse Large B-cell Lymphoma	September 2, 2010	Phase 2\|Phase 3
NCT00438880	Mayo Clinic\|National Cancer Institute (NCI)	Adult Non-Hodgkin Lymphoma\|Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue\|Nodal Marginal Zone Lymphoma\|Recurrent Adult Diffuse Large Cell Lymphoma\|Recurrent Grade 1 Follicular Lymphoma\|Recurrent Grade 2 Follicular Lymphoma\|Recurrent Grade 3 Follicular Lymphoma\|Recurrent Mantle Cell Lymphoma\|Recurrent Marginal Zone Lymphoma\|Recurrent Small Lymphocytic Lymphoma\|Splenic Marginal Zone Lymphoma\|Waldenstrom Macroglobulinemia	October 2004	Phase 1\|Phase 2
NCT02881086	Goethe University	Acute Lymphoblastic Leukemia\|Lymphoblastic Lymphoma	August 2016	Phase 3
NCT00486759	Hoffmann-La Roche\|Genentech, Inc.	B-cell Lymphoma	July 26, 2007	Phase 3
NCT00525603	M.D. Anderson Cancer Center\|Bayer	Leukemia\|Chronic Lymphocytic Leukemia	June 2005	Phase 2
NCT00880815	M.D. Anderson Cancer Center\|National Cancer Institute (NCI)	CD20 Positive\|Chronic Lymphocytic Leukemia\|Follicular Lymphoma\|Mantle Cell Lymphoma\|Marginal Zone Lymphoma\|Recurrent Diffuse Large B-Cell Lymphoma\|T-Cell Non-Hodgkin Lymphoma	February 17, 2009	Phase 1
NCT05379647	Zhejiang University\|Hangzhou Qihan Biotech Co.,Ltd.	B-cell Lymphoma\|B-cell Acute Lymphoblastic Leukemia	November 4, 2021	Phase 1
NCT03576547	M.D. Anderson Cancer Center\|National Cancer Institute (NCI)	Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive\|Philadelphia Chromosome Positive\|Recurrent Acute Lymphoblastic Leukemia\|Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive\|Refractory Acute Lymphoblastic Leukemia\|Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive\|t(9;22)	June 26, 2018	Phase 1\|Phase 2
NCT05389423	National Cancer Institute (NCI)\|National Institutes of Health Clinical Center (CC)	Diffuse Large Cell Lymphoma\|Non-Hodgkin Lymphoma\|Burkitt Lymphoma\|Plasmablastic Lymphoma\|B-Cell Neoplasm	November 28, 2022	Phase 1
NCT03523975	University of Michigan Rogel Cancer Center	Mantle Cell Lymphoma	December 24, 2018	Phase 1
NCT05551936	Vaishalee Kenkre\|Epizyme, Inc.\|University of Wisconsin, Madison\|Big Ten Cancer Research Consortium	Follicular Lymphoma	November 2022	Phase 1\|Phase 2
NCT00225212	Stanford University	Non-Hodgkin´s Lymphoma\|Diffuse Large Cell Lymphoma\|Mantle Cell Lymphoma\|Transformed Lymphoma\|Other Subtypes of B-cell Lymphoma\|Lymphoma	November 1997	Phase 2
NCT05052528	Mehrdad Abedi, MD\|National Cancer Institute (NCI)\|University of California, Davis	Recurrent Diffuse Large B-Cell Lymphoma\|Refractory Diffuse Large B-Cell Lymphoma	September 17, 2021	Phase 1
NCT00288067	National Cancer Institute (NCI)	Adult Nodular Lymphocyte Predominant Hodgkin Lymphoma\|B-cell Chronic Lymphocytic Leukemia\|Contiguous Stage II Adult Burkitt Lymphoma\|Contiguous Stage II Adult Diffuse Large Cell Lymphoma\|Contiguous Stage II Adult Lymphoblastic Lymphoma\|Contiguous Stage II Grade 1 Follicular Lymphoma\|Contiguous Stage II Grade 2 Follicular Lymphoma\|Contiguous Stage II Mantle Cell Lymphoma\|Stage II Marginal Zone Lymphoma\|Stage II Small Lymphocytic Lymphoma\|Extranodal Marginal Zone B-cell Lymphoma\|Nodal Marginal Zone B-cell Lymphoma\|Noncontiguous Stage II Adult Burkitt Lymphoma\|Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma\|Noncontiguous Stage II Adult Lymphoblastic Lymphoma\|Noncontiguous Stage II Grade 1 Follicular Lymphoma\|Noncontiguous Stage II Grade 2 Follicular Lymphoma\|Noncontiguous Stage II Mantle Cell Lymphoma\|Recurrent Adult Burkitt Lymphoma\|Recurrent Adult Diffuse Large Cell Lymphoma\|Recurrent Adult Hodgkin Lymphoma\|Recurrent Adult Lymphoblastic Lymphoma\|Recurrent Grade 1 Follicular Lymphoma\|Recurrent Grade 2 Follicular Lymphoma\|Recurrent Mantle Cell Lymphoma\|Recurrent Marginal Zone Lymphoma\|Recurrent Small Lymphocytic Lymphoma\|Refractory Chronic Lymphocytic Leukemia\|Splenic Marginal Zone Lymphoma\|Stage I Adult Burkitt Lymphoma\|Stage I Adult Diffuse Large Cell Lymphoma\|Stage I Adult Hodgkin Lymphoma\|Stage I Adult Lymphoblastic Lymphoma\|Stage I Chronic Lymphocytic Leukemia\|Stage I Grade 1 Follicular Lymphoma\|Stage I Grade 2 Follicular Lymphoma\|Stage I Small Lymphocytic Lymphoma\|Stage II Adult Hodgkin Lymphoma\|Stage II Chronic Lymphocytic Leukemia\|Stage III Adult Burkitt Lymphoma\|Stage III Adult Diffuse Large Cell Lymphoma\|Stage III Adult Hodgkin Lymphoma\|Stage III Adult Lymphoblastic Lymphoma\|Stage III Chronic Lymphocytic Leukemia\|Stage III Grade 1 Follicular Lymphoma\|Stage III Grade 2 Follicular Lymphoma\|Stage III Mantle Cell Lymphoma\|Stage III Marginal Zone Lymphoma\|Stage III Small Lymphocytic Lymphoma\|Stage IV Adult Burkitt Lymphoma\|Stage IV Adult Diffuse Large Cell Lymphoma\|Stage IV Adult Hodgkin Lymphoma\|Stage IV Adult Lymphoblastic Lymphoma\|Stage IV Chronic Lymphocytic Leukemia\|Stage IV Grade 1 Follicular Lymphoma\|Stage IV Grade 2 Follicular Lymphoma\|Stage IV Mantle Cell Lymphoma\|Stage IV Marginal Zone Lymphoma\|Stage IV Small Lymphocytic Lymphoma\|Waldenström Macroglobulinemia	October 2005	Phase 1\|Phase 2
NCT00373594	University of Bergen	Cold Agglutinin Disease	June 2005	Phase 2
NCT02731560	Prof. Abid Z. Farooqi\|Aga Khan University\|Fatima Memorial Hospital\|Fauji Foundation Hospital, Rawalpindi\|Pakistan Institute of Medical Sciences	Rheumatoid Arthritis	January 2010	Phase 4
NCT02149121	Celltrion	Rheumatoid Arthritis	August 2014	Phase 3
NCT03670888	JHL Biotech, Inc.	B Cell Lymphoma	November 16, 2018	Phase 1
NCT00096460	Medical College of Wisconsin\|National Heart, Lung, and Blood Institute (NHLBI)\|Blood and Marrow Transplant Clinical Trials Network\|National Cancer Institute (NCI)\|National Marrow Donor Program	Recurrent Grade 1 Follicular Lymphoma\|Recurrent Grade 2 Follicular Lymphoma\|Recurrent Grade 3 Follicular Lymphoma\|Follicular Lymphoma	August 2004	Phase 2\|Phase 3
NCT02408042	Western Regional Medical Center	Lymphoma\|Hodgkin´s Lymphoma\|Non-hodgkin´s Lymphoma	April 2015	Phase 1\|Phase 2
NCT02203526	National Cancer Institute (NCI)\|National Institutes of Health Clinical Center (CC)	Primary Central Nervous System Lymphoma	August 14, 2014	Phase 1
NCT00060684	CTI BioPharma	Lymphoma, Low-Grade\|Lymphoma, Small Lymphocytic\|Lymphoma, Mixed-Cell, Follicular\|Lymphoma, Small Cleaved-Cell, Follicular	December 2001	Phase 1
NCT00089115	Favrille\|National Cancer Institute (NCI)	Lymphoma	July 2004	Phase 3
NCT04899570	Peking Union Medical College Hospital	Intravascular Large B-Cell Lymphoma	April 1, 2021	Phase 2
NCT00577629	Duke University\|GlaxoSmithKline	Lymphoma, B-Cell	June 18, 2005	Phase 2
NCT00110006	Case Comprehensive Cancer Center\|National Cancer Institute (NCI)	Lymphoma	December 2004	Not Applicable
NCT00499018	Fondazione Italiana Linfomi ONLUS\|Centro di Riferimento per l´Epidemiologia e la Prev. Oncologica Piemonte	Diffuse Large B-Cell Lymphoma\|IPI?2	January 2006	Phase 3
NCT05078177	St. Petersburg State Pavlov Medical University	Multiple Sclerosis	December 21, 2020	Phase 1
NCT01611259	Arbeitsgemeinschaft medikamentoese Tumortherapie	Lymphoma of the Mucosa Associated Lymphoid Tissue (MALT)	May 2012	Phase 2
NCT03653338	Paul Szabolcs\|University of Pittsburgh	Sickle Cell Anemia\|Beta-thalassemia Major\|Diamond-blackfan Anemia	August 2, 2018	Phase 1\|Phase 2
NCT00275613	Mayo Clinic	Glomerulonephritis, Membranoproliferative	November 2005	Phase 1
NCT00054639	National Cancer Institute (NCI)	Cutaneous B-cell Non-Hodgkin Lymphoma\|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue\|Intraocular Lymphoma\|Nodal Marginal Zone B-cell Lymphoma\|Recurrent Adult Burkitt Lymphoma\|Recurrent Adult Diffuse Large Cell Lymphoma\|Recurrent Adult Diffuse Mixed Cell Lymphoma\|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma\|Recurrent Adult Grade III Lymphomatoid Granulomatosis\|Recurrent Adult Immunoblastic Large Cell Lymphoma\|Recurrent Adult Lymphoblastic Lymphoma\|Recurrent Grade 1 Follicular Lymphoma\|Recurrent Grade 2 Follicular Lymphoma\|Recurrent Grade 3 Follicular Lymphoma\|Recurrent Mantle Cell Lymphoma\|Recurrent Marginal Zone Lymphoma\|Recurrent Small Lymphocytic Lymphoma\|Small Intestine Lymphoma\|Splenic Marginal Zone Lymphoma\|Testicular Lymphoma\|Waldenström Macroglobulinemia	January 2003	Phase 2
NCT00911183	Institut Bergonié\|National Cancer Institute, France	Lymphoma	December 2, 2008	Phase 2
NCT01776840	Janssen Research & Development, LLC\|Pharmacyclics LLC.	Mantle Cell Lymphoma	May 16, 2013	Phase 3
NCT00003605	Hoag Memorial Hospital Presbyterian\|Cancer Biotherapy Research Group	Lymphoma	May 1998	Phase 2
NCT04231877	University of Washington\|Genentech, Inc.	Aggressive Non-Hodgkin Lymphoma\|ALK-Positive Large B-Cell Lymphoma\|B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma\|Diffuse Large B-Cell Lymphoma, Not Otherwise Specified\|EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified\|High Grade B-Cell Lymphoma With MYC and BCL2 and+or BCL6 Rearrangements\|High Grade B-Cell Lymphoma, Not Otherwise Specified\|Primary Mediastinal (Thymic) Large B-Cell Lymphoma\|T-Cell+Histiocyte-Rich Large B-Cell Lymphoma	October 27, 2020	Phase 1
NCT01181999	Chonnam National University Hospital\|Samsung Medical Center\|Asan Medical Center\|Severance Hospital	Lymphoma, Large B-cell, Diffuse	August 2010	Phase 2
NCT04783675	Children´s Hospital of Fudan University\|Children´s Hospital of Nanjing Medical University\|The Children´s Hospital of Zhejiang University School of Medicine\|Wuhan Union Hospital, China\|Anhui Provincial Children´s Hospital\|Children´s Hospital Affiliated to Zhengzhou University+Henan Children´s Hospital\|The first affiliated hospital of Zhongshan university\|Shandong Provincial Hospital\|Xuzhou Children´s Hospital	Steroid-Sensitive Nephrotic Syndrome	April 13, 2021	Phase 2
NCT01283386	Hoffmann-La Roche	Lymphocytic Leukemia, Chronic	April 27, 2011	Phase 4
NCT00577161	CTI BioPharma	Non-Hodgkin´s Lymphoma	September 2007	Phase 3
NCT01010217	M.D. Anderson Cancer Center	Blood Stem Cell Transplant Failure\|Leukemia\|Hematologic Malignancies	November 5, 2009	Phase 2
NCT00379587	Dana-Farber Cancer Institute\|Genentech, Inc.\|Biogen	Hematological Malignancies	September 2006	Phase 1\|Phase 2
NCT00400478	Arbeitsgemeinschaft medikamentoese Tumortherapie\|Hoffmann-La Roche	Diffuse Large B-Cell Lymphoma (DLBCL)\|Follicular NHL Grade 3b	January 2006	Phase 3
NCT01925612	Seagen Inc.	Lymphoma, B-cell\|Lymphoma, Large B-cell, Diffuse	August 2013	Phase 2
NCT03259529	St. Petersburg State Pavlov Medical University	Diffuse Large B Cell Lymphoma	March 27, 2017	Phase 1\|Phase 2
NCT04607772	Karyopharm Therapeutics Inc	Relapsed or Refractory Diffuse Large B-Cell Lymphoma	November 18, 2020	Phase 1\|Phase 2
NCT00216762	Johns Hopkins University\|Genentech, Inc.	Urticaria	January 2006	Phase 1\|Phase 2
NCT00101829	National Institute of Allergy and Infectious Diseases (NIAID)\|Autoimmunity Centers of Excellence	Sjogren´s Syndrome	April 2004	Phase 1
NCT00248534	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins\|National Cancer Institute (NCI)	Lymphoma	September 2005	Phase 2
NCT00634179	Emory University\|Millennium Pharmaceuticals, Inc.	Lymphoma, B-Cell\|Follicular Lymphoma	February 2008	Phase 1\|Phase 2
NCT03837873	Institute of Hematology & Blood Diseases Hospital	Diffuse Large B Cell Lymphoma\|High-grade B-cell Lymphoma\|Transformed Lymphoma	January 21, 2019	Phase 2
NCT02532257	M.D. Anderson Cancer Center\|National Cancer Institute (NCI)	Ann Arbor Stage II Follicular Lymphoma\|Ann Arbor Stage II Marginal Zone Lymphoma\|Ann Arbor Stage III Follicular Lymphoma\|Ann Arbor Stage III Marginal Zone Lymphoma\|Ann Arbor Stage IV Follicular Lymphoma\|Ann Arbor Stage IV Marginal Zone Lymphoma\|CD20 Positive\|Grade 1 Follicular Lymphoma\|Grade 2 Follicular Lymphoma\|Grade 3a Follicular Lymphoma	April 11, 2016	Phase 2
NCT00066469	Children´s Oncology Group\|National Cancer Institute (NCI)	Lymphoproliferative Disorder	April 2004	Phase 2
NCT00007852	University of Nebraska\|National Cancer Institute (NCI)\|Genentech, Inc.	Lymphoma	September 2000	Phase 2
NCT01538472	M.D. Anderson Cancer Center\|Biogen	Lymphoma	September 2003	Phase 1\|Phase 2
NCT02957019	Philogen S.p.A.	Diffuse Large B-cell Lymphoma (DLBCL)	July 31, 2013	Phase 1\|Phase 2
NCT00301795	National Cancer Institute (NCI)	Stage III Grade 1 Follicular Lymphoma\|Stage III Grade 2 Follicular Lymphoma\|Stage III Grade 3 Follicular Lymphoma\|Stage IV Grade 1 Follicular Lymphoma\|Stage IV Grade 2 Follicular Lymphoma\|Stage IV Grade 3 Follicular Lymphoma	March 2006	Phase 2
NCT00090051	Hoffmann-La Roche\|Biogen\|Genentech, Inc.	Chronic Lymphocytic Leukemia	July 31, 2003	Phase 3
NCT03700229	Peking Union Medical College Hospital	Acquired Hemophilia A	October 10, 2018	Phase 2
NCT00502840	Hoffmann-La Roche	Rheumatoid Arthritis	July 23, 2007	Phase 3
NCT03856216	M.D. Anderson Cancer Center\|National Cancer Institute (NCI)	Acute Lymphoblastic Leukemia\|B Acute Lymphoblastic Leukemia\|Lymphocytic Neoplasm\|Lymphoma	October 28, 2019	Phase 2
NCT03742258	Northwestern University\|National Cancer Institute (NCI)	Diffuse Large B-Cell Lymphoma\|Diffuse Large B-Cell Lymphoma Activated B-Cell Type\|Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type\|Diffuse Large B-Cell Lymphoma, Not Otherwise Specified\|High Grade B-Cell Lymphoma With MYC and BCL2 and+or BCL6 Rearrangements\|High Grade B-Cell Lymphoma, Not Otherwise Specified\|T-Cell+Histiocyte-Rich Large B-Cell Lymphoma	March 13, 2019	Phase 1
NCT00098488	National Cancer Institute (NCI)	B-cell Chronic Lymphocytic Leukemia\|Prolymphocytic Leukemia\|Refractory Chronic Lymphocytic Leukemia	April 2005	Phase 1
NCT01022021	University of Kansas Medical Center\|Cephalon	Lymphoma	January 2010	Early Phase 1
NCT02384954	Altor BioScience	Relapsed+Refractory Indolent B Cell Non-Hodgkin Lymphoma	April 2015	Phase 1\|Phase 2
NCT00878254	University of Miami	Mantle-Cell Lymphoma	March 25, 2009	Phase 2
NCT01234467	UNC Lineberger Comprehensive Cancer Center\|Cephalon	Diffuse Large B-Cell Lymphoma\|Lymphoma, Diffuse Large-Cell\|Diffuse Large-Cell Lymphoma\|Lymphoma	March 2011	Phase 2
NCT02072967	Astellas Pharma Europe B.V.\|Astellas Pharma Inc	Lymphoma, Non-Hodgkin	May 2012
NCT03467867	Georgetown University\|Hackensack Meridian Health	Chronic Lymphocytic Leukemia	April 26, 2018	Phase 2
NCT02564744	Debiopharm International SA	Diffuse Large B-Cell Lymphoma\|B-cell Non-Hodgkin´s Lymphoma	June 15, 2016	Phase 2
NCT01272908	Hoffmann-La Roche	Rheumatoid Arthritis	July 18, 2006	Phase 3
NCT00556127	Gruppo Italiano Multiregionale per lo studio dei Linfomi e delle Leucemie	Diffuse Large B-Cell Lymphoma\|POOR PROGNOSIS	June 2002	Phase 2
NCT00193479	SCRI Development Innovations, LLC\|Genentech, Inc.\|Amgen	Non-Hodgkins Lymphoma	April 2003	Phase 2
NCT01180036	Mayo Clinic\|Columbia University\|University of British Columbia\|Ohio State University\|Stanford University\|University of Washington\|University of Michigan\|University of Alabama at Birmingham\|Case Western Reserve University\|The Cleveland Clinic\|University of Kansas Medical Center\|University of Manchester\|University Health Network, Toronto\|University of Toronto\|CHU de Quebec-Universite Laval\|Washington University School of Medicine\|Florida International University\|University of Mississippi Medical Center\|NYU Langone Health\|Medical College of Wisconsin\|University of Arizona\|Sunnybrook Health Sciences Centre\|Applied Health Research Centre\|Fulk Family Foundation	Idiopathic Membranous Nephropathy	November 2011	Phase 2\|Phase 3
NCT01939730	M.D. Anderson Cancer Center\|Genentech, Inc.	Lymphoma	August 1999	Phase 2
NCT00844714	University of California, San Francisco\|Genentech, Inc.	Endothelial Function\|Rheumatoid Arthritis\|Inflammation	November 2009	Not Applicable
NCT01434472	Fred Hutchinson Cancer Center\|National Cancer Institute (NCI)	Post-Transplant Lymphoproliferative Disorder\|Recurrent Adult Diffuse Large Cell Lymphoma\|Recurrent B-Cell Non-Hodgkin Lymphoma\|Recurrent Burkitt Lymphoma\|Refractory B-Cell Non-Hodgkin Lymphoma\|Refractory Burkitt Lymphoma\|Refractory Diffuse Large B-Cell Lymphoma	November 16, 2011	Phase 2
NCT04161248	Canadian Cancer Trials Group\|Roche Pharma AG\|AbbVie	Lymphoma, B-Cell	December 6, 2019	Early Phase 1
NCT03997968	Cyteir Therapeutics, Inc.	Malignancy\|Non-hodgkin Lymphoma\|Multiple Myeloma\|Breast Cancer\|Ovarian Cancer\|Soft Tissue Sarcoma\|Head and Neck Cancer\|DLBCL\|Mantle Cell Lymphoma\|Follicular Lymphoma\|Pancreatic Cancer\|CLL\|Small Cell Lung Cancer\|Squamous Cell Carcinoma of Head and Neck\|Triple Negative Breast Cancer	October 9, 2019	Phase 1\|Phase 2
NCT02626845	Hospital for Special Surgery, New York\|Genentech, Inc.\|Roche Pharma AG	Granulomatosis With Polyangiitis (Wegener´s Granulomatosis)	December 2015	Phase 4
NCT03136146	M.D. Anderson Cancer Center\|National Cancer Institute (NCI)	Recurrent Acute Lymphoblastic Leukemia\|Recurrent Adult Lymphoblastic Lymphoma\|Recurrent Burkitt Leukemia\|Recurrent Burkitt Lymphoma\|Recurrent Childhood Lymphoblastic Lymphoma\|Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements\|Refractory Acute Lymphoblastic Leukemia\|Refractory Burkitt Leukemia\|Refractory Burkitt Lymphoma\|Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements\|Refractory Lymphoblastic Lymphoma	August 9, 2017	Phase 2
NCT05324917	The Affiliated Hospital of Qingdao University	Rituximab\|Children\|Blood Disease	April 10, 2022
NCT03220022	National Cancer Institute (NCI)	AIDS-Related Lymphoma\|Ann Arbor Stage II Diffuse Large B-Cell Lymphoma\|Ann Arbor Stage III Diffuse Large B-Cell Lymphoma\|Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma	November 3, 2017	Phase 1
NCT00422799	Dana-Farber Cancer Institute\|Millennium Pharmaceuticals, Inc.	Waldenstrom´s Macroglobulinemia	August 30, 2006	Phase 2
NCT05586737	Angelica Lindén Hirschberg\|Karolinska University Hospital	Autoimmune Diseases\|Premature Ovarian Insufficiency	April 29, 2019	Phase 2
NCT00509184	Klaus Herfarth, MD\|German Low Grade Lymphoma Study Group\|Roche Pharma AG\|Heidelberg University	Lymphoma, Malignant	March 2008	Phase 2
NCT02834286	Hospital Universitario Dr. Jose E. Gonzalez	Immune Thrombocytopenia	March 2015	Phase 2
NCT01011920	International Extranodal Lymphoma Study Group (IELSG)	Central Nervous System Lymphoma	November 2009	Phase 2
NCT00006708	Southwest Oncology Group\|National Cancer Institute (NCI)	Lymphoma	October 2000	Phase 3
NCT00053092	Institute of Cancer Research, United Kingdom\|Australasian Leukaemia and Lymphoma Group\|National Cancer Institute (NCI)	Lymphoma	October 2002	Phase 2
NCT01287741	Hoffmann-La Roche\|Fondazione Italiana Linfomi ONLUS	Diffuse Large B-Cell Lymphoma	July 26, 2011	Phase 3
NCT04002297	BeiGene	Mantle Cell Lymphoma; Non-Hodgkin Lymphoma	August 21, 2019	Phase 3
NCT02746744	Anders Svenningsson\|Karolinska Institutet	Multiple Sclerosis, Relapsing-Remitting	May 2016	Phase 3
NCT02592876	Seagen Inc.	Lymphoma, B-cell\|Lymphoma, Large B-Cell, Diffuse\|Lymphoma, Follicular, Grade 3b\|Follicular Lymphoma, Grade 3b	October 2015	Phase 2
NCT00493467	M.D. Anderson Cancer Center\|Biogen\|CTI BioPharma	Lymphoma	June 2006	Phase 2
NCT04745949	M.D. Anderson Cancer Center	Ann Arbor Stage I Primary Mediastinal (Thymic) Large B-Cell Lymphoma\|Ann Arbor Stage II Primary Mediastinal (Thymic) Large B-Cell Lymphoma\|Ann Arbor Stage III Primary Mediastinal (Thymic) Large B-Cell Lymphoma\|Ann Arbor Stage IV Primary Mediastinal (Thymic) Large B-Cell Lymphoma	May 10, 2021	Phase 2
NCT00072449	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins\|National Cancer Institute (NCI)	Lymphoma	May 2004	Phase 2
NCT04665765	City of Hope Medical Center\|National Cancer Institute (NCI)	Diffuse Large B-Cell Lymphoma Unclassifiable\|Recurrent Diffuse Large B-Cell Lymphoma\|Recurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma\|Recurrent Transformed B-Cell Non-Hodgkin Lymphoma\|Refractory Diffuse Large B-Cell Lymphoma\|Refractory Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma\|Refractory Transformed B-Cell Non-Hodgkin Lymphoma	January 18, 2021	Phase 2
NCT01750697	Hoffmann-La Roche	Granulomatosis With Polyangiitis	May 23, 2013	Phase 2
NCT01732913	Gilead Sciences	Indolent Non-Hodgkin´s Lymphomas	January 16, 2013	Phase 3
NCT01277172	Probiomed S.A. de C.V.	Diffuse Large B Cell Lymphoma	October 2010	Phase 2\|Phase 3
NCT04981912	University of California, San Diego	Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma	September 2, 2021	Phase 1
NCT01521689	Institut Paoli-Calmettes	Chronic Lymphocytic Leukemia	December 2011	Phase 2
NCT00309881	German CLL Study Group	Chronic Lymphocytic Leukemia	April 2003	Phase 2
NCT03003039	Nanjing Yoko Biomedical Co., Ltd.	B-Cell Lymphoma	June 5, 2017	Phase 1
NCT00983944	Ohio State University Comprehensive Cancer Center	Lymphoma	September 2009	Phase 2
NCT01933711	University Hospital Heidelberg	CD20&addition; Aggressive Lymphoma, Mantle Cell Lymphoma	July 2002	Phase 3
NCT02624492	Boehringer Ingelheim	Lymphoma, Large B-Cell, Diffuse	January 28, 2016	Phase 2
NCT03298698	Radboud University Medical Center	Idiopathic Nephrotic Syndrome\|Minimal Change Disease\|Focal Segmental Glomerulosclerosis	August 22, 2018	Phase 3
NCT00259974	Assistance Publique - Hôpitaux de Paris\|Groupe Hospitalier Pitie-Salpetriere\|University Hospital, Bordeaux\|University Hospital, Limoges\|Henri Mondor University Hospital\|University Hospital, Marseille\|Hospices Civils de Lyon\|University Hospital, Basel, Switzerland	Polyneuropathy	April 2006	Phase 3
NCT00619671	University of Vermont\|Genentech, Inc.	Refractory Myasthenia Gravis	April 2004	Phase 1\|Phase 2

Appearance

Liquid

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

References

[1] Kamburova EG, et al. In vitro effects of rituximab on the proliferation, activation and differentiation of human B cells. Am J Transplant. 2012 Feb;12(2):341-50.
[2] Manches O, et al. In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas. Blood. 2003 Feb 1;101(3):949-54.
[3] Byrd JC, et al. The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction. Blood. 2002 Feb 1;99(3):1038-43.

Synonyms

Immunoglobulin G1, anti-(human CD20 (antigen)) (human-mouse monoclonal IDEC-C2B8 γ₁-chain), disulfide with human-mouse monoclonal IDEC-C2B8 κ-chain, dimer

Immunoglobulin G 1 (human-mouse monoclonal IDEC-C2B8 γ1-chain anti-human antigen CD 20), disulfide with human-mouse monoclonal IDEC-C2B8 κ-chain, dimer

IDEC 102

Rituximab

IDEC-C 2B8

Rituxan

MabThera

Retuxin

5: PN: WO2008003319 PAGE: 45 claimed protein

Reditux

Kikuzubam

GP 2013

1: PN: WO2016077505 PAGE: 164 claimed sequence

RG 105

Request a Quote

Please fill in your details below to request a COA for our product. We will send the COA to the provided email address promptly.

Arctom is a premier supply platform offering over 600K unique items of Building Blocks, Bioactive Molecules, Natural Products, ADC PEG Linkers, Antibodies, and other Research Chemicals for global pharmaceutical, biotech, university, and industrial customers. We accelerate your research by providing better and faster purchasing experience & services.

Information

Shipping
Privacy notice
Terms of Service
About us
Contact us

Customer service

Search
Custom Synthesis

My account

My account
Orders
Addresses
Shopping cart